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ABSTRACT 
Introduction: The prevalence of the Human Immunodeficiency Virus (HIV) in South Africa 
was 17.8% among 15 to 49 year olds in 2010. Antiretroviral therapy (ART) has thus played a 
crucial role in mitigating the impact of the HIV epidemic. Themba Lethu Clinic is one of the 
largest single clinics providing ART in South Africa. One of the challenges of ART provision 
is ensuring adherence to taking the medication. To date there has been no clear consensus on 
the ideal way to measure adherence in resource limited settings (RLS). Viral load is perhaps 
the best and most reliable indicator of poor adherence but is expensive and not easily 
accessible or available in many RLS. Surrogate markers such as mean cell volume (MCV), 
CD4 cell count, self-reported adherence and missed visits have been shown to be useful to 
measure adherence but their reliability remains unclear. The aim of the study was to identify 
other markers that can be used to measure adherence using viral load as the gold standard.  
 
Materials and methods: The study was a retrospective analysis of HIV-positive ART-naïve 
adults (≥ 18 years) initiating standard first-line ART at the Themba Lethu Clinic in 
Johannesburg, South Africa between April 2004 and January 2012.  The association between 
the last self-reported adherence, change in MCV calculated from baseline to 6 months, 
change in CD4 count calculated from baseline to 6 months (≥ or < the expected increase of 
50 cells/mm
3
 at 6 months) and missed visits (defined as a scheduled appointment that had 
been missed by ≥ 7 days but not by more than 3 months) and poor adherence (defined as a 
viral load ≥ 400copies/ml after 6 months on ART) was tested using Poisson regression 
models with robust error variance to estimate incidence rate ratio (IRR) and 95% confidence 
interval (CI). The IRR was used to approximate the relative risk (RR) of poor adherence. 
Interacting variables were stratified by each other, to create a new variable. The diagnostic 
accuracy of each identified marker of adherence was also tested using sensitivity, specificity, 
positive predictive values and negative predictive values.   
 
Results: 7160 patients were eligible for the study and of these 63.2% were female. The 
median age was 36.7 years. The median CD4 count was 101 cells/mm
3 
at baseline and 18.9% 
of the patients had poor adherence at 6 months. Variables associated with poor adherence at 6 
months were change in CD4 count stratified by change in MCV at 6 months (change in CD4 
count  ≥ expected and change in MCV ≥ 14.5fL; adjusted relative risk (aRR) 1, change in 
CD4 count  ≥ expected and change in MCV < 14.5fL; aRR 3.11 95% CI 2.41 – 4.02, change 
in CD4 < expected and change in MCV ≥ 14.5fL; aRR 1.23 95% CI 0.76 – 2.00 and change 
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in CD4 count < expected and change in MCV < 14.5fL; aRR 6.98 95% CI 5.35 – 9.09), CD4 
count at baseline (> 200 cells/mm
3
; aRR 1, 101 – 200 cells/mm3; aRR 1.05 95% CI 0.80 – 
1.38, 51 – 100 cells/mm3; aRR 1.08 95% CI 0.80 – 1.47 and ≤ 50cells/mm3; aRR 1.34 95% 
CI 1.02 – 1.76) , WHO stage at baseline (stage I; aRR 1, stage II; aRR 1.16 95% CI 0.90 – 
1.48, stage III; aRR 1.27 95% CI 1.04 – 1.55 and stage IV; aRR 1.44 95% CI 1.12 – 1.84) 
and MCV at baseline (< 80fL; aRR 1, 80 – 100fL; aRR 1.33 95% CI 1.01 – 1.75 and > 100fL 
aRR 0.98 95% CI 0.62 – 1.55).  Sensitivity and specificity of the change in CD4 stratified by 
change in MCV at 6 months to predict poor adherence were 86.5% and 37.3% respectively 
for all eligible patients. For patients on AZT-based regimens the variables associated with 
poor adherence at 6 months were change in CD4 count at 6 months (≥ expected; aRR 1 and < 
expected; aRR 7.66 95% CI 0.98 – 59.91) and pregnancy during the first 6 months on ART 
(Never pregnant; aRR 1 and pregnant during follow up; aRR 9.11 95% CI 2.17 – 38.25). 
Sensitivity and specificity of the change in CD4 count at 6 months to predict poor adherence 
were 64.7% and 75.2% respectively for all eligible patients on AZT-based regimens. 
Sensitivity and specificity of pregnancy during the first 6 months on ART to predict poor 
adherence were 20% and 97.6% respectively for all eligible patients on AZT-based regimens. 
 
 Discussion: Change in CD4 count stratified by change in MCV at 6 months was an expected 
marker of adherence as CD4 count is expected to rise in adherent patients on ART and since 
most patients (62.9%) were on d4T or AZT-based regimens. Pregnancy during the first 6 
months on ART appeared as a marker of adherence for patients on AZT-based regimens 
before multiple imputation possibly due to missing data hence results for this variable should 
be interpreted with caution. Contrary to previous studies, self-reported adherence was not 
associated with poor adherence at 6 months before multiple imputation. This could have been 
due to the fact that that > 50% of patients had missing data for this variable. The variable is 
also vulnerable to recall and reporting bias so even after multiple imputation, the area under 
the receiver operating characteristic (ROC) curve remained < 0.55. The number of missed 
medical visits and regimen change were also markers of adherence in a few of the models 
after multiple imputation and require further investigation. In conclusion, the markers of 
adherence to ART are change in CD4 count stratified by change in MCV at 6 months and 
pregnancy during the first 6 months on ART for patients on AZT-based regimens. These 
could help health workers identify poor adherence in the absence of viral load testing and 
target patients for adherence interventions to prevent virological failure.  
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CHAPTER ONE 
 
INTRODUCTION: 
In this chapter, the extent of the Human Immunodeficiency Virus (HIV) and Acquired 
Immune Deficiency Syndrome (AIDS) globally, regionally and in South Africa is presented. I 
also introduce key elements from the guidelines for antiretroviral therapy (ART) provision in 
South Africa. Good adherence to ART is defined and the consequences of poor adherence are 
outlined. The definition of a marker of adherence is also given. Adherence assessment, as 
carried out at Themba Lethu Clinic, is outlined and the challenges of measuring adherence 
using different methods/markers are explained. The available literature on adherence and its 
surrogate and non-surrogate markers is also reviewed. From here the case for the need of 
ideal markers of adherence at Themba Lethu Clinic is made. The chapter ends with the aims 
and objectives of the study.   
 
1.1 Background:  
1.1.1 The global and South African situations: 
HIV/AIDS is a global pandemic, the impact of which has been mitigated by the provision of 
ART. The world had an estimated 34 million people living with HIV in 2010
(1)
. The majority 
of these (68%) were from sub-Saharan Africa
(2)
. Provision of ART is thus a major part of 
health service delivery on the subcontinent. In South Africa, about 5.6 million people were 
living with HIV in 2010, with a prevalence of 17.8% among 15 to 49 year olds
(3, 4)
. 
Approximately 1.5 million of those were in need of ART
(5)
. This translates to an unmet need 
for ART of about 45%
(6)
. 
 
1.1.2 Themba Lethu Clinic: 
Themba Lethu is one clinic providing ART in South Africa. It is an urban clinic, located at 
the Helen Joseph Hospital in Johannesburg. Johannesburg is located in Gauteng province, 
which has the second largest number of patients on ART in South Africa
(7)
. The clinic is an 
accredited public sector Comprehensive Care, Management and Treatment (CCMT) site for 
HIV positive patients. It was established in 2004 and is one of the largest single clinics 
providing HIV treatment in South Africa
(8)
. By October 2011, 21 101 patients had ever 
received ART at Themba Lethu Clinic. ART is initiated according to the South African 
National Guidelines
(7)
.  
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1.1.3 The South African National ART Guidelines: 
In 2004, adults were initiated on ART at a CD4 count of < 200 cells/mm
3
 regardless of World 
Health Organization (WHO) stage or WHO stage IV irrespective of CD4 cell (cluster of 
differentiation number 4 helper T lymphocytes) count. The first-line regimen was stavudine 
and lamivudine combined with either efavirenz or nevirapine (d4T/3TC/EFV or 
d4T/3TC/NVP). The second-line regimen was zidovudine and didanosine with ritonavir-
boosted lopinavir (AZT/ddI/LPV/r) 
(9)
. 
 
In 2010, the guidelines changed. ART was to be initiated at a CD4 count of ≤ 350 in pregnant 
women and tuberculosis (TB) co-infected patients. In patients with drug-resistant TB, ART 
was to be initiated as soon as possible regardless of CD4 count or WHO stage. In addition, 
the new first-line regimens became tenofovir and lamivudine or emtricitabine combined with 
either efavirenz or nevirapine (TDF/3TC/EFV, TDF/FTC/EFV, TDF/3TC/NVP or 
TDF/FTC/NVP). Where TDF was contraindicated, it was to be replaced with zidovudine 
(AZT) in the regimens (AZT/3TC/NVP or AZT/3TC/EFV). The new second-line regimen 
became AZT/3TC/LPV/r. For those previously on an AZT or a d4T-based first-line regimen, 
the new second-line regimen became TDF/3TC/LPV/r or TDF/FTC/LPV/r
(10)
. In September 
2011, the National Guidelines were updated again to make HIV-positive adults with a CD4 ≤ 
350 eligible for ART
(7)
.  
 
1.2 Statement of the Problem: 
One of the challenges of ART provision is ensuring adherence to the drugs. Unfortunately, 
there has been no clear consensus on the ideal way to monitor adherence in resource-limited 
settings. This means that poor adherence may go undetected.  
 
Patients at Themba Lethu Clinic have adherence measured by calculating the number of 
missed visits from visit schedules and by self-reporting
(7)
. There is no standardized method of 
measuring self-reported adherence and various studies have assessed it in different ways (11-
13)
. At Themba Lethu Clinic, self-reported treatment adherence is assessed at routine clinic 
visits and is based on the patient’s assessment of pills taken in the last week out of those 
expected to have been taken. Self-reported adherence in the electronic patient management 
system (TherapyEdge-HIV
TM
) at the site is categorised as > 90% (all pills), > 60-90% (most 
pills), > 30-60% (about half the pills), 10-30% (a few of the pills) and < 10% (none of the 
pills). Another proxy measure, missed visits (missed medical visit or missed ARV drug 
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pickup by at least 7 days), is also used to measure adherence
(14)
. Patients come for ARV 
pickups monthly for the first 6–12 months on treatment and, once stable, every 2 months 
thereafter. Patients also have a full blood count (FBC) from which mean cell volume of red 
blood cells (MCV) is obtained, CD4 count and viral load in accordance with the National 
Guidelines
(7, 9, 10, 15)
.  Before 2010, the MCV was measured at baseline then at 1, 2, 3 and 6 
months on ART then 6 monthly for patients on AZT-based regimens. The 2010 National 
ART Guidelines then stipulated that MCV was to be measured only at baseline, 1, 2, 3 and 6 
months on ART for patients on AZT-based regimens. The latest (2013) National ART 
Guidelines, however, stipulate that an FBC, from which MCV is obtained be done only at 3 
and 6 months for patients on AZT-based regimens (15). For patients taking an AZT-based 
regimen, after 1 month of treatment, the MCV rises above the normal range (80 – 100fL) (16, 
17)
. Before 2010, CD4 count and viral load were both measured at baseline then 6 monthly 
thereafter. Between 2010 and 2013, the CD4 count was measured at baseline then at 6 
months, 1 year and yearly thereafter once on ART. Based on the latest (2013) National 
Guidelines, CD4 count is now measured at baseline and one year only, meaning that 
subsequent monitoring of a patient’s response to ART is done by viral load(15). The viral load 
is measured at 6 months, 1 year and yearly thereafter. The MCV measured as part of an FBC 
costs R124.60 per test while a CD4 count test costs R88.20 per test. 
 
Of these methods, viral load is the most reliable marker of adherence. It is the gold standard 
measure of adherence (14, 18, 19). Studies have shown that measuring viral load at 6 months is a 
reliable indicator of adherence or effectiveness of treatment (20, 21). A viral load of < 400 
copies/ml indicates good adherence while a viral load of ≥ 400 copies/ml indicates poor 
adherence. Viral load is an expensive test (R606.40 per test). It, however, serves as the 
benchmark against which the efficacy of other routinely collected and more affordable 
markers in this study will be assessed as measures of adherence. Routinely collected markers 
found to be dependable measures of adherence will then be used to assess adherence at each 
visit.       
 
1.3 Justification for the study: 
1.3.1 Definition of a marker: 
For the purposes of this study, a marker was defined as a variable that gives an indication of 
whether adherence is good or poor. Markers may be surrogate or non-surrogate.  
 
 4 
 
1.3.2 Surrogate markers: 
The surrogate clinical markers of adherence are viral load, CD4 cell count, MCV for patients 
on AZT, serum lactate for patients on d4T and serum lipid levels for patients on protease 
inhibitors (PIs)
(12, 17, 22, 23)
. Serum lactate and lipid levels are not measured routinely at 
Themba Lethu Clinic
(7)
. Since all the markers have disadvantages, using a combination of 
markers could give a more reliable measure of adherence. This study thus aims to identify a 
group of already routinely performed, affordable tests that can be used as markers to assess 
adherence levels, using viral load as the gold standard. Having these markers could help 
clinic staff improve adherence thereby improving the health of the individual patient by 
lowering viral load. A patient with an undetectable viral load is less likely to transmit the 
virus and, in case of transmission, is less likely to transmit drug-resistant viral strains.  
 
1.3.3 Non-surrogate markers for measuring adherence:  
Measuring drug levels in serum or hair could be considered the ideal way to test for 
adherence
(24, 25)
. This is because these are non-surrogate clinical measures. In addition, 
measuring drug levels in serum or hair may help in the detection or prevention of drug 
toxicity, which can lead to poor adherence
(11)
. Unfortunately, serum drug levels, unlike drug 
levels in hair, have the disadvantage of detecting only recent adherence
(11, 24)
. They are thus 
vulnerable to white coat adherence
(11)
. This is full adherence for a short interval prior to a 
clinic visit, making serum drug monitoring unreliable
(26)
. Another disadvantage of therapeutic 
drug monitoring using serum drug levels is the fact that it cannot routinely measure 
nucleoside reverse transcriptase inhibitor (NRTI) levels because active moieties are 
intracellular. In other words in vivo correlates are with intracellular NRTI concentrations 
rather than plasma NRTI concentrations
(11, 16)
. An additional disadvantage is the substantial 
intra-patient variation in drug concentrations (11, 16). Furthermore drug levels in serum and hair 
may be low for reasons other than poor adherence e.g diet, drug interactions
(11)
. Measuring 
serum or hair drug levels is also expensive (approximately R385 for a 4 ARV drug panel) and 
is not routinely performed at any HIV treatment site. Directly observed therapy (DOT) is 
another non-surrogate measure for enhancing and monitoring adherence
(27, 28)
. This, however, 
requires the guaranteed presence of a constant treatment supporter who is willing and able to 
directly observe medication being taken correctly and may, thus, may not be practical. 
 
Considering the large number of patients on ART, any marker of adherence should not only 
already be routinely collected and affordable but should also be obtainable without causing 
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lengthy waiting times. The latter cannot be said about pill count, which is discussed in more 
detail below.    
 
 
1.4 Literature review: 
1.4.1 Adherence: 
Good adherence means taking at least 95% of the correct medication, in the correct 
quantities, at the correct time and following any associated recommendations such as those 
pertaining to food
(13, 29-33)
. EFV, for example, should be taken on an empty stomach or with a 
low fat meal
(16)
. The widely accepted definition of using 95% was derived from a prospective 
observational study by Paterson and colleagues (2000), of patients on unboosted protease 
inhibitors (PIs) in the USA
(34)
. Other studies have, however, shown that less than 95% or at 
least 80% adherence may be sufficient to maintain virological suppression
(21, 35, 36)
. For this 
reason, some studies on adherence have used definitions of taking at least 80% of prescribed 
medication as good adherence
(37, 38)
, whilst others have defined good adherence as taking at 
least 90% of prescribed medication
(39, 40)
.  
 
Despite the varying definitions of adherence, there is consensus that the highest possible level 
of adherence needs to be achieved to delay the development of drug resistant viral strains, 
and thus preventing clinical deterioration. Furthermore, patients who are adherent are less 
likely to transmit the virus to others. The public health implications of transmission of drug 
resistant strains include the need for newer, more expensive drugs. Other studies have thus 
gone on to distinguish between complete (100%) and incomplete adherence (< 100%) (41, 42).  
 
A cross-sectional survey of adult adherence in countries on different continents found that 
“overall, 57% of patients reported a 30-day recall of 100% adherence (Latin America: 89%; 
Africa: 73% vs North America: 45% and Asia Pacific: 47%) 
(38)
.” In the same study, 77% of 
Africans reported adherence of over 80%. An earlier meta-analysis had similar findings with 
73% of patients in Sub-Saharan Africa found to be adherent as compared to 55% in North 
America
(43)
. Other cross-sectional studies done on levels of adherence in adults in developed 
and developing countries have found levels of over 70% per patient
(13, 31)
.   
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1.4.2 Surrogate methods for measuring adherence: 
A variety of surrogate methods are used to assess adherence around the world
(43)
. 
Adherence measurements using micro-electronic monitoring (MEM) are said to correlate 
more closely with viral load
(11)
. MEM is, however, considered too costly for developing 
countries (R1148 to R1283 per cap). In addition, it is vulnerable to technological 
malfunction
(11)
. Furthermore, it tells you the time the pill bottle was opened but not whether 
medication was actually taken or whether food restrictions were adhered to. MEM may also 
underestimate adherence rates among patients who remove an additional dose from their pill 
bottle with the intention of taking it later, making the use of pill boxes problematic
(11, 33)
. 
 
Pill count is prone to error as the patient may remove medication and throw it away so this 
measure may be more accurate if the pill count is unannounced
(36, 44)
. It is also time-
consuming and does not tell you whether the medication was taken at the correct time with 
the appropriate dietary requirements. Self-reporting, on the other hand, is subject to errors 
from patient recall or dishonesty
(11, 12)
. This introduces bias and creates misclassification of 
adherence levels. The visual analogue scale (VAS) is also used for self-reported adherence 
measurement. It relies on patients estimating their adherence by placing a mark on the scale. 
Despite being less-time consuming, it is subject to the same errors of patient recall and 
dishonesty found with ordinary self-reporting. In confirmation of the limitations of both 
methods, one prospective cohort study by Kunutsor and co-workers in Uganda (2010), found 
no difference in adherence levels by self-reporting and by pill count
(45)
. A meta-analysis by 
Nieuwkerk and colleagues (2005), however, determined that “self-reported adherence 
measures can distinguish between clinically meaningful patterns of medication-taking 
behaviour
(19)
.” In other words, self-reported adherence measures were found to distinguish 
between poor and good adherence as defined by detectable and undetectable viral loads 
respectively.  
 
Appointment keeping may also be used to estimate adherence
(14)
. On-time drug pick up does 
not, however, guarantee adherence
(46)
. In addition, an adherent patient who misses an 
appointment due to having enough medication left over cannot be classified as non-adherent. 
 
Surrogate clinical methods, on the other hand, may be specific for the type of drug the patient 
is on. In addition, these methods detect long-term adherence but are poor at detecting recent 
adherence levels. An example is MCV for patients on AZT
(12, 17, 47, 48)
. This is because, in 
 7 
 
virtually all patients on AZT, after 4 weeks of AZT use, the MCV rises above the normal 
range (80-100fL)
(16, 17)
. Mugisha and colleagues (2012) reported that 12 weekly MCV 
measurements may be useful in monitoring adherence to AZT-containing regimens in low-
income countries, where HIV RNA may be unavailable
(18)
. Some studies have also shown 
elevation of MCV in patients on d4T 
(12, 47, 48)
. Studies have found that patients with 
virological failure have significantly smaller mean increases in MCV
(12, 49)
. An elevated MCV 
may, however, also be due to other factors such as vitamin B12 and/or folic acid deficiency, 
hepatic disease and alcoholism. The most common cause of HIV treatment failure is poor 
adherence. CD4 cell count may thus also be used as a surrogate clinical method to monitor 
adherence. Caution is needed in interpreting results, however, as it is a poor predictor of 
treatment failure
(50-53)
. Viral load remains the more reliable indicator of treatment failure and, 
hence, a more suitable proxy against which to gauge the reliability of other potential markers 
of adherence
(14, 54)
. Furthermore, there is no consensus on the expected rate of CD4 count rise 
for patients on ART
(16, 55-57)
. Interestingly, another prospective study by Oyugi and co-
workers in Uganda (2004), found no difference in adherence levels measured by clinical 
(viral load) or non-clinical methods (self-report, visual analogue scale, MEM and pill count) 
(54)
. Surrogate and non-surrogate methods for measuring adherence are summarized in 
Appendix 1. 
 
1.4.3 Factors that influence adherence: 
When looking at ways to measure adherence, it is also important to consider the factors that 
influence adherence. This is because they may confound any relationship between markers 
and adherence levels. These factors are similar across various studies in both developed and 
developing countries. Younger age, for example, has been associated with poorer 
adherence
(33, 45, 58-60)
. Gender has also been cited by some researchers. For instance, Godin 
and colleagues in a longitudinal study in the USA (2005), found male gender to be a predictor 
of good adherence
(61)
. Maqutu and co-workers in a retrospective review of patient records in 
South Africa (2011), also found that males have better adherence than females but discovered 
that after the age of 50, females have better adherence levels than males
(32)
.  
 
Poor adherence may also result from inadequate adherence education, stigma and non-
disclosure
(61-63)
. In addition, Muyingo and co-workers in the Development of Antiretroviral 
Therapy in Africa (DART) trial in Uganda and Zimbabwe (2008), found that complete 
(100%) adherence was independently associated with having only one sexual partner
(41)
. 
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Adverse effects, complexity and pill burden of ARV regimen and co-morbidities have also 
been associated with poor adherence
(41, 44, 58, 63, 64)
. Comorbidities compound the problem of 
pill burden and may also impair the ability to adhere due to aggravating severe ill health thus 
affecting memory or strength to take medication. In particular, neurocognitive 
impairment/mental ill health, including that resulting from substance abuse, are known to 
compromise adherence
(33, 58, 63, 65)
. Furthermore, forgetfulness in the absence of severe ill 
health or impaired neurocognitive function, being away from home and leaving medications 
at home, have all been cited as contributors to poor adherence
(21, 41, 44, 62, 63)
.   
 
Low CD4 count at ART initiation is another factor that has been linked to poor adherence
(41)
. 
Low education levels and lack of support from a partner have also been associated with poor 
adherence
(21, 58)
. Cultural or religious beliefs contrary to adherence, lack of faith in treatment, 
poor patient-provider relationship and inability to get time off work are other factors 
associated with poor adherence.
(10, 16, 61, 63, 65, 66)
. Political unrest, natural disaster and drug 
shortages could also result in poor adherence.   
 
In essence, surrogate measures have been used to assess adherence, particularly in resource-
limited settings since they are cheaper. There is consensus on viral load as the gold standard 
proxy marker of adherence but no consensus on the ranking of other surrogate measures. It is 
this lack of consensus, together with the high cost of viral load, MEM and non-surrogate 
measures that has prompted a study on suitable markers of adherence at Themba Lethu 
Clinic, while taking into consideration the factors that influence adherence. 
 
1.5 Study aims and objectives: 
1.5.1 Study question: 
What are the markers of adherence to treatment among HIV positive adults on ART at 
Themba Lethu Clinic? 
 
1.5.2 Aim: 
To identify variables that can be used routinely to assess adherence to ART at Themba Lethu 
Clinic in Johannesburg, South Africa, using viral load as the gold standard. 
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1.5.3 Objectives: 
1. To describe the demographic and clinical characteristics of patients over the age of 18, 
initiated on ART between 1
st
 April 2004 and 1
st
 January 2012 at Themba Lethu Clinic.  
2. To identify any differences in adherence levels of the study subjects by demographic and 
clinical characteristics, using viral load at 6 months as the gold standard to define adherence 
or effectiveness of treatment. 
3. To identify affordable and routinely collected variables or markers of adherence, using 
viral load at 6 months as the gold standard to define adherence or effectiveness of treatment. 
4. To find the sensitivity, specificity, positive predictive values, negative predictive values 
and receiver operating characteristics of the identified markers of adherence. 
5. To identify affordable and routinely collected variables or markers of adherence, using 
viral load at 6 months as the gold standard to define adherence or effectiveness of treatment, 
in a subgroup of patients with a documented viral load at 6 months but excluding patients 
with a documented history of prior ART use such as NVP prophylaxis and patients changed 
to a non-standard ART regimen or second-line ART before 6 months on treatment.  
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CHAPTER TWO 
 
MATERIALS AND METHODS: 
This chapter describes materials and methods that were used and includes study design, study 
population, inclusion and exclusion criteria and source of data. The outcome variable, 
explanatory variables and all other covariates are outlined. In addition, data processing and 
analysis procedures are described. 
 
2.1 Data source: 
Data were obtained from the electronic management system called TherapyEdge-HIV
TM
. 
This system contains data on the Themba Lethu clinical cohort, which is made up of HIV 
positive patients on ART at Themba Lethu Clinic. Data have been entered into this system 
since the inception of the cohort in 2004
(7)
. The data are collected routinely for monitoring of, 
evaluation of and reporting on, the progress of the cohort. The progress is measured using 
records in the database on patient vitals (height, weight, Body Mass Index (BMI) and blood 
pressure), appointment keeping, ART regimen, the use of cotrimoxazole prophylaxis, other 
drugs prescribed, self-reported adherence, HIV-related opportunistic infections such as TB, 
non-HIV-related medical and surgical conditions and results of laboratory tests such as CD4 
count, viral load, full blood count, liver function tests, renal function tests and treatment 
outcomes (down-referral, transfer out, loss to follow-up or death). The database is the ideal 
source of information as it captures demographic and treatment-related information on all 
patients in the cohort. These data are also ideal to answer the research question as Themba 
Lethu is one of the largest single clinics providing ART in South Africa
(8)
. Prior to 2007, data 
were entered from patient files into the database. Currently data are entered into the system as 
the patient is being seen. Laboratory results are downloaded from the National Health 
Laboratory Service (NHLS) database directly into TherapyEdge-HIV
TM
.  
 
2.2 Study design: 
This was a retrospective cohort design using secondary data taken from the TherapyEdge-
HIV
TM 
database. The design was suitable for comparing baseline measures with outcome 
measures and exploring the effects of several demographic and clinical level exposures on 
adherence.  
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2. 3 Patient selection and eligibility criteria: 
Being a retrospective study using secondary data, the analysis included all patients in the 
TherapyEdge-HIV
TM 
database who met the eligibility criteria. 
 
2.3.1 Inclusion criteria:  
The following inclusion criteria were adhered to: 
- ART-naïve patients aged 18 years and above initiated on a standard first-line ART regimen 
between 1
st
 April 2004 and 1
st
 January 2012 at Themba Lethu Clinic. The standard first-line 
regimens considered were either of the following: d4T/3TC/EFV, d4T/3TC/NVP, 
TDF/3TC/NVP, TDF/FTC/NVP, TDF/3TC/EFV, TDF/FTC/EFV, AZT/3TC/EFV or 
AZT/3TC/NVP
(9, 10)
. Patients included had been on ART for at least 6 months.  
 
2.3.2 Exclusion criteria: 
-Patients under 18 years of age. 
-Patients initiated on ART before 1
st
 April 2004 or after 1
st
 January 2012. 
-Patients initiated on ART outside Themba Lethu Clinic. 
-Patients with a history of prior ART use as evidenced by a baseline viral load of < 400 
copies/ml or in the absence of a baseline viral load, a baseline CD4 count of > 1000 
cells/mm
3
 with a baseline WHO stage that was I, II or missing.  
-Patients initiated on a non-standard first-line ART regimen. 
-Loss to follow up (LTFU) within the first 6 months on ART i.e being more than 3 months (> 
90 days) late for a scheduled visit
(67)
. 
-Transfer out or death within the first 6 months on ART.  
 
2.3.3 Rationale for eligibility criteria: 
The eligibility criteria focussed on HIV-positive ART-naïve adults so that we obtain a 
homogenous study sample. These individuals were initiated on the same standard ART 
regimens, formulations and doses at initiation. The purpose was to minimize the confounding 
effect of different physiological and treatment-related factors. On the other hand, patients 
with a history of ART use may have residual resistance to ART and may exhibit a dissimilar 
and poor virological response despite good adherence.  
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2. 4 Measurement: 
2.4.1 Working definitions: 
 (a) Three month period: This was defined as 70 to 110 days after ART initiation to cater for 
people who may come earlier or later for their three month visit.  
 (b) Six month period: The value for a variable at 6 months was defined as the first available 
value 150 to 300 days after initiation. According to the National Guidelines, the first CD4 
count and first viral load should be done at 6 months. In some patients, however, it was found 
to have been done a bit earlier or later, hence the use of 150 to 300 days. Likewise, for some 
patients MCV and CD4 count at 6 months were found to have been done a bit earlier or later, 
hence the use of 150 to 300 days.   
(c) The end point: was defined as the date of doing the first viral load, 150 to 300 days after 
ART initiation. For the sensitivity analysis, however, where the end-point viral load was 
missing, the end-point was set at 183 days after ART initiation i.e 30.5 days × 6 as 6 months 
is usually a period of about 183 days. 
  
2.4.2 Outcome and explanatory variables and their definitions/categories: 
Outcome variable: 
Adherence at 6 months measured by viral load at 6 months (gold standard): The first viral 
load done 150 to 300 days after ART initiation. This could be undetectable (< 400 copies/ml, 
a proxy for good adherence) or detectable (≥ 400 copies/ml, a proxy for poor adherence). 
 
Explanatory variables: 
Demographic characteristics 
1. Gender: male or female. 
2. Age at ART initiation: ≤ median age or > median age. 
3. Education level at ART initiation: ≥ secondary school, primary school or < primary school 
4. Professional status at ART initiation: Employed or unemployed. 
 
Clinical characteristics: 
1. Self-reported adherence: This is the patient’s assessment of pills taken in the last week 
computed to a percentage. This variable was assessed as the last self-reported adherence 
levels on, or after, the 3 month visit (70 days post-initiation) and not more than 3 months 
(110 days) before the date of the viral load but at least 28 days before the viral load was done. 
The range was selected to capture adherence for as many patients as possible in light of the 
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noted inconsistency in adherence measurement. The range was also chosen as a reasonable 
period within which documented adherence may have an impact on the viral load at the end 
of the study period. Self-reported adherence in the electronic patient management system 
(TherapyEdge-HIV
TM
) at the site is categorized as > 90% (all pills), > 60 – 90% (most pills), 
> 30 –60% (about half the pills), 10 – 30% (a few of the pills) and < 10% (none of the pills) 
(Appendix 2). Since there were very few people in the latter 3 categories, the variable was 
categorized as > 90%, > 60 – 90% and ≤ 60%. 
2. Number of missed visits during the study period: A missed visit was defined as a 
scheduled appointment that had been missed by 7 or more days
(14)
 but less than 91 days as 
missing by over 90 days is LTFU
(67)
. The variable was categorized as missed visits, missed 
ARV visits and missed medical visits. Each of these categories was further broken down into 
0, 1 or ≥ 2 missed visits. An ARV visit is scheduled for refilling of ARV medication and 
involves the taking of weight and/or height as well as adherence assessment and TB 
screening. A medical visit involves all the components of an ARV visit, more comprehensive 
clinical assessment and scheduled laboratory tests.  
3. BMI (Body Mass Index) at initiation: This is calculated as weight in kg ÷ (height in 
metres)
2
.
 
The variable was thus categorized according to the WHO classification as ≥ 
30kg/m
2
 (obese), 25 – < 30kg/m2 (overweight), 18.5 – < 25 kg/m2 (normal) and < 18.5kg/m2 
(underweight). 
4. BMI (Body Mass Index) at 6 months: The variable was also categorized according to the 
WHO classification as ≥ 30kg/m2 (obese), 25 – < 30kg/m2 (overweight), 18.5 – < 25 kg/m2 
(normal) and < 18.5kg/m
2
 (underweight). 
5. Baseline haemoglobin level. This was thus categorized as ≤ 8g/dl and > 8g/dl. 
6. Haemoglobin level at 6 months. This was also categorized as ≤ 8g/dl and > 8g/dl. 
7. MCV at baseline: mean cell volume at baseline. The normal range is 80 – 100fL. The 
variable was thus categorized as < 80fL (low), 80 – 100fL (normal) and > 100fL (high). 
8. MCV at 6 months: mean cell volume at 6 months. The variable was also categorized based 
on the normal range as < 80fL (low), 80 – 100fL (normal) and > 100fL (high).  
9. Change in MCV at 6 months: The difference between the MCV at baseline and the MCV 
at 6 months i.e MCV at 6 months ─ MCV at baseline. Kamya and colleagues (2007) 
demonstrated that adults on ART with virological suppression, had significantly higher mean 
increases (14.5 ± 0.4 fL) than those without virological suppression (5.6 ± 2.4fL) 
(49)
. The 
variable change in MCV at 6 months was thus categorized as ≥ 14.5fL and < 14.5fL.  
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10. CD4 cell count at baseline: The normal range is 500 – 1500 cells/mm3. The variable was 
categorized as > 200 cells/mm
3
, 101 – 200 cells/mm3, 51 – 100 cells/mm3 and ≤ 50 
cells/mm
3
. These are categories that have been used in previous studies (14, 68). 
11. Change in CD4 count at 6 months in cells/mm
3
: The difference between the CD4 count at 
6 months (the first CD4 count done 150 to 300 days after initiation) and the CD4 count at 
baseline i.e CD4 count at 6 months – the CD4 count at baseline. CD4 count is expected to 
rise by 100 cells/mm
3
/year or 50 cells/mm
3 
in 6 months
 (14, 16, 55)
. The variable was thus 
categorized as follows: 
 ≥ expected (≥ 100 cells/mm3/year × duration of treatment in years). 
 < expected (< 100 cells/mm3/year × duration of treatment in years). 
12. WHO stage at baseline categorized as WHO stage I – IV. 
13. Regimen change:  
 No: Remained on the same first-line regimen prescribed at initiation during the study 
period. 
 Yes: Regimen changed during the study period. 
14. TB: Whether or not the patient was on TB treatment during the first 6 months on ART: 
 Never: Never on TB treatment during the study period. 
 At baseline: On TB treatment at baseline. 
 During follow up: Started TB treatment during follow-up. 
15. Pregnancy: Whether or not the patient was pregnant during the first 6 months on ART: 
 Never: Never pregnant during the study period. 
 At baseline: Pregnant at baseline. 
 During follow up: Pregnant during follow-up. 
16. Adverse events or side effects: Whether or not the patient experienced at least one of the 
following during the first 6 months on treatment as a result of ART: peripheral neuropathy, 
lipodystrophy, lactic acidosis, pancreatitis, anaemia (haemoglobin ≤ 8g/dl), NVP rash, rash 
due to EFV, renal toxicity, hepatotoxicity, neuropsychiatric disturbances.   
 
2. 5 Data management: 
2. 5 .1 Data cleaning and coding: 
Data were exported from TherapyEdge-HIV
TM
 as raw csv files then imported into SAS, for 
cleaning. Analytic datasets were made; some were wide files (single observation per patient) 
while others were long files (multiple observations per patient). The relevant data were then 
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exported from SAS into STATA Release 12.1 (StataCorp, College station, Texas) for 
analysis.  
 
These data were contained in 7 datasets containing information on: 
 Socio-demographic variables, baseline CD4 count, baseline viral load and baseline 
WHO stage, date of ART initiation and first ART regimen. 
 Treatment outcomes (down-referral, transfer out, loss to follow-up or death). 
 ARV drug use including begin and end dates and doses. 
 Appointment keeping (scheduled and visit dates). 
 Self-reported adherence 
 Patient vitals including height, weight, Body Mass Index (BMI) and blood pressure. 
 TB treatment start and stop dates. 
 Medical conditions classified according to ICD10 (International Classification of 
Diseases: 10
th
 revision) and drugs that caused the condition, where applicable. 
 Lab tests done, lab test dates and lab results. 
 
The data underwent further cleaning and patients that did not meet the eligibility criteria were 
dropped from the analysis. Inconsistent and extreme values were also corrected where 
information was available. Values that were erroneous were set to missing. Thereafter 
datasets were merged, creating a single wide file for data analysis.  
 
2.5.2 Statistical methods: 
Descriptive Statistics: 
The demographic and clinical characteristics (at baseline and 6 months) were described using 
frequencies with percentages for categorical variables and medians with interquartile ranges 
(IQRs) for continuous variables that were not normally distributed. Means and standard 
deviations were used for continuous variables that were normally distributed.  
 
Inferential Statistics: 
Inferential statistics were used to identify any differences in adherence levels of the study 
subjects by demographic and clinical characteristics, using viral load at 6 months to define 
adherence or effectiveness of treatment.  
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Hypothesis:  
There is an association between demographic and clinical characteristics and adherence level 
measured using viral load at 6 months. 
 
(a) For all patients, comparison of those with detectable and undetectable viral load at 6 
months was done for all the variables. The chi-square test was used for categorical variables 
and the t-test was used for continuous variables and p-values were obtained. Non-parametric 
tests (Wilcoxon rank sum test or median test) were used for continuous variables that were 
not normally distributed. A p-value of ≤ 0.05 was considered significant.   
 
(b) For patients on AZT, comparison of those with detectable and undetectable viral load at 6 
months was done for all the variables. The chi-square test and Fisher’s exact test were used 
for categorical variables and the t-test was used for continuous variables and p-values were 
obtained. Non-parametric tests (Wilcoxon rank sum test or median test) were used for 
continuous variables that were not normally distributed. A p-value of ≤ 0.05 was considered 
significant.   
 
Univariate and multivariate regression analyses: 
Log-binomial regression using RRs was replaced with Poisson regression with robust error 
variance due to the frequent occurrence of failure to converge. Poisson regression with robust 
error variance was thus used to identify affordable and routinely collected variables or 
markers of adherence using viral load at 6 months to define adherence or effectiveness of 
treatment. The IRRs were used to approximate the RRs of poor adherence.  
 
Univariate analysis: 
Association of each individual variable to viral load at 6 months was assessed. Incidence rate 
ratios (IRRs) were obtained and a p-value of ≤ 0.05 was considered significant.   
 
Multivariate analysis: 
Multivariate Poisson regression analysis with robust error variance was done first for all 
eligible patients then for all eligible patients on AZT-based regimens. Variables with a p < 
0.2 on univariate analysis were selected for the construction of the multivariate regression 
models. A p < 0.2 was used as variables that are associated with the viral load at 6 months 
may appear to have no significant association at the 5% level on univariate analysis due to 
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confounding factors. In a model with other variables, however, some variables with a p > 
0.05 and < 0.2 on univariate analysis may be found to be significantly associated with the 
viral load at 6 months (p ≤ 0.05) on multivariate regression analysis. The variables (with p < 
0.2 on univariate analysis) were added into the multivariate model one after the other. With 
each variable added, Akaike’s and Schwarz’s Bayesian information criteria (AIC and BIC) 
were assessed to find out which variable had the biggest effect on the AIC and BIC statistics. 
Variables that did not improve the model were left out except for CD4 count at baseline, 
gender and age at initiation. Interaction terms were then used to identify any significant 
interactions for inclusion in the model. A variable that had a significant interaction with 
another was stratified by the other variable, to create a new variable that was put into the 
model in place of the two interacting variables. Model fit was assessed using the link test 
(specification link test for single equation models) and p ≤ 0.05 was considered significant. 
The diagnostic accuracy of each identified marker of adherence was tested using sensitivity, 
specificity, positive predictive values (PPVs) and negative predictive values (NPVs). 
Receiver operating characteristics (ROCs) of each identified marker of adherence were also 
investigated.  
 
Sensitivity analyses: 
Descriptive and inferential analyses including Poisson regression (with robust error variance) 
were done by assuming that all patients with a missing viral load result at the end-point had a 
viral load measurement of < 400 copies/ml. This was done first for all patients then for all 
patients on AZT-based regimens. The analyses were repeated assuming that all patients with 
a missing viral load had a viral load measurement of ≥ 400 copies/ml.  
 
Subgroup analysis: 
A subgroup analysis was then done for patients with a viral load at 6 months, excluding 
patients with a documented history of prior ART use such as NVP prophylaxis and patients 
changed to a non-standard ART regimen or second-line ART before 6 months on treatment. 
Poisson regression with robust error variance was done first for all eligible patients then for 
all eligible patients on AZT-based regimens.  
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Other analyses: 
Since the viral load may be done as early as 4 months after ART initiation at Themba Lethu 
Clinic (7), analyses were repeated for all patients with a documented viral load done 90 – 270 
after ART initiation. 
 
Multiple imputation: 
Multiple imputation was done using multivariate normal regression. It was done for all 
patients with a documented viral load result, using explanatory variables with missing values. 
New models were fitted first for all patients then for all patients on AZT-based regimens, 
using the data with imputed values. The equal fractions missing information test (FMI test) 
was used to assess model fit and whether additional variables improved the model. Variables 
that did not improve the model were left out except for CD4 count at baseline, gender and age 
at initiation.   
 
2.6 Ethical considerations: 
TherapyEdge-HIV
TM
 data are covered by Ethical Approval Clearance Certificate Number 
M110I40. Permission to use this data was obtained from the Clinical HIV Research Unit 
(CHRU) of the University of the Witwatersrand (Appendix 10). The study was approved by 
the University of the Witwatersrand Human Research and Ethics Committee; Clearance 
Certificate number M120858 (Appendix 11). The Medical Superintendent of Helen Joseph 
Hospital authorised use of the data after receiving the Ethical Clearance Certificate and a 
signed confidentiality agreement (Appendix 12).  All data provided had no personal 
identifiers. 
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CHAPTER THREE 
 
RESULTS:  
In this chapter, the results of data analysis are presented. This begins with a step by step 
breakdown of the initial number of patients and how they were reduced to produce the final 
cohort for data analysis. The rest of the data are presented in tables. Firstly, baseline 
characteristics are presented. This is followed by results depicting the association of the 
variables to the viral load at 6 months in univariate and multivariate Poisson regression 
models with robust error variance. Results after multiple imputation are also presented. 
Sensitivity, specificity, PPV, NPV and ROC curves of identified markers of adherence are 
also presented. The effect of patients excluded due to missing viral load at the end-point is 
assessed through sensitivity analyses. 
 
3.1 SELECTION PROCESS FOR ELIGIBLE PATIENTS: 
This section shows the process by which patients were dropped from the study based on the 
exclusion criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26278 patients initially 
432 patients not initiated 
at Themba Lethu Clinic. 
2034 patients started on a 
non-standard first-line 
regimen.   
125 patients below the 
age of 18 years.  
3219 patients initiated 
before 1
st
 April 2004 or 
after 1
st
 January 2012. 
983 patients that were not 
ART naïve (viral load < 
400 copies/ml at baseline 
or in the absence of viral 
load, a baseline CD4 
count > 1000 cells/mm
3
 
with a baseline WHO 
stage that was I, II or 
missing).  
). 
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Figure 1: Patient flow chart for selection of patients eligible for the study 
Patients who were not eligible for the study are shown in the boxes on the right. These 
patients were dropped from the dataset of 26278 patients, leaving 14384 patients, for whom 
sensitivity analyses were done to minimize selection bias. From the 14384 patients, a further 
7224 patients with no documented viral load at 6 months, were dropped, leaving 7160 
patients for the main analysis of the study. The baseline and 6 month characteristics as well 
as the poisson regression results were then compared to the results of the main analysis. To 
minimise selection bias, multiple imputation was also done, for exposure variables with 
missing values. The baseline and 6 month characteristics as well as the poisson regression 
results of this data were also compared to the results of the main analysis. 
14384 patients for the sensitivity analysis 
7160 patients eligible for the study  
7224 patients with no viral 
load at 6 months. 
1738 patients with no 
documented scheduled visit 
in the first 6 months on 
ART. 
3363 patients lost to follow 
up, transferred out or dead 
before 6 months on ART. 
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3.2: STATISTICAL ANALYSIS 
3.2.1: Descriptive analysis:  
In this section the baseline and 6 month characteristics of patients in the study with a documented viral load result at 6 months are presented. 
 
 Table 1a: Baseline demographic characteristics and their associations with poor adherence for all eligible patients and eligible patients 
on AZT-based regimens with a documented viral load result 
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 7160 
Viral load 
< 400 copies/ml 
N = 5806 
Viral load 
≥ 400 copies/ml 
N = 1354 
P-value Total 
N = 177 
Viral load 
< 400 copies/ml 
N = 143 
Viral load 
≥ 400 copies/ml 
N = 34 
P-value 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Gender  
Females               
Males 
 
4523 (63.2%) 
2637 (36.8%) 
 
3716 (64%) 
2090 (36%) 
 
807 (59.6%) 
547 (40.4%) 
 
0.002 
 
97 (54.8%) 
80 (45.2%) 
 
82 (57.3%) 
61 (42.7%) 
 
15 (44.1%) 
19 (55.9%) 
 
0.164 
Age at initiation in years 
Median (IQR) / Mean ± 
standard deviation (SD) 
 
 
36.7 (31.4 – 43.4) 
 
 
36.8 (31.6 – 43.5) 
 
 
36.3 (30.7 – 42.9) 
 
 
0.0204
Þ
 
 
 
41.2 ± 9.1 
 
 
41.8 ± 8.9      
 
 
38.4 ± 9.6      
 
 
0.0242
ƫ
 
Age at initiation in years 
≤ median (36.7)
α
 
> median (36.7) 
 
3603 (50.3%) 
3557 (49.7%) 
 
2901 (50.0%) 
2905 (50.0%) 
 
702 (51.8%) 
652 (48.2%) 
 
0.213 
 
60 (33.9%) 
117 (66.1%) 
  
43 (30.1%) 
100 (69.9%) 
 
17 (50%) 
17 (50%) 
 
0.027 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
Missing 
 
4482 (62.6%) 
910 (12.7%) 
220 (3.1%) 
1548 (21.6%) 
 
3573 (61.5%) 
744 (12.8%) 
184 (3.2%) 
1305 (22.5%) 
 
909 (67.1%) 
166 (12.3%) 
36 (2.7%) 
243 (17.9%) 
 
0.159 
 
94 (53.1%) 
24 (13.6%) 
7 (4.0%) 
52 (29.3%) 
 
76 (53.1%) 
18 (12.6%) 
6 (4.2%) 
43 (30.1%) 
 
18 (52.9%) 
6 (17.6%) 
1 (2.9%) 
9 (26.6%) 
 
0.840
ð 
Professional status    
Employed 
Unemployed 
 
3685 (51.5%) 
3362 (47.0%) 
 
3020 (52.0%) 
2700 (46.5%) 
 
665 (49.1%) 
662 (48.9%) 
 
0.078 
 
89 (50.3%) 
85 (48.0%) 
 
71 (49.7%) 
70 (49.0%) 
 
18 (52.9%) 
15 (44.1%) 
 
0.665 
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Missing 113 (1.5%) 86 (1.5%) 27 (2.0%) 3 (1.7%) 2 (1.3%) 1 (3.0%) 
* 
On AZT-based regimens throughout the study period. 
 α 
The median age at ART initiation for all eligible patients with a documented viral load result.  
Þ 
Wilcoxon rank sum 
test.
   ƫ 
t-test.
  ð Fisher’s exact test.  AZT: Zidovudine.  IQR: Interquartile range.  SD: Standard deviation. 
 
The table above shows the baseline demographic characteristics of all eligible patients and eligible patients on AZT-based regimens. The 
characteristics were described using frequencies with percentages and medians with interquartile ranges or means with standard deviations. Of 
the 7160 patients eligible for the study 18.9% had poor adherence while out of the 177 patients on AZT-based regimens, 19.2% had poor 
adherence. Almost two thirds of all eligible patients were female. This is not surprising as females are more vulnerable to HIV infection than 
men
(69)
. Their median age at initiation was 36.7 years (IQR: 31.4 – 43.4) but the overall age range at initiation was 18.1 – 74.4 years. The table 
also shows p-values for the association between different variables and poor adherence at 6 months measured by viral load at 6 months. Except 
where otherwise stated, the chi-square test was used. 
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Table 1b: Baseline clinical characteristics and their associations with poor adherence for all eligible patients and eligible patients on 
AZT-based regimens with a documented viral load result 
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 7160 
Viral load 
< 400 copies/ml 
N = 5806 
Viral load 
≥ 400 copies/ml 
N = 1354 
P-value Total 
N = 177 
Viral load 
< 400 copies/ml 
N = 143 
Viral load 
≥ 400 copies/ml 
N = 34 
P-value 
n (%)  n (%) n(%) n (%)  n (%) n (%) 
BMI at initiation in kg/m
2
 
Median (IQR) 
 
22 (19.1 – 25) 
 
22 (19.7 – 25) 
 
22  (19 – 25) 
 
0.260
 ϻ
 
 
22.7  (20.0 – 27) 
 
22.3  (20.0 – 29) 
 
23  (20 – 24.0) 
 
0.5455
 Þ
 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
Missing 
 
989 (13.8%) 
3330 (46.5%) 
1176 (16.4%) 
558 (7.8%) 
1107 (15.5%) 
 
782 (13.5%) 
2719 (46.8%) 
966 (16.6%) 
462 (8.0%) 
877 (15.1%) 
 
207 (15.3%) 
611 (45.1%) 
210 (15.5%) 
96 (7.1%) 
230 (17.0%) 
 
0.184 
 
19 (10.7%) 
68 (38.4%) 
20 (11.3%) 
24 (13.6%) 
46 (26.0%) 
 
17 (11.9%) 
51 (35.7%) 
16 (11.2%) 
23 (16.1%) 
36 (25.1%) 
 
2 (5.9%) 
17 (50%) 
4 (11.8%) 
1 (2.9%) 
10 (29.4%) 
 
0.109
ð
 
Baseline haemoglobin in g/dl 
Median (IQR) / Mean ± SD 
 
11.7 (10.1 – 13.1) 
 
11.7 (10.2 – 13.1) 
 
11.5 (10.1 – 13) 
 
0.0759
Þ
 
 
12.8 ± 1.8 
 
12.6 ± 1.8 
 
13.3 ± 1.4 
 
0.0838
ƫ
 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
336 (4.7%) 
6022 (84.1%) 
802 (11.2%) 
 
273 (4.7%) 
4901 (84.4%) 
632 (10.9%) 
 
63 (4.7%) 
1121 (82.8%) 
170 (12.5%) 
 
0.951 
 
1 (0.6%) 
136 (76.8%) 
40 (22.6%) 
 
1 (0.7%) 
112 (78.3%) 
30 (21.0%) 
 
0 (0%) 
24 (70.6%) 
10 (29.4%) 
 
1.000
ð
 
MCV at baseline in fL  
Median (IQR)  
 
88.4 (84 – 92.4) 
 
88.4 (83.9 – 92.3) 
 
88.8  (84.3 – 92.6) 
 
0.0267
Þ 
 
91.4 (86.9 – 101.9) 
 
91.9  (87.4 – 102.2) 
 
89.5 (82.9 – 97.4) 
 
0.1856
Þ
 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
648 (9.1%) 
4533 (63.3%) 
246 (3.4%) 
1733 (24.2%) 
 
557 (9.6%) 
3749 (64.6%) 
199 (3.4%) 
1301 (22.4%) 
 
91 (6.7%) 
784 (57.9%) 
47 (3.5%) 
432 (31.9%) 
 
0.079 
 
13 (7.3%) 
74 (41.8%) 
38 (21.5%) 
52 (29.4%) 
 
9 (6.3%) 
60 (41.9%) 
33 (23.1%) 
41 (28.7%) 
 
4 (11.8%) 
14 (41.2%) 
5 (14.7%) 
11 (32.3%) 
 
0.374
ð
 
Baseline CD4 count in cells/mm
3 
Median (IQR)  
 
101 (39 – 175) 
 
104 (40 – 176) 
 
90 (34 – 170) 
 
0.0011
Þ 
 
156 (74 – 244) 
 
154  (74 – 243) 
 
169 (61 – 249) 
 
0.9246
Þ
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Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
Missing 
 
1001 (14.0%) 
2100 (29.3%) 
1207 (16.9%) 
1864 (26.0%) 
988 (13.8%) 
 
826 (14.2%) 
1749 (30.1%) 
976 (16.8%) 
1476 (25.4%) 
779 (13.5%) 
 
175 (12.9%) 
351 (25.9%) 
231 (17.1%) 
388 (28.7%) 
209 (15.4%) 
 
0.007 
 
53 (29.9%) 
36 (20.3%) 
23 (13.0 %) 
25 (14.1%) 
40 (22.7%) 
 
41 (28.7%) 
30 (21.0%) 
19 (13.3%) 
20 (14.0%) 
33 (23.0%) 
 
12 (35.3%) 
6 (17.6%) 
4 (11.8%) 
5 (14.7%) 
7 (20.6%) 
 
0.917 
WHO stage at baseline 
 I 
II 
III 
IV 
Missing 
 
2161 (30.2%) 
1135 (15.9%) 
1744 (24.4%) 
716 (10%) 
1404 (19.5%) 
 
1826 (31.5%) 
920 (15.8%) 
1409 (24.3%) 
572 (9.9%) 
1079 (18.5%) 
 
335 (24.7%) 
215 (15.9%) 
335 (24.7%) 
144 (10.6%) 
325 (24.1%) 
 
0.003 
 
75 (42.4%) 
15 (8.5%) 
25 (14.1%) 
11 (6.2%) 
51 (28.8%) 
 
61 (42.7%) 
13 (9.1%) 
19 (13.3%) 
11 (7.7%) 
39 (27.2%) 
 
14 (41.2%) 
2 (5.9%) 
6 (17.6%) 
0 (0%) 
12 (35.3%) 
 
0.390
ð
 
* 
On AZT-based regimens throughout the study period. 
 ϻ
 Median test. 
 Þ 
Wilcoxon rank sum test.
   ƫ t-test.
   ð Fisher’s exact test.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile 
range.  MCV: Mean cell volume.  SD: Standard  deviation.  WHO: World Health Organization. 
 
The table above shows the baseline clinical characteristics of all eligible patients and eligible patients on AZT-based regimens. The 
characteristics were described using frequencies with percentages and medians with interquartile ranges or means with standard deviations. The 
majority of patients had WHO stage I (30.2%) or WHO stage III (24.4%) at initiation. A median CD4 count of 101 cells/mm
3
 (IQR: 39 – 175) 
was obtained for all eligible patients. This is a reflection on the South African National ART Guidelines criteria for ART initiation. At baseline, 
63.3% of all patients had a normal MCV. A median BMI of 22 (IQR: 19.1 – 25) kg/m2 was found for all eligible patients. The median 
haemoglobin level of all eligible patients was 11.7 g/dl (IQR: 10.1 – 13.1) at the time of initiation. The table also shows p-values for the 
association between different variables and poor adherence at 6 months measured by viral load at 6 months. Except where otherwise stated, the 
chi-square test was used. 
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Table 1c: 6 month clinical characteristics and their associations with poor adherence for all eligible patients and eligible patients on 
AZT-based regimens with a documented viral load result   
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 7160 
Viral load 
< 400 copies/ml 
N = 5806 
Viral load 
≥ 400 copies/ml 
N = 1354 
P- 
value 
Total 
N = 177 
Viral load 
< 400 copies/ml 
N = 143 
Viral load 
≥ 400 copies/ml 
N = 34 
P- value 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Self-reported adherence
δ
 
> 90% 
> 60 – 90% 
≤ 60% 
Missing 
 
2718 (38.0%) 
300 (4.2%) 
71 (1%) 
4071 (56.8%) 
 
2106 (36.3%) 
227 (3.9%) 
49 (0.8%) 
3424 (59.0%) 
 
612 (45.2%) 
73 (5.4%) 
22 (1.6%) 
647 (47.8%) 
0.201  
45 (25.4%) 
6 (3.4%) 
2 (1.1%) 
124 (70.1%) 
 
38 (26.6%) 
5 (3.5%) 
1 (0.7%) 
99 (69.2%) 
 
7 (20.6%) 
1 (2.9%) 
1 (2.9%) 
25 (73.6%) 
 
0.355
ð
 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
Missing 
 
Number of missed medical visits 
0: 
1: 
≥ 2: 
Missing: 
 
4617 (64.5%) 
1804 (25.2%) 
623 (8.7%) 
116 (1.6%) 
 
 
5238 (73.2%) 
1497 (20.9%) 
302 (4.2%) 
123 (1.7%) 
 
 
5353 (74.8%) 
1411 (19.7%) 
273 (3.8%) 
123 (1.7%) 
 
3731 (64.3%) 
1475 (25.4%) 
509 (8.8%) 
91 (1.5%) 
 
 
4257 (73.3%) 
1219 (21.0%) 
233 (4.0%) 
97 (1.7%) 
 
 
4360 (75.1%) 
1139 (19.6%) 
210 (3.6%) 
97 (1.7%) 
 
886 (65.4%) 
329 (24.3%) 
114 (8.5%) 
25 (1.8%) 
 
 
981 (72.5%) 
278 (20.5%) 
69 (5.1%) 
26 (1.9%) 
 
 
993 (73.3%) 
272 (20.1%) 
63 (4.7%) 
26 (1.9%) 
 
0.633 
 
 
 
 
 
0.194 
 
 
 
 
 
0.160 
 
107 (60.5%) 
44 (24.9%) 
16 (9.0%) 
10 (5.6%) 
 
 
120 (67.8%) 
37 (21.0%) 
10 (5.6%) 
10 (5.6%) 
 
 
125 (70.6%) 
37 (21.0%) 
5 (2.8%) 
10 (5.6%) 
 
88 (61.5%) 
39 (27.3%) 
10 (7.0%) 
6 (4.2%) 
 
 
99 (69.2%) 
30 (21.0%) 
8 (5.6%) 
6 (4.2%) 
 
 
106 (74.1%) 
29 (20.3%) 
2 (1.4%) 
6 (4.2%) 
 
19 (55.9%) 
5 (14.7%) 
6 (17.6%) 
4 (11.8%) 
 
 
21 (61.8%) 
7 (20.6%) 
2 (5.8%) 
4 (11.8%) 
 
 
19 (55.9%) 
8 (23.5%) 
3 (8.8%) 
4 (11.8%) 
 
0.066 
 
 
 
 
 
0.942
ð 
 
 
 
 
0.044
ð 
BMI at 6 months in kg/m
2
 
Median (IQR) 
 
23.3 (21 – 27) 
 
23.7 (21 – 27) 
 
23 (20.7 – 26) 
 
0.0001
Þ 
 
23.8 (21.6 – 27.7)  
 
24 (21.7 – 28.2) 
 
23 (20.7 – 25)  
 
0.2055
Þ 
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BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
Missing 
 
463 (6.5%) 
3344 (46.7%) 
1684 (23.5%) 
835 (11.7%) 
834 (11.6%) 
 
351 (6.0%) 
2683 (46.2%) 
1375 (23.7%) 
695 (11.9%) 
702 (12.2%) 
 
112 (8.3%) 
662 (48.9%) 
306 (22.6%) 
142 (10.5%) 
132 (9.7%) 
 
0.008 
 
12 (6.8%) 
72 (40.7%) 
39 (22.0%) 
22 (12.4%) 
32 (18.1%) 
 
10 (7.0%) 
55 (38.5%) 
33 (23.1%) 
20 (14.0%) 
25 (17.4%) 
 
2 (5.9%) 
17 (50%) 
6 (17.6%) 
2 (5.9%) 
7 (20.6%) 
 
0.476
ð 
Haemoglobin at 6 months in g/dl 
Median (IQR)  
 
13.2 (12.1 – 14.5) 
 
13.3 (12.1 – 14.5) 
 
13.1 (12 – 14.3) 
 
0.0131
Þ 
 
13.3 (12.3 – 14.6) 
 
13.1 (12.1 – 14.6) 
 
13.7 (12.5 – 14.7) 
 
0.6436
Þ 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
50 (0.7%) 
5190 (72.5%) 
1920 (26.8%) 
 
37 (0.6%) 
4298 (74.0%) 
1471 (25.4%) 
 
13 (1.0%) 
892 (65.9%) 
449 (33.2%) 
 
0.101
 
 
1 (0.6%) 
120 (67.8%) 
56 (31.6%) 
 
0 (0%) 
103 (72.0%) 
40 (28.0%) 
 
1 (2.9%) 
17 (50%) 
16 (47.1%) 
 
0.149
ð
 
MCV at 6 months in fL 
Median (IQR) 
 
99.6 (93 – 106.6) 
 
100.6 (94 – 107.5) 
 
95.2 (90.4 – 101.2)
 
 
0.0000
 Þ
 
 
107.6  (102.4 – 113.5) 
 
109.2 (103.3 – 114.2) 
 
100.2 (92.3 – 108.3)  
 
0.0005
Þ
 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
218 (3.0%) 
2896 (40.4%) 
2918 (40.8%) 
1128 (15.8%) 
 
177 (3.0%) 
2203 (37.9%) 
2624 (45.2%) 
802 (13.9%) 
 
41 (3.0%)  
693 (51.2%) 
294 (21.7%) 
326 (24.1%) 
 
0.000 
 
2 (1.1%) 
23 (13.0%) 
125 (70.6%) 
27 (15.3%) 
 
1 (0.7%) 
12 (8.4%) 
113 (79.0%) 
17 (11.9%) 
 
1 (2.9%) 
11 (32.4%) 
12 (35.3%) 
10 (29.4%) 
 
0.000
ð
 
Change in MCV at 6 months in fL 
Median (IQR) 
 
12.5 (5.8 – 18.5) 
 
13.6 (6.8 – 19) 
 
6.8 (2.6 – 11.8) 
 
0.0000
Þ 
 
15.1 (4.2 – 20.7) 
 
16.1  (5.9 – 22) 
 
7.4 (3.2 – 16.9) 
 
0.0336
Þ 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
Missing 
 
1902 (26.5%) 
2626 (36.7%) 
2632 (36.8%) 
 
1785 (30.7%) 
2073 (35.7%) 
1948 (33.6%) 
 
117 (8.6%) 
553 (40.8%) 
684 (50.6%) 
 
0.000 
 
53 (29.9%) 
52 (29.4%) 
72 (40.7%) 
 
49 (34.3%) 
41 (28.7%) 
53 (37.0%) 
 
4 (11.8%) 
11 (32.4%) 
19 (55.8%) 
 
0.055
ð 
Change in CD4 count at 6 months 
in cells/mm
3
 
Median (IQR) 
 
 
129 (69 – 205) 
 
 
135 (76 – 208) 
 
 
97 (33 – 180) 
 
 
0.0000
 Þ
 
 
 
95.5 (45 – 140) 
 
 
102 (54 – 145) 
 
 
52 ( -9 – 61) 
 
 
0.0044
Þ 
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Change in CD4 count at 6 months 
in cells/mm
3
 
≥ expected  
< expected  
Missing 
 
 
4348 (60.7%) 
1156 (16.1%) 
1656 (23.2%) 
 
 
3738 (64.4%) 
856 (14.7%) 
1212 (20.9%) 
 
 
610 (45.1%) 
300 (22.2%) 
444 (32.7%) 
 
 
0.000 
 
 
85 (48%) 
37 (20.9%) 
55 (31.1%) 
 
 
79 (55.2%) 
26 (18.2%) 
38 (26.6%) 
 
 
6 (17.6%) 
11 (32.4%) 
17 (50%) 
 
 
0.001 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
Missing: 
 
 
 
 
1412 (19.7%) 
 
1863 (26.0%) 
 
358 (5%) 
 
537 (7.5%) 
2990 (41.8%) 
 
 
 
 
1331 (22.9%) 
 
1553 (26.7%) 
 
337 (5.8%) 
  
349 (6.0%) 
2236 (38.5%) 
 
 
 
 
81 (6.0%) 
 
310 (22.9%) 
 
21 (1.6%) 
 
188 (13.9%) 
754 (55.6%) 
 
 
 
 
0.000 
 
 
 
 
37 (20.9%) 
 
29 (16.4%) 
 
11 (6.2%) 
 
20 (11.3%) 
80 (45.2%) 
 
 
 
 
35 (24.5%) 
 
26 (18.2%) 
 
9 (6.3%) 
 
13 (9.1%) 
60 (41.9%) 
 
 
 
 
2 (5.9%) 
 
3 (8.8%) 
 
2 (5.9%) 
 
7 (20.5%) 
20 (58.9%) 
 
 
 
 
0.022
ð
 
Regimen change 
No 
Yes 
 
6445 (90.0%) 
715 (10.0%) 
 
5210 (89.7%) 
596 (10.3%) 
 
1235 (91.2%) 
119 (8.8%) 
 
0.103 
 
171 (96.6%) 
6 (3.4%) 
 
140 (97.9%) 
3 (2.1%)  
 
31 (91.2%) 
3 (8.8%) 
 
0.086
ð 
TB
α
: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
5355 (74.8%) 
1493 (20.9%) 
312 (4.3%) 
 
 
4345 (74.8%) 
1204 (20.7%) 
257 (4.5%) 
 
 
1010 (74.6%) 
289 (21.3%) 
55 (4.1%) 
 
 
0.764 
 
 
150 (84.7%) 
24 (13.6%) 
3 (1.7%) 
 
 
120 (83.9%) 
20 (14.0%) 
3 (2.1%) 
 
 
30 (88.2%) 
4 (11.8%) 
0 (0%) 
 
 
1.000
ð 
Pregnancy
α
: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
Missing
γ
 
 
 
4294 (60.0%) 
82 (1.1%) 
147 (2.1%) 
2637 (36.8%) 
 
 
3534 (60.9%) 
67 (1.2%) 
115 (1.9%) 
2090 (36.0%) 
 
 
760 (56.1%) 
15 (1.1%) 
32 (2.4%) 
547 (40.4%) 
 
 
0.445 
 
 
 
92 (52.0%) 
0 (0%) 
5 (2.8%) 
80 (45.2%) 
 
 
80 (55.9%) 
0 (0%) 
2 (1.4%) 
61 (42.7%) 
 
 
12 (35.3%) 
0 (0%) 
3 (8.8%) 
19 (55.9%) 
 
 
0.025
ð 
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Adverse events or side effects 
No 
Yes 
 
6955 (97.1%) 
205 (2.9%) 
 
5618 (96.8%) 
188 (3.2%) 
 
1337 (98.7%) 
17 (1.3%) 
 
0.000 
 
176 (99.4%) 
1 (0.6%) 
 
142 (99.3%) 
1 (0.7%) 
 
34 (100%) 
0 (0%) 
 
1.000
ð 
* 
On AZT-based regimens throughout the study period.  
Þ 
Wilcoxon rank sum test.
  ð Fisher’s exact test.  
 δ 
The last self-reported adherence levels on, or after, the 3 month visit (70 days post-initiation) and 
not more than 3 months (110 days) before the date of the viral load but at least 28 days before the viral load was done.  
α 
Variable has baseline and 6 month components.  
γ 
Male patients.  ART: 
Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile range.  MCV: Mean cell volume.  TB: Tuberculosis.    
 
The table above shows the clinical characteristics of all eligible patients and eligible patients on AZT-based regimens at 6 months. The 
characteristics were described using frequencies with percentages and medians with interquartile ranges. There were a large number of missing 
values. Over half of the patients did not have a documented self-reported adherence. Missing values for a missed medical visit, missed ARV 
drug pickup or missing either a medical or ARV visit were the result of the patient having only one documented scheduled visit during the study 
period (excluding the ART initiation visit) i.e there was no possibility of the patient falling into the group with ≥ 2 missed visits. Over 60% of 
the patients did not miss a single visit. 40.4 % of all eligible patients had a normal MCV at 6 months and 40.8% of all eligible patients had a high 
MCV at 6 months. A median change in CD4 count of 129 cells/mm
3
 (IQR: 69 – 205) was obtained for all eligible patients at 6 months. 5.1% of 
the females were pregnant during the study period. About a quarter of the patients were on TB treatment during the study period but adverse 
events or side effects were rare. 10% of patients had a regimen change during the first 6 months on ART. The table also shows p-values for the 
association between different variables and poor adherence at 6 months measured by viral load at 6 months. Except where otherwise stated, the 
chi-square test was used. 
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Table 2: Table showing the point at which the ART adherence was reported and the points at which the MCV, CD4 count and viral load 
at 6 months were done for eligible patients with a documented viral load result 
 
 
 
 
 
 
 
 
                      
* 
On AZT-based regimens throughout the study period. 
 
AZT: Zidovudine.  IQR: Interquartile range.  MCV: Mean cell volume.   
 
The table above shows that despite the value for a variable at 6 months being defined as the first available value between 150 and 300 days after 
ART initiation, the MCV, CD4 count and viral load at 6 months for all eligible patients were done at approximately the same time as the same 
tests for all eligible patients on AZT-based regimens. Self-reported adherence, assessed as the last self-reported adherence levels on, or after, the 
3 month visit (70 days post-initiation) and not more than 3 months (110 days) before the date of the viral load but at least 28 days before the viral 
load was done, had differences in the medians between all eligible patients and eligible patients on AZT-based regimens.   
 
 
 
 
 
Variable All eligible patients Eligible patients on AZT-based regimens
*
 
Median(IQR) Median (IQR) 
Self-reported adherence 63 days (IQR: 56 – 84) before the viral load was 
done. 
56 days (IQR: 41 – 84) before the viral load 
was done. 
MCV at 6 months 202 days (IQR: 170 – 268) after ART initiation. 203.5 days (IQR: 175 – 261) after ART 
initiation. 
CD4 count at 6 months 204 days (IQR: 171 – 272) after ART initiation. 210.5 days (IQR: 176 – 265.5) after ART 
initiation. 
Viral load at 6 months 203 days (IQR: 173 – 267) after ART initiation. 205 days (IQR: 176 – 261) after ART 
initiation. 
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3.2.2 Poisson regression with robust error variance: 
In this section, Poisson regression models (with robust error variance) for patients with a documented viral load result at 6 months are presented. 
 
 Table 3a: Univariate and multivariate Poisson regression models with robust error variance for all eligible patients and eligible patients   
 on AZT-based regimens with a documented viral load result 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Crude IRR 
 (95% CI) 
P -
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Gender  
Females             
Males 
 
1 
1.16 (1.05 – 1.28) 
 
- 
0.002 
 
1 
1.09 (0.92 – 1.28) 
 
- 
0.320 
 
1  
1.54 (0.83 – 2.83) 
 
- 
0.168 
 
- 
- 
 
- 
- 
Age at initiation  
≤ 36.7 years 
> 36.7 years 
 
1 
0.94 (0.85 – 1.04) 
 
- 
0.213 
 
1 
0.94 (0.80 – 1.11) 
 
- 
0.463 
 
1  
0.51 (0.28 – 0.93) 
 
- 
0.028 
 
1 
1.18 (0.31 – 4.53) 
 
- 
0.808 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.90 (0.77 – 1.04) 
0.81 (0.60 – 1.09) 
 
- 
0.164 
0.167 
 
- 
- 
- 
 
- 
- 
- 
 
1  
1.31 (0.58 – 2.94) 
0.75 (0.12 – 4.84) 
 
- 
0.519 
0.759 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.09 (0.99 – 1.20) 
 
- 
0.078 
 
- 
- 
 
- 
- 
 
1 
0.87 (0.47 – 1.62) 
 
- 
0.666 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.88 (0.76 – 1.01) 
0.85 (0.72 – 1.01) 
0.82 (0.66 – 1.02) 
 
- 
0.067 
0.071 
0.079 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
2.38 (0.60 – 9.43) 
1.9 (0.39 – 9.25) 
0.40 (0.04 – 4.08) 
 
- 
0.219 
0.427 
0.436 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.99 (0.79 – 1.25) 
 
- 
0.951 
 
- 
- 
 
- 
- 
 
1 
-
‡ 
 
- 
- 
 
- 
- 
 
- 
- 
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MCV at baseline  
< 80fL 
80 – 100fL 
> 100fl 
 
1 
1.23 (1.01 – 1.51) 
1.36 (0.99 – 1.87) 
 
- 
0.042 
0.059 
 
1 
1.33 (1.01 – 1.75) 
0.98 (0.62 – 1.55) 
 
- 
0.044 
0.937 
 
1 
0.61 (0.24 – 1.58) 
0.43 (0.13 – 1.36) 
 
- 
0.314 
0.151 
 
- 
- 
- 
 
- 
- 
- 
Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
 
1  
0.96 (0.81 – 1.13) 
1.09 (0.92 – 1.31) 
1.19 (1.01 – 1.40) 
 
- 
0.594 
0.318 
0.034 
 
1  
1.05 (0.80 – 1.38) 
1.08 (0.80 – 1.47) 
1.34 (1.02 – 1.76) 
 
- 
0.716 
0.612 
0.035 
 
1 
0.74 (0.30 – 1.79) 
0.77 (0.28 – 2.14) 
0.88 (0.35 – 2.24) 
 
- 
0.498 
0.614 
0.794 
 
1 
0.82 (0.07 – 9.24) 
3.11 (0.47 – 20.67) 
2.10 (0.12 – 37.31) 
 
- 
0.870 
0.240 
0.612 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.22 (1.05 – 1.43) 
1.24 (1.08 – 1.42) 
1.30 (1.09 – 1.55) 
 
- 
0.012 
0.002 
0.004 
 
1 
1.16 (0.90 – 1.48) 
1.27 (1.04 – 1.55) 
1.44 (1.12 – 1.84) 
 
- 
0.248 
0.021 
0.004 
 
1 
0.71 (0.18 – 2.84) 
1.29 (0.55 – 3.00) 
-
‡
 
 
- 
0.653 
0.560 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.08 (0.87 – 1.34) 
1.38 (0.97 – 1.96) 
 
- 
0.472 
0.077 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.07 (0.16 – 7.40) 
3.21 (0.68 – 15.28) 
 
- 
0.944 
0.142 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
0.95 (0.85 – 1.07) 
0.95 (0.80 – 1.14) 
 
 
1 
0.99 (0.88 – 1.12) 
1.22 (0.98 – 1.51) 
 
 
1 
1.04 (0.92 – 1.17) 
1.24 (0.99 – 1.56) 
 
- 
0.382 
0.597 
 
 
- 
0.890 
0.070 
 
 
- 
0.532 
0.056 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.64 (0.25 – 1.61) 
2.11 (0.99 – 4.49) 
 
 
1 
1.08 (0.50 – 2.34) 
1.14 (0.31 – 4.21) 
 
 
1 
1.42 (0.68 – 2.99) 
3.95 (1.72 – 9.05) 
 
- 
0.343 
0.052 
 
 
- 
0.844 
0.841 
 
 
- 
0.352 
0.001 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.82 (0.69 – 0.97) 
0.75 (0.62 – 0.91) 
0.70 (0.56 – 0.87) 
 
- 
0.025 
0.003 
0.002 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.42 (0.37 – 5.39) 
0.92 (0.21 – 4.01) 
0.55 (0.49 – 3.42) 
 
- 
0.609 
0.915 
0.518 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.66 (0.41 – 1.06) 
 
- 
0.085 
 
- 
- 
 
- 
- 
 
1 
0.14 (0.09 – 0.22) 
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.27 (0.96 – 1.69) 
0.54 (0.40 – 0.72) 
 
- 
0.096 
0.000 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.96 (0.22 – 4.10) 
0.19 (0.04 – 0.85) 
 
- 
0.952 
0.030 
 
- 
- 
- 
 
- 
- 
- 
Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
3.42 (2.83 – 4.14) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
2.80 ( 0.95 – 8.28) 
 
- 
0.062 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months 
in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.85 (1.64 – 2.09) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
4.21 (1.68 – 10.57) 
 
 
- 
0.002 
 
 
1 
7.66 (0.98 – 59.91) 
 
 
- 
0.052 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected and 
change in MCV < 14.5fL: 
-Change in CD4 count < expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected and 
change in MCV < 14.5fL: 
 
 
 
 
1 
 
2.90 (2.29 – 3.66) 
 
1.02 (0.64 – 1.63) 
 
6.10 (4.80 – 7.76) 
 
 
 
 
- 
 
0.000 
 
0.925 
 
0.000 
 
 
 
 
1 
 
3.11 (2.41 – 4.02) 
 
1.23 (0.76 – 2.00) 
 
6.98 (5.35 – 9.09) 
 
 
 
 
- 
 
0.000 
 
0.394 
 
0.000 
 
 
 
 
1 
 
1.91 (0.34 – 10.80) 
 
3.36 (0.53 – 21.40) 
 
6.48 (1.47 – 28.50) 
 
 
 
 
- 
 
0.462 
 
0.199 
 
0.013 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.87 (0.73 – 1.03) 
 
- 
0.107 
 
- 
- 
 
- 
- 
 
1 
2.76 (1.16 – 6.54) 
 
- 
0.021 
 
- 
- 
 
- 
- 
 33 
 
TB: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.03 (0.91 – 1.15) 
0.93 (0.73 – 1.20) 
 
 
- 
0.665 
0.591 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.83 (0.32 – 2.16) 
-
‡
 
 
 
- 
0.708 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Pregnancy: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
 
 
1 
1.03 (0.65 – 1.64) 
1.23 (0.90 – 1.68) 
 
 
- 
0.889 
0.195 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
4.6 (1.88 – 11.24) 
 
 
- 
- 
0.001 
 
 
1 
-
‡ 
9.11 (2.17 – 38.25) 
 
 
- 
- 
0.003 
Adverse events or side effects  
No 
Yes 
 
1 
0.43 (0.27 – 0.68) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
- 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period. 
 ‡ Cell has no observations.  ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  
CI: Confidence interval.   IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis. WHO: World Health Organization. 
 
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens. After adjusting for potential confounders, the variables independently associated with poor adherence for all 
eligible patients were change in CD4 count at 6 months stratified by change in MCV at 6 months, CD4 count at baseline, WHO stage at baseline 
and MCV at baseline. The IRR of poor adherence increased with decreasing CD4 count and increasing WHO stage at baseline. Model fit was 
good as evidenced by a p-value of 0.914 on the link test.  Change in CD4 count at 6 months and pregnancy during the first 6 months on ART 
were the only independent predictors of poor adherence in the final multivariate model for patients on AZT-based regimens. Model fit for this 
model was also good as evidenced by a p-value of 0.812 on the link test.  
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Table 3b: Univariate and multivariate Poisson regression models with robust error variance for all eligible patients and eligible patients 
on AZT-based regimens with a documented viral load result after multiple imputation 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Crude IRR 
 (95% CI) 
P -
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Gender  
Females             
Males 
 
1 
1.16 (1.05 – 1.28) 
 
- 
0.002 
 
1 
1.07 (0.97 – 1.18) 
 
- 
0.166 
 
1  
1.54 (0.83 – 2.83) 
 
- 
0.168 
 
1 
1 .48 (0.81 – 2.73) 
 
- 
0.202 
Age at initiation  
≤ 36.7 years  
> 36.7 years  
 
1 
0.94 (0.85 – 1.04) 
 
- 
0.213 
 
1 
0.96 (0.87 – 1.06) 
 
- 
0.415 
 
1  
0.51 (0.28 – 0.93) 
 
- 
0.028 
 
1 
0.54 (0.30 – 0.98) 
 
- 
0.041 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.89 (0.77 – 1.03) 
0.82 (0.61 – 1.12) 
 
- 
0.107 
0.217 
 
- 
- 
- 
 
- 
- 
- 
 
1  
1.09 (0.48 – 2.50) 
0.68 (0.10 – 4.39) 
 
- 
0.835 
0.684 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.09 (0.99 – 1.20) 
 
- 
0.072 
 
- 
- 
 
- 
- 
 
1 
0.88 (0.47 – 1.63) 
 
- 
0.677 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.89 (0.78 – 1.02) 
0.86 (0.73 – 1.02) 
0.79 (0.64 – 0.98) 
 
- 
0.086 
0.082 
0.030 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.66 (0.46 – 6.00) 
1.39 (0.33 – 5.79) 
0.45 (0.06 – 3.49) 
 
- 
0.435 
0.652 
0.447 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
1 
1.00 (0.80 – 1.26) 
 
- 
0.968 
 
- 
- 
 
- 
- 
 
1 
-
‡ 
 
- 
- 
 
- 
- 
 
- 
- 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fl 
 
1 
1.20 (1.00 – 1.44) 
1.24 (0.89 – 1.72) 
 
- 
0.056 
0.196 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.65 (0.26 – 1.60) 
0.45 (0.15 – 1.40) 
 
- 
0.347 
0.169 
 
- 
- 
- 
 
- 
- 
- 
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Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
 
1  
0.97 (0.83 – 1.13) 
1.10 (0.92 – 1.31) 
1.21 (1.02 – 1.41) 
 
- 
0.666 
0.297 
0.026 
 
1  
1.10 (0.94 – 1.29) 
1.31 (1.09 – 1.56) 
1.49 (1.27 – 1.74) 
 
- 
0.212 
0.003 
0.000 
 
1 
0.74 (0.30 – 1.82) 
0.81 (0.31 – 2.15) 
0.92 (0.37 – 2.29) 
 
- 
0.506 
0.677 
0.857 
 
1 
0.76 (0.31 – 1.86) 
0.92 (0.35 – 2.44) 
1.07 (0.45 – 2.54) 
 
- 
0.553 
0.873 
0.885 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.21 (1.03 – 1.41) 
1.24 (1.08 – 1.42) 
1.28 (1.09 – 1.51) 
 
- 
0.018 
0.002 
0.003 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
0.83 (0.25 – 2.77) 
1.17 (0.52 – 2.62) 
-
‡ 
 
- 
0.765 
0.701 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.06 (0.83 – 1.35) 
1.64 (1.15 – 2.34) 
 
- 
0.647 
0.006 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.84 (0.16 – 4.45) 
2.64 (0.63 – 11.03) 
 
- 
0.838 
0.184 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
0.95 (0.85 – 1.07) 
0.95 (0.80 – 1.14) 
 
 
1 
0.99 (0.88 – 1.12) 
1.22 (0.98 – 1.51) 
 
 
1 
1.04 (0.92 – 1.17) 
1.24 (0.99 – 1.55) 
 
- 
0.382 
0.597 
 
 
- 
0.885 
0.069 
 
 
- 
0.547 
0.063 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.64 (0.25 – 1.61) 
2.11 (0.99 – 4.49) 
 
 
1 
1.07 (0.50 – 2.31) 
1.15 (0.32 – 4.09) 
 
 
1 
1.37 (0.67 – 2.80) 
3.54 (1.54 – 8.16) 
 
- 
0.343 
0.052 
 
 
- 
0.860 
0.834 
 
 
- 
0.393 
0.003 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.82 (0.69 – 0.97) 
0.76 (0.63 – 0.92) 
0.69 (0.56 – 0.86) 
 
- 
0.024 
0.004 
0.001 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.43 (0.38 – 5.36) 
1.06 (0.26 – 4.25) 
0.54 (0.09 – 3.26) 
 
- 
0.592 
0.938 
0.501 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
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Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.72 (0.45 – 1.16) 
 
- 
0.178 
 
- 
- 
 
- 
- 
 
1 
0.19 (0.14 – 0.26) 
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.32 (1.00 – 1.75) 
0.60 (0.45 – 0.80) 
 
- 
0.054 
0.001 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.92 (0.22 – 3.78) 
0.22 (0.05 – 0.94) 
 
- 
0.908 
0.041 
 
- 
- 
- 
 
- 
- 
- 
Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
2.61 (2.22 – 3.04) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
2.36 ( 1.09 – 5.08) 
 
- 
0.029 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months 
in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.76 (1.58 – 1.96) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
2.50 (1.18 – 5.32) 
 
 
- 
0.017 
 
 
1 
2.34 (1.07 – 5.12) 
 
 
- 
0.033 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected and 
change in MCV < 14.5fL: 
-Change in CD4 count < expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected and 
change in MCV < 14.5fL: 
 
 
 
 
1 
 
2.46 (2.00 – 3.02) 
 
1.53 (1.08 – 2.15) 
 
4.38 (3.59 – 5.34) 
 
 
 
 
- 
 
0.000 
 
0.017 
 
0.000 
 
 
 
 
1 
 
2.52 (2.04 – 3.10) 
 
1.61 (1.13 – 2..27) 
 
4.65 (3.79 – 5.70) 
 
 
 
 
- 
 
0.000 
 
0.008 
 
0.000 
 
 
 
 
1 
 
2.16 (0.68 – 6.85) 
 
2.34 (0.58 – 9.39) 
 
4.83 (1.71 – 13.66) 
 
 
 
 
- 
 
0.192 
 
0.229 
 
0.003 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.87 (0.73 – 1.03) 
 
- 
0.107 
 
- 
- 
 
- 
- 
 
1 
2.76 (1.16 – 6.54) 
 
- 
0.021 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.03 (0.91 – 1.15) 
0.93 (0.73 – 1.20) 
 
 
- 
0.665 
0.591 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.83 (0.32 – 2.16) 
-
‡
 
 
 
- 
0.708 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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Pregnancy: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
 
 
1 
1.03 (0.65 – 1.64) 
1.23 (0.90 – 1.68) 
 
 
- 
0.889 
0.195 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
4.6 (1.88 – 11.24) 
 
 
- 
- 
0.001 
 
 
- 
- 
- 
 
 
- 
- 
- 
Adverse events or side effects  
No 
Yes 
 
1 
0.43 (0.27 – 0.68) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
- 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period. 
 
. 
 ‡ Cell in one or more imputations has no observations.  ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: 
Zidovudine.  CI: Confidence interval.   IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis. WHO: World Health Organization.  
 
For the table above, multiple imputation (20 imputations) was done for all patients with a documented viral load result using multivariate normal 
regression. The imputation was done for explanatory variables with missing values. Multiple imputation was followed by multivariate Poisson 
regression analysis with robust error variance. After adjusting for potential confounders, the variables independently associated with poor 
adherence for all eligible patients were change in CD4 count at 6 months stratified by change in MCV at 6 months and CD4 count at baseline. 
The IRR of poor adherence increased with decreasing CD4 count. Model fit was good as evidenced by a p-value of < 0.05 on the FMI test.  
Change in CD4 count at 6 months and age at initiation were the only independent predictors of poor adherence in the final multivariate model for 
patients on AZT-based regimens. Model fit for this model was also good as evidenced by a p-value of < 0.05 on the FMI test. 
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3.3: MEASURES OF VALIDITY 
3.3.1 Sensitivity, specificity, PPV and NPV: 
In this section, sensitivity, specificity, positive and negative predictive values are presented in a series of tables and graphs. 
 
Table 4a: Sensitivity, specificity, PPV and NPV of markers to identify poor adherence, using viral load as the gold standard, for all 
patients with a documented viral load result 
 
VARIABLE BEFORE MULTIPLE IMPUTATION AFTER MULTIPLE IMPUTATION 
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
Change in MCV at 6 months for patients on d4T or 
AZT-based regimens* 
70.2% 61.4% 18.2% 94.4% 71.1% 58.5% 23.0% 92.1% 
Change in MCV at 6 months for patients on TDF-
based  regimens** 
97.4% 3.1% 24.4% 78.4% 89.2% 15.4% 27.2% 80.1% 
Change in CD4 count at 6 months 33% 81.4% 26% 86% 33% 80.7% 28.5% 83.8% 
Change in CD4 count at 6 months for patients on 
AZT-based regimens*** 
64.7% 75.2% 29.7% 92.9% 51.3% 75.5% 33.2% 86.7% 
Change in CD4 count stratified by change in MCV 86.5% 37.3% 18.8% 94.3% 85.5% 35.6% 23.6% 91.3% 
Change in CD4 count stratified by change in MCV  
for patients on d4T or AZT-based regimens* 
76.8% 49.2% 15% 94.8% 79.3% 46.6% 20.6% 92.8% 
Change in CD4 count stratified by change in MCV  
for patients on TDF-based regimens** 
98.2% 2.4% 24.2% 80.8% 92.5% 13% 27.4% 83.1% 
Pregnant during the first 6 months on ART for 
patients on AZT-based  regimens*** 
20% 97.6% 60% 87% 20% 97.6% 60% 87% 
*On d4T or AZT-based regimens throughout the study period.  **On TDF-based regimens throughout the study period.  ***On AZT-based regimens throughout the 
study period.  ART: Antiretroviral Therapy. AZT: Zidovudine.  d4T: Stavudine.  MCV: Mean cell volume. NPV: Negative predictive value. PPV: Positive predictive 
value. TDF: Tenofovir. 
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Table 4b: Table showing sensitivity, specificity, PPV and NPV for each category of change in CD4 count stratified by change in MCV at 
6 months, for all patients with a documented viral load result  
 
 
 
 
 
 
 
 
 
 
MCV: Mean cell volume. NPV: Negative predictive value. PPV: Positive predictive value.  
 
 
 
 
 
 
 
 
 
 
 
 
VARIABLE CATEGORY BEFORE MULTIPLE IMPUTATION AFTER MULTIPLE IMPUTATION 
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
Change in CD4 count ≥ expected 
and change in MCV< 14.5fL 
79.3% 46.2% 16.6% 94.3% 78.3% 44.1% 21.3% 91.3% 
Change in CD4 count < expected 
and change in MCV ≥ 14.5fL 
20.6% 79.8% 5.9% 94.3% 28.7% 80% 13.3% 91.3% 
Change in CD4 count < expected 
and change in MCV< 14.5fL 
69.9% 79.2% 35.0% 94.3% 65.1% 77.5% 38.0% 91.3% 
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3.3.2 Receiver operating characteristic (ROC) curves: 
 
 
Figure 2a: ROC curves for different markers of adherence for eligible patients with a 
documented viral load result: The graph above shows ROC curves for individual markers 
of adherence as well as the ROC curve for the final multivariate model. The area under each 
curve is also shown. 
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Figure 2b: ROC curves for different markers of adherence for eligible patients with a 
documented viral load result after multiple imputation: The graph above shows ROC 
curves for individual markers of adherence as well as the ROC curve for the final 
multivariate model. The area under each curve is also shown. 
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Figure 2c: ROC curves for different markers of adherence for all eligible patients on 
AZT-based regimens with a documented viral load result: The graph above shows 
different ROC curves for individual markers of adherence as well as the ROC curve for the 
final multivariate model for patients on AZT-based regimens. The area under each curve is 
also shown. 
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Figure 2d: ROC curves for different markers of adherence for all eligible patients on 
AZT-based regimens with a documented viral load result after multiple imputation: The 
graph above shows different ROC curves for individual markers of adherence as well as the 
ROC curve for the final multivariate model for patients on AZT-based regimens. The area 
under each curve is also shown. 
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3.4 SENSITIVITY ANALYSES: 
3.4.1 Descriptive analysis: 
In this section the baseline and 6 month characteristics of all patients including those without a documented viral load result at 6 months are 
presented. 
 
Table 5a: Baseline demographic characteristics and their associations with poor adherence for all patients including those excluded due 
to missing viral load results assuming that those with missing viral load results had a viral load ≥ 400 copies/ml  
Characteristics All patients All patients on AZT-based regimens
*
 
Total 
N = 14384 
Viral load 
< 400 copies/ml 
N = 5806 
Viral load 
≥ 400 copies/ml 
N = 8578 
P-value Total  
N = 370 
Viral load 
< 400 copies/ml 
N = 143 
Viral load 
≥ 400 copies/ml 
N = 227 
P-value 
n (%)  n (%) n (%) n (%)  n (%) n(%) 
Gender  
Females                
Males 
 
9051 (62.9%) 
5333 (37.1%) 
 
3716 (64%) 
2090 (36%) 
 
5335 (62.2%) 
3243 (37.8%) 
 
0.028 
 
204 (55.1%) 
166 (44.9%) 
 
82 (57.3%) 
61 (42.7%) 
 
122 (53.7%) 
105 (46.3%) 
 
0.498 
Age at initiation 
in years 
Median (IQR) 
 
 
36.6 (31.4 – 43.2) 
 
 
36.8 (31.6 – 43.5) 
 
 
36.5 (31.3 – 43.1) 
 
 
0.0240
Þ 
 
 
39.6  (33.6 – 45.7) 
 
 
40.6  (35.6 – 48)      
 
 
39.3  (32.7 – 45.5) 
 
 
0.0198
Þ 
Age at initiation 
in years 
≤ 36.7 
> 36.7 
 
 
7263 (50.5%) 
7121 (49.5%) 
 
 
2901 (50.0%) 
2905 (50.0%) 
 
 
4362 (50.9%) 
4216 (49.1%) 
 
 
0.297 
 
 
134 (36.2%) 
236 (63.8%) 
  
 
43 (30.1%) 
100 (69.9%) 
 
 
91 (40.1%) 
136 (59.9%) 
 
 
0.051 
Education level 
≥ Secondary school 
Primary school  
< Primary school 
Missing 
 
8740 (60.8%) 
1812 (12.6%) 
426 (3.0%) 
3406 (23.6%) 
 
3573 (61.5%) 
744 (12.8%) 
184 (3.2%) 
1305 (22.5%) 
 
5167 (60.2%) 
1068 (12.5%) 
242 (2.8%) 
2101 (24.5%) 
 
0.638 
 
197 (53.2%) 
57 (15.4%) 
12 (3.2%) 
104 (28.2%) 
 
76 (53.1%) 
18 (12.6%) 
6 (4.2%) 
43 (30.1%) 
 
121 (53.3%) 
39 (17.2%) 
6 (2.6%) 
61 (26.9%) 
 
0.417 
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        *On AZT-based regimens throughout the study period. 
 Þ 
Wilcoxon rank sum test.
   
AZT: Zidovudine.  IQR: Interquartile range. 
 
The table above shows the baseline demographic characteristics of all patients and patients on AZT-based regimens. The characteristics were 
described using frequencies with percentages and medians with interquartile ranges. The table demonstrates that the baseline demographic 
characteristics of all patients including those excluded due to missing viral load results at the end-point were similar to those of the study 
population (Table 1a). This implies that the 7160 eligible patients in the main analysis, with a documented viral load result, are representative of 
the total study population. The majority of the patients in the sensitivity analysis (62.9%) were female. The median age at initiation was 36.6 
years (IQR: 31.4 – 43.2) but the overall age range at initiation was 18 – 79.9 years. The table also shows p-values for the association between 
different variables and poor adherence at 6 months measured by viral load at 6 months. Except where otherwise stated, the chi-square test was 
used.  
 
 
 
 
 
 
Professional 
status    
Employed 
Unemployed 
Missing 
 
 
7191 (50.0%) 
6973 (48.5%) 
220 (1.5%) 
 
 
3020 (52.0%) 
2700 (46.5%) 
86 (1.5%) 
 
 
4171 (48.6%) 
4273 (49.8%) 
134 (1.6%) 
 
 
0.000 
 
 
180 (48.7%) 
184 (49.7%) 
6 (1.6%) 
 
 
71 (49.7%) 
70 (49.0%) 
2 (1.3%) 
 
 
109 (48.0%) 
114 (50.2%) 
4 (1.8%) 
 
 
0.784 
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Table 5b: Baseline clinical characteristics and their associations with poor adherence for all patients including those excluded due to 
missing viral load results assuming that those with missing viral load results had a viral load ≥ 400 copies/ml  
    
 
Characteristics All patients All patients on AZT-based regimens
*
 
Total 
N = 14384 
Viral load 
<400 copies/ml 
N = 5806 
Viral load 
≥400 copies/ml 
N = 8578 
P-value Total  
N = 370 
Viral load 
<400 copies/ml 
N = 143 
Viral load 
≥400 copies/ml 
N = 227 
P-value 
n (%)  n (%) n (%) n (%)  n (%) n(%) 
BMI at initiation in kg/m
2
  
Median (IQR) 
 
22 (19 – 25) 
 
22 (19.7 – 25) 
 
22.0 (19 – 25) 
 
0.000
ϻ 
 
22.0 (19.3 – 28.0) 
 
22.3 (20.0 – 29) 
 
22 (19 – 26.5) 
 
0.5301
Þ 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30  
Missing 
 
2179 (15.1%) 
6693 (46.5%) 
2290 (15.9%) 
1089 (7.6%) 
2133 (14.9%) 
 
782 (13.5%) 
2719 (46.8%) 
966 (16.6%) 
462 (8.0%) 
877 (15.1%) 
 
1397 (16.3%) 
3974 (46.3%) 
1324 (15.4%) 
627 (7.3%) 
1256 (14.7%) 
 
0.000 
 
45 (12.2%) 
129 (34.9%) 
40 (10.8%) 
52 (14.1%) 
104 (28.0%) 
 
17 (11.9%) 
51 (35.7%) 
16 (11.2%) 
23 (16.1%) 
36 (25.1%) 
 
28 (12.3%) 
78 (34.4%) 
24 (10.6%) 
29 (12.8%) 
68 (29.9%) 
 
0.922 
Baseline haemoglobin in g/dl 
Median (IQR)  
 
11.7 (10.1 – 13.1) 
 
11.7 (10.2 – 13.1) 
 
11.6 (10.1 – 13) 
 
0.1328
Þ
 
 
12.6 (11.4 – 13.8) 
 
12.5 (11.5 – 13.9) 
 
12.6 (11.4 – 13.8) 
 
0.8953
Þ 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
688 (4.8%) 
12298 (85.5%) 
1398 (9.7%) 
 
273 (4.7%) 
4901 (84.4%) 
632 (10.9%) 
 
415 (4.8%) 
7397 (86.2%) 
766 (9.0%) 
 
0.929 
 
1 (0.3%) 
285 (77.0%) 
84 (22.7%) 
 
1 (0.7%) 
112 (78.3%) 
30 (21.0%) 
 
0 (0%) 
173 (76.2%) 
54 (23.8%) 
 
0.395
ð 
MCV at baseline in fL  
Median (IQR)  
 
88.2 (83.7 – 92.2) 
 
88.4 (83.9 – 92.3) 
 
88.1 (83.6 – 92.2) 
 
0.1727
 Þ
 
 
90.8 (85.7 – 97.4) 
 
91.9  (87.4 – 102.2) 
 
90.3 (85 – 95.7) 
 
0.0526
 Þ
 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
Missing: 
 
1427 (9.9%) 
9757 (67.8%) 
475 (3.3%) 
2725 (19.0%) 
 
557 (9.6%) 
3749 (64.6%) 
199 (3.4%) 
1301 (22.4%) 
 
870 (10.1%) 
6008 (70.0%) 
276 (3.2%) 
1424 (16.7%) 
 
0.300 
 
26 (7.0%) 
188 (50.8%) 
55 (14.9%) 
101 (27.3%) 
 
9 (6.3%) 
60 (41.9%) 
33 (23.1%) 
41 (28.7%) 
 
17 (7.5%) 
128 (56.4%) 
22 (9.7%) 
60 (26.4%) 
 
0.001 
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*
On AZT-based regimens throughout the study period. 
 ϻ
 Median test. 
 Þ 
Wilcoxon rank sum test 
ð 
Fisher’s exact test.  AZT: Zidovudine.  BMI: Body Mass Index.   IQR: Interquartile range.  
MCV: Mean cell volume.  WHO: World Health Organization.  
 
The table above shows the baseline clinical characteristics of all patients and patients on AZT-based regimens. The characteristics were 
described using frequencies with percentages and medians with interquartile ranges. The table demonstrates that the baseline clinical 
characteristics of all patients including those excluded due to missing viral load results at the end-point were similar to those of the study 
population (Table 1b). This implies that the 7160 eligible patients in the main analysis, with a documented viral load result, are representative of 
the total study population. The majority of patients in the sensitivity analysis were initiated in WHO stage I (32.3%) or III (25.6%). The MCV at 
baseline was normal in 67.8% of all patients. A median CD4 count of 101 cells/mm
3
 (IQR: 39 – 172) was obtained for all eligible patients at 
baseline. A median BMI of 22 kg/m
2
 (IQR: 19 – 25) was obtained for all eligible patients at baseline. The median haemoglobin level was 11.7 
g/dl (IQR: 10.1 – 13.1) at the time of initiation.  The table also shows p-values for the association between different variables and poor 
adherence at 6 months measured by viral load at 6 months. Except where otherwise stated, the chi-square test was used.  
Baseline CD4 count in 
cells/mm
3
 
Median (IQR)  
 
 
101 (39 – 172) 
 
 
104 (40 – 176)  
 
 
99 (39 – 169) 
 
 
0.0025
 Þ
 
 
 
128 (61 – 218) 
 
 
154  (74 – 243) 
 
 
122 (52 – 207) 
 
 
0.0714
 Þ
 
Baseline CD4 in cells/mm
3
 
> 200 
101 – 200 
51 – 100 
≤ 50  
Missing 
 
1858 (12.9%) 
4443 (30.9%) 
2489 (17.3%) 
3762 (26.2%) 
1832 (12.7%) 
 
826 (14.2%) 
1749 (30.1%) 
976 (16.8%) 
1476 (25.4%) 
779 (13.5%) 
 
1032 (12.0%) 
2694 (31.4%) 
1513 (17.6%) 
2286 (26.6%) 
1053 (12.3%) 
 
0.001 
 
87 (23.5%) 
81 (21.9%) 
51 (13.8%) 
60 (16.2%) 
91 (24.6%) 
 
41 (28.7%) 
30 (21.0%) 
19 (13.3%) 
20 (14.0%) 
33 (23.0%) 
 
46 (20.3%) 
51 (22.5%) 
32 (14.1%) 
40 (17.6%) 
58 (25.5%) 
 
0.336 
WHO stage at baseline 
 I 
II 
III 
IV 
Missing 
 
4650 (32.3%) 
2376 (16.5%) 
3685 (25.6%) 
1337 (9.3%) 
2336 (16.3%) 
 
1826 (31.5%) 
920 (15.8%) 
1409 (24.3%) 
572 (9.9%) 
1079 (18.5%) 
 
2824 (32.9%) 
1456 (17.0%) 
2276 (26.5%) 
765 (8.9%) 
1257 (14.7%) 
 
0.031 
 
133 (35.9%) 
27 (7.3%) 
70 (18.9%) 
27 (7.3%) 
113 (30.6%) 
 
61 (42.7%) 
13 (9.1%) 
19 (13.3%) 
11 (7.7%) 
39 (27.2%) 
 
72 (31.7%) 
14 (6.2%) 
51 (22.5%) 
16 (7.0%) 
74 (32.6%)  
 
0.059 
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Table 5c: 6 month clinical characteristics and their associations with poor adherence for all patients including those excluded due to 
missing viral load results assuming that those with missing viral load results had a viral load ≥ 400 copies/ml  
 
Characteristics All patients All patients on AZT-based regimens
*
 
Total 
N = 14384 
Viral load 
< 400 copies/ml 
N = 5806 
Viral load 
≥ 400 copies/ml 
N = 8578 
P- 
Value 
Total  
N = 370 
Viral load 
< 400 copies/ml 
N = 143 
Viral load 
≥ 400 copies/ml 
N = 227 
P- 
Value 
n (%)  n (%) n (%) n (%)  n (%) n (%)  
Self-reported adherence
δ 
> 90% 
> 60 – 90% 
≤ 60% 
Missing: 
 
6491 (45.1%) 
738 (5.1%) 
171 (1.2%) 
6984 (48.6%) 
 
2106 (36.3%) 
227 (3.9%) 
49 (0.8%) 
3424 (59.0%) 
 
4385 (51.1%) 
511 (6.0%) 
122 (1.4%) 
3560 (41.5%) 
 
0.394 
 
147 (39.7%) 
12 (3.2%) 
6 (1.6%) 
205 (55.5%) 
 
38 (26.6%) 
5 (3.5%) 
1 (0.7%) 
99 (69.2%) 
 
109 (48.0%) 
7 (3.1%) 
5 (2.2%) 
106 (46.7%) 
 
0.545
ð 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
Missing 
 
Number of missed medical visits 
0 
1 
≥ 2 
Missing 
 
9697 (67.4%) 
3363 (23.4%) 
989 (6.9%) 
335 (2.3%) 
 
 
10950 (76.1%) 
2622 (18.2%) 
450 (3.1%) 
362 (2.6%) 
 
 
11002 (76.5%) 
2580 (17.9%) 
440 (3.0%) 
362 (2.6%) 
 
3731 (64.3%) 
1475 (25.4%) 
509 (8.8%) 
91 (1.5%) 
 
 
4257 (73.3%) 
1219 (21.0%) 
233 (4.0%) 
97 (1.7%) 
 
 
4360 (75.1%) 
1139 (19.6%) 
210 (3.6%) 
97 (1.7%)  
 
5966 (69.6%) 
1888 (22.0%) 
480 (5.6%) 
244 (2.8%) 
 
 
6693 (78.0%) 
1403 (16.4%) 
217 (2.5%) 
265 (3.1%) 
 
 
6642 (77.4%) 
1441 (16.8%) 
230 (2.7%) 
265 (3.1%) 
 
0.000 
 
 
 
 
 
0.000 
 
 
 
 
 
0.000 
 
 
250 (67.6%) 
78 (21.1%) 
26 (7.0%) 
16 (4.3%) 
 
 
273 (73.8%) 
66 (17.8%) 
15 (4.1%) 
16 (4.3%) 
 
 
281 (75.9%) 
65 (17.6%) 
8 (2.2%) 
16 (4.3%) 
 
88 (61.5%) 
39 (27.3%) 
10 (7.0%) 
6 (4.2%) 
 
 
99 (69.2%) 
30 (21.0%) 
8 (5.6%) 
6 (4.2%) 
 
 
106 (74.1%) 
29 (20.3%) 
2 (1.4%) 
6 (4.2%) 
 
162 (71.4%) 
39 (17.2%) 
16 (7.0%) 
10 (4.4%) 
 
 
174 (76.7%) 
36 (15.9%) 
7 (3.0%) 
10 (4.4%) 
 
 
175 (77.1%) 
36 (15.9%) 
6 (2.6%) 
10 (4.4%) 
 
0.064 
 
 
 
 
 
0.191 
 
 
 
 
 
0.472
ð 
BMI at 6 months in kg/m
2
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Median (IQR) 23 (21 – 27) 23.7 (21 – 27) 20.8 (19 – 23) 0.0000
Þ
  24 (21 – 28.0) 24 (21.7 – 28.2) 24 (20.7 – 28) 0.564
ϻ 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30  
Missing 
 
690 (4.8%) 
4755 (33.1%) 
2341 (16.3%) 
1174 (8.2%) 
5424 (37.6%) 
 
351 (6.0%) 
2683 (46.2%) 
1375 (23.7%) 
695 (11.9%) 
702 (12.2%) 
 
339 (4.0%) 
2072 (24.2%) 
966 (11.3%) 
479 (5.6%) 
4722 (54.9%) 
 
0.001 
 
21 (5.7%) 
102 (27.6%) 
54 (14.6%) 
42 (11.4%) 
151 (40.7%) 
 
10 (7.0%) 
55 (38.5%) 
33 (23.1%) 
20 (14.0%) 
25 (17.4%) 
 
11 (4.8%) 
47 (20.7%) 
21 (9.3%) 
22 (9.7%) 
126 (55.5%) 
 
0.546 
Haemoglobin at 6 months in g/dl 
Median (IQR) / Mean ± SD 
 
13.2 (12 – 14.4) 
 
13.3 (12.1 – 14.5) 
 
13.1 (11.9 – 14.3) 
 
0.0000
Þ 
 
13.2 ± 1.8 
 
13.4 ± 1.7 
 
12.7 ± 2.0 
 
0.0613
ƫ 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
66 (0.5%) 
5694 (39.6%) 
8624 (59.9%) 
 
37 (0.6%) 
4298 (74.0%) 
1471 (25.4%) 
 
29 (0.3%) 
1396 (16.3%) 
7153 (83.4%)  
 
0.000 
 
1 (0.3%) 
135 (36.5%) 
234 (63.2%) 
 
0 (0%) 
103 (72.0%) 
40 (28.0%) 
 
1 (0.4%) 
32 (14.1%) 
194 (85.5%) 
 
0.243
ð 
MCV at 6 months in fL 
Median (IQR) 
 
99.5 (92.9 – 106.5) 
 
100.6 (94 – 107.5) 
 
95.3 (90.5 – 102) 
 
0.0000
 Þ
 
 
107.7 (102.5 – 113.5) 
 
109.2 (103.3 – 114.2) 
 
103.4 (96.4 – 112.6) 
 
0.0043
 Þ
 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
227 (1.6%) 
3030 (21.1%) 
3004 (20.9%) 
8123 (56.4%) 
 
177 (3.0%) 
2203 (37.9%) 
2624 (45.2%) 
802 (13.9%) 
 
50 (0.6%) 
827 (9.6%) 
380 (4.4%) 
7321 (85.4%) 
 
0.000 
 
2 (0.5%) 
24 (6.5%) 
131 (35.4%) 
213 (57.6%) 
 
1 (0.7%) 
12 (8.4%) 
113 (79.0%) 
17 (11.9%) 
 
1 (0.4%) 
12 (5.3%) 
18 (7.9%) 
196 (86.4%) 
 
0.000
ð 
 
Change in MCV at 6 months in fL 
Median (IQR)  
 
12.3 (5.7 – 18.4) 
 
13.6 (6.8 – 19) 
 
7.1 (2.7 – 12.6) 
 
0.0000
Þ
 
 
15.4 (4.6 – 20.6) 
 
16.1 (5.9 – 22) 
 
8.9 (3.7 – 17.2) 
 
0.0600
Þ 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
Missing 
 
1952 (13.6%) 
2737 (19.0%) 
9695 (67.4%) 
 
1785 (30.7%) 
2073 (35.7%) 
1948 (33.6%) 
 
167 (1.9%) 
664 (7.7%) 
7747 (90.4%) 
 
0.000 
 
56 (15.1%) 
53 (14.3%) 
261 (70.6%) 
 
49 (34.3%) 
41 (28.7%) 
53 (37.0%) 
 
7 (3.1%) 
12 (5.3%) 
208 (91.6%) 
 
0.163 
Change in CD4 count at 6 months 
in cells/mm
3
 
Median (IQR) 
 
 
128 (69 – 204) 
 
 
135 (76 – 208) 
 
 
96 (35.5 – 177) 
 
 
0.0000
Þ 
 
 
95 (45 – 140) 
 
 
102 (54 – 145) 
 
 
52.5 (-9 – 89)  
 
 
0.0050
Þ 
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Change in CD4 count at 6 months 
in cells/mm
3
 
≥ expected  
< expected  
Missing 
 
 
4463 (31.0%) 
1191 (8.3%) 
8730 (60.7%) 
 
 
3738 (64.4%) 
856 (14.7%) 
1212 (20.9%) 
 
 
725 (8.5%) 
335 (3.9%) 
7518 (87.6%) 
 
 
0.000 
 
 
86 (23.2%) 
37 (10%) 
247 (66.8%) 
 
 
79 (55.2%) 
26 (18.2%) 
38 (26.6%) 
 
 
7 (3.1%) 
11 (4.8%) 
209 (92.1%) 
 
 
0.002 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL:  
-Missing: 
 
 
 
 
1428 (9.9%) 
 
1906 (13.3%) 
 
362 (2.5%) 
 
555 (3.9%) 
10133 (70.4%) 
 
 
 
 
1331 (22.9%) 
 
1553 (26.7%) 
 
337 (5.8%) 
  
349 (6.0%) 
2236 (38.5%) 
 
 
 
 
97 (1.1%) 
 
353 (4.1%) 
 
25 (0.3%) 
 
206 (2.4%) 
7897 (92.1%) 
 
 
 
 
0.003 
 
 
 
 
37 (10%) 
 
29 (7.8%) 
 
11 (3.0%) 
 
20 (5.4%) 
273 (73.8%) 
 
 
 
 
35 (24.5%) 
 
26 (18.2%) 
 
9 (6.3%) 
 
13 (9.1%) 
60 (41.9%) 
 
 
 
 
2 (0.9%) 
 
3 (1.3%) 
 
2 (0.9%) 
 
7 (3.1%) 
213 (93.8%) 
 
 
 
 
0.022
ð
 
Regimen change 
No 
Yes 
 
13092 (91.0%) 
1292 (9.0%) 
 
5210 (89.7%) 
596 (10.3%) 
 
7882 (91.9%) 
696 (8.1%)  
 
0.000 
 
358 (96.8%) 
12 (3.2%) 
 
140 (97.9%) 
3 (2.1%) 
 
218 (96.8%) 
9 (3.2%) 
 
0.383
ð 
TB
α
: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
10743 (74.7%) 
3027 (21.0%) 
614 (4.3%) 
 
 
4345 (74.8%) 
1204 (20.7%) 
257 (4.5%) 
 
 
6398 (74.6%) 
1823 (21.3%) 
357 (4.1%) 
 
 
0.597 
 
 
287 (77.6%) 
76 (20.5%) 
7 (1.9%) 
 
 
120 (83.9%) 
20 (14.0%) 
3 (2.1%) 
 
 
167 (73.6%) 
56 (24.7%) 
4 (1.7%) 
 
 
0.041
ð 
Pregnancy
α
: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
Missing
γ
 
 
 
8664 (60.2%) 
163 (1.1%) 
224 (1.6%) 
5333 (37.1%) 
 
 
3534 (60.9%) 
67 (1.2%) 
115 (1.9%) 
2090 (36.0%) 
 
 
5130 (59.8%) 
96 (1.1%) 
109 (1.3%) 
3243 (37.8%) 
 
 
0.007 
 
 
195 (52.7%) 
3 (0.8%) 
6 (1.6%) 
166 (44.9%) 
 
 
80 (55.9%) 
0 (0%) 
2 (1.4%) 
61 (42.7%) 
 
 
115 (50.7%) 
3 (1.3%) 
4 (1.7%) 
105 (46.3%) 
 
 
0.490
ð 
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*
On AZT-based regimens throughout the study period. 
 Þ 
Wilcoxon rank sum test.
  ð Fisher’s exact test. 
 ϻ
 Median test.
 ƫ 
t-test.
  δ 
The last self-reported adherence levels on, or after, the 3 month visit (70 
days post-initiation) and not more than 3 months (110 days) before the date of the viral load but at least 28 days before the viral load was done.  
α 
Variable has baseline and 6 month components.  
γ 
Male  
patients.  ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile range.  MCV: Mean cell volume.  SD: Standard deviation.  TB: Tuberculosis.   
 
The table above shows the clinical characteristics of all patients and patients on AZT-based regimens at 6 months. The characteristics were 
described using frequencies with percentages and medians with interquartile ranges. Missing values for a missed medical visit, missed ARV 
drug pickup or missing either a medical or ARV visit were the result of the patient having only one documented scheduled visit during the study 
period (excluding the ART initiation visit) i.e there was no possibility of the patient falling into the group with ≥ 2 missed visits. The table 
demonstrates that some of the 6 month clinical characteristics of all patients including those excluded due to missing viral load results at the end-
point are similar to those of the study population (Table 1c). Like the main analysis, the sensitivity analysis also showed a large proportion 
(almost 50%) of missing values for self-reported adherence. There were, however, differences in 6 month characteristics for the variables 
haemoglobin (59.9% of values missing), BMI, MCV, change in MCV and CD4 count due to the larger percentages of missing values at 6 
months. This implies that most of the patients excluded from the main analysis due to missing viral load results also lack the scheduled 
haemoglobin, MCV and/or CD4 count at 6 months. Only 21.1% of all patients had a normal MCV at 6 months and only 20.9% had a high MCV 
at 6 months. A median change in CD4 count of 128 cells/mm
3
 (IQR: 69 – 204) was obtained for all patients at 6 months. 4.3% of females were 
pregnant during the study period. About a quarter of the patients were on TB treatment during the study period but adverse events or side effects 
were rare.  The table also shows p-values for the association between different variables and poor adherence at 6 months measured by viral load 
at 6 months. Except where otherwise stated, the chi-square test was used. 
 
 
 
Adverse events or side effects 
No 
Yes 
 
13986 (97.2%) 
398 (2.8%) 
 
5618 (96.8%) 
188 (3.2%) 
 
8368 (97.6%) 
210 (2.4%) 
 
0.005 
 
368 (99.5%) 
2 (0.5%) 
 
226 (99.6%) 
1 (0.4%) 
 
142 (99.3%) 
1 (0.7%) 
 
1.000
ð 
 52 
 
Table 5d: Baseline demographic characteristics and their associations with poor adherence for all patients including those excluded due 
to missing viral load results assuming that those with missing viral load results had a viral load < 400 copies/ml  
* 
On AZT-based regimens throughout the study period. 
 Þ 
Wilcoxon rank sum test.  AZT: Zidovudine.  IQR: Interquartile range.  
 
Characteristics All patients All patients on AZT-based regimens
*
 
Total 
N = 14384 
Viral load 
< 400 copies/ml 
N = 13030 
Viral load 
≥ 400 copies/ml 
N = 1354 
P-value Total  
N = 370 
Viral load 
< 400 copies/ml 
N = 336 
Viral load 
≥ 400 copies/ml 
N = 34 
P-value 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Gender  
Females          
Males 
 
9051 (62.9%) 
5333 (37.1%) 
 
8244 (63.3%) 
4786 (36.7%) 
 
807 (59.6%) 
547 (40.4%) 
 
0.008 
 
204 (55.1%) 
166 (44.9%) 
 
189 (56.3%) 
147 (43.7%) 
 
15 (44.1%) 
19 (55.9%) 
 
0.175 
Age at initiation 
in years 
Median (IQR) 
 
 
36.6 (31.4 – 43.2) 
 
 
36.7 (31.4 – 43.3) 
 
 
36.3 (30.7 – 42.9) 
 
 
0.0675
Þ 
 
 
39.6 (33.6 – 45.7) 
  
 
39.7 (33.9 – 45.8) 
 
 
36.3 (30.7 – 44.9)      
 
 
0.1222
Þ 
Age at initiation 
in years 
≤ 36.7 
> 36.7 
 
 
7263 (50.5%) 
7121 (49.5%) 
 
 
6561 (50.4%) 
6469 (49.6%) 
 
 
702 (51.8%) 
652 (48.2%) 
 
 
0.296 
 
 
134 (36.2%) 
236 (63.8%) 
 
 
117 (34.8%) 
219 (65.2%) 
 
 
17 (50%) 
17(50%) 
 
 
0.079 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
Missing:  
 
8740 (60.8%) 
1812 (12.6%) 
426 (3.0%) 
3406 (23.6%) 
 
7831 (60.1%) 
1646 (12.6%) 
390 (3.0%) 
3163 (24.3%) 
 
909 (67.1%) 
166 (12.3%) 
36 (2.7%) 
243 (17.9%) 
 
0.143 
 
197 (53.2%) 
57 (15.4%) 
12 (3.2%) 
104 (28.2%) 
 
179 (53.3%) 
51 (15.2%) 
11 (3.3%) 
95 (28.2%) 
 
18 (52.9%) 
6 (17.6%) 
1 (2.9%) 
9 (26.6%) 
 
0.921 
Professional 
status    
Employed 
Unemployed 
Missing 
 
 
7191 (50.0%) 
6973 (48.5%) 
220 (1.5%) 
 
 
6526 (50.1%) 
6311 (48.4%) 
193 (1.5%) 
 
 
665 (49.1%) 
662 (48.9%) 
27 (2.0%) 
 
 
0.615 
 
 
180 (48.7%) 
184 (49.7%) 
6 (1.6%) 
 
 
162 (48.2%) 
169 (50.3%) 
5 (1.5%) 
 
 
18 (52.9%) 
15 (44.1%) 
1 (3.0%) 
 
 
0.539 
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The baseline demographic characteristics in the table above are the same as those shown in the table assuming that those with missing results 
had a viral load ≥ 400 copies/ml (Table 5a). They differ only in the distribution of patients in each variable by whether the viral load was < or ≥ 
400 copies/ml. The table also shows p-values for the association between different variables and poor adherence at 6 months measured by viral 
load at 6 months. Except where otherwise stated, the chi-square test was used.  
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Table 5e: Baseline clinical characteristics and their associations with poor adherence for all patients including those excluded due to 
missing viral load results assuming that those with missing viral load results had a viral load < 400 copies/ml  
Characteristics All patients All patients on AZT-based regimens
*
 
Total 
N = 14384 
Viral load 
< 400 copies/ml 
N = 13030 
Viral load 
≥ 400 copies/ml 
N = 1354 
P-value Total  
N = 370 
Viral load 
< 400 copies/ml 
N = 336 
Viral load 
≥ 400 copies/ml 
N = 34 
P-value 
n (%)  n (%) n (%)  n (%) n (%)  n (%) 
BMI at initiation in kg/m
2
 
Median (IQR) 
 
22 (19 – 25) 
 
22 (19 – 25) 
 
22 (19 – 25) 
 
0.846
ϻ
 
 
22.0 (19.3 – 28.0) 
 
22.0 (19.3 – 28.0) 
 
23 (20 – 24.0) 
 
0.6742
Þ 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
Missing 
 
2179 (15.1%) 
6693 (46.5%) 
2290 (15.9%) 
1089 (7.6%) 
2133 (14.9%) 
 
1972 (15.1%) 
6082 (46.7%) 
2080 (16.0%) 
993 (7.6%) 
1903 (14.6%) 
 
207 (15.3%) 
611 (45.1%) 
210 (15.5%) 
96 (7.1%) 
230 (17.0%) 
 
0.927 
 
45 (12.2%) 
129 (34.9%) 
40 (10.8%) 
52 (14.1%) 
104 (28.0%) 
 
43 (12.8%) 
112 (33.3%) 
36 (10.7%) 
51 (15.2%) 
94 (28.0%) 
 
2 (5.9%) 
17 (50%) 
4 (11.8%) 
1 (2.9%) 
10 (29.4%) 
 
0.062 
Baseline haemoglobin in g/dl 
Median (IQR) / mean ± SD 
 
11.7 (10.1 – 13.1) 
 
11.7 (10.1 – 13.1) 
 
11.5 (10.1 – 13) 
 
0.1364
Þ 
 
12.6 ± 1.8 
 
12.5 ± 1.8 
 
13.3 ± 1.4 
 
0.0402
ƫ 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
688 (4.8%) 
12298 (85.5%) 
1398 (9.7%) 
 
625 (4.8%) 
11177 (85.8%) 
1228 (9.4%) 
 
63 (4.7%) 
1121 (82.8%) 
170 (12.5%) 
 
0.971 
 
1 (0.3%) 
285 (77.0%) 
84 (22.7%) 
 
1 (0.3%) 
261 (77.7%) 
74 (22.0%) 
 
0 (0%) 
24 (70.6%) 
10 (29.4%) 
 
1.000
ð 
MCV at baseline in fL  
Median (IQR) 
 
88.2 (83.7 – 92.2) 
 
88.2 (83.6 – 92.2) 
 
88.8 (84.3 – 92.6) 
 
0.0064
Þ 
 
90.8 (85.7 – 97.4) 
 
91.0 (85.7 – 97.5) 
 
89.5 (82.9 – 97.4) 
 
0.5637
Þ 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
1427 (9.9%) 
9757 (67.8%) 
475 (3.3%) 
2725 (19.0%) 
 
1336 (10.3%) 
8973 (68.9%) 
428 (3.3%) 
2293 (17.5%) 
 
91 (6.7%) 
784 (57.9%) 
47 (3.5%) 
432 (31.9%)  
 
0.025 
 
26 (7.0%) 
188 (50.8%) 
55 (14.9%) 
101 (27.3%) 
 
22 (6.5%) 
174 (51.8%) 
50 (14.9%) 
90 (26.8%) 
 
4 (11.8%) 
14 (41.2%) 
5 (14.7%) 
11 (32.3%)  
 
0.358 
Baseline CD4 count in cells/mm
3
 
Median (IQR)  
 
101 (39 – 172) 
 
102 (40 – 172) 
 
90 (34 – 170) 
 
0.0071
Þ
 
 
128 (61 – 218) 
 
126.5 (60 – 211.5) 
 
169 (61 – 249) 
 
0.4026
Þ
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* 
On AZT-based regimens throughout the study period. 
 ϻ
 Median test. 
 Þ 
Wilcoxon rank sum test.
   ƫ t-test.
   ð Fisher’s exact test.  AZT: Zidovudine.  BMI: Body Mass Index.     
IQR: Interquartile range.  MCV: Mean cell volume.  SD: Standard deviation.  WHO: World Health Organization.  
 
The baseline clinical characteristics in the table above are the same as those shown in the table assuming that those with missing results had a 
viral load ≥ 400 copies/ml (Table 5b). They differ only in the distribution of patients in each variable by whether the viral load was < or ≥ 400 
copies/ml. The table also shows p-values for the association between different variables and poor adherence at 6 months measured by viral load 
at 6 months. Except where otherwise stated, the chi-square test was used. 
 
 
 
 
 
 
Baseline CD4 in cells/mm
3
 
> 200 
101 – 200 
51 – 100 
≤ 50  
Missing 
 
1858 (12.9%) 
4443 (30.9%) 
2489 (17.3%) 
3762 (26.2%) 
1832 (12.7%) 
 
1683 (12.9%) 
4092 (31.4%) 
2258 (17.3%) 
3374 (25.9%) 
1623 (12.5%) 
 
175 (12.9%) 
351 (25.9%) 
231 (17.1%) 
388 (28.7%) 
209 (15.4%)  
 
0.002 
 
87 (23.5%) 
81 (21.9%) 
51 (13.8%) 
60 (16.2%) 
91 (24.6%) 
 
75 (22.3%) 
75 (22.3%) 
47 (14.0%) 
55 (16.4%) 
84 (25%) 
 
12 (35.3%) 
6 (17.6%) 
4 (11.8%) 
5 (14.7%) 
7 (20.6%) 
 
0.539
ð 
WHO stage at baseline 
 I 
II 
III 
IV 
Missing 
 
4650 (32.3%) 
2376 (16.5%) 
3685 (25.6%) 
1337 (9.3%) 
2336 (16.3%) 
 
4315 (33.1%) 
2161 (16.6%) 
3350 (25.7%) 
1193 (9.2%) 
2011 (15.4%) 
 
335 (24.7%) 
215 (15.9%) 
335 (24.7%) 
144 (10.6%) 
325 (24.1%) 
 
0.000 
 
133 (35.9%) 
27 (7.3%) 
70 (18.9%) 
27 (7.3%) 
113 (30.6%) 
 
119 (35.4%) 
25 (7.4%) 
64 (19.0%) 
27 (8.0%) 
101 (30.2%) 
 
14 (41.2%) 
2 (5.9%) 
6 (17.6%) 
0 (0%) 
12 (35.3%) 
 
0.397 
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 Table 5f: 6 month clinical characteristics and their associations with poor adherence for all patients including those excluded due to 
missing viral load results assuming that those with missing viral load results had a viral load < 400 copies/ml  
 
 
Characteristic All patients All patients on AZT-based regimens
*
 
Total 
N =  14384 
Viral load 
< 400 copies/ml 
N = 13030 
Viral load 
≥ 400 copies/ml 
N = 1354 
P-value Total  
N = 370 
Viral load 
< 400 copies/ml 
N = 336 
Viral load 
≥ 400 copies/ml 
N = 34 
P-value 
 
n (%)  n (%) n (%)  n (%) n (%)  n (%) 
Self-reported adherence
δ 
> 90% 
> 60 – 90% 
≤ 60% 
Missing 
 
6491 (45.1%) 
738 (5.1%) 
171 (1.2%) 
6984 (48.6%) 
 
5879 (45.1%) 
665 (5.1%) 
149 (1.1%) 
6337 (48.7%) 
 
612 (45.2%) 
73 (5.4%) 
22 (1.6%) 
647 (47.8%) 
 
0.303 
 
147 (39.7%) 
12 (3.2%) 
6 (1.6%) 
205 (55.5%) 
 
140 (41.7%) 
11 (3.3%) 
5 (1.5%) 
180 (53.5%) 
 
7 (20.6%) 
1 (2.9%) 
1 (2.9%) 
25 (73.6%)  
 
0.255
ð 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
Missing 
 
Number of missed medical visits 
0 
1 
≥ 2 
Missing 
 
9697 (67.4%) 
3363 (23.4%) 
989 (6.9%) 
335 (2.3%) 
 
 
10950 (76.1%) 
2622 (18.2%) 
450 (3.1%) 
362 (2.6%) 
 
 
11002 (76.5%) 
2580 (17.9%) 
440 (3.0%) 
362 (2.6%)  
 
8811 (67.6%) 
3034 (23.3%) 
875 (6.7%) 
310 (2.4%) 
 
 
9969 (76.5%) 
2344 (18.0%) 
381 (2.9%) 
336 (2.6%) 
 
 
10009 (76.8%) 
2308 (17.7%) 
377 (2.9%) 
336 (2.6%) 
 
886 (65.4%) 
329 (24.3%) 
114 (8.5%) 
25 (1.8%) 
 
 
981 (72.5%) 
278 (20.5%) 
69 (5.1%) 
26 (1.9%) 
 
 
993 (73.3%) 
272 (20.1%) 
63 (4.7%) 
26 (1.9%) 
 
0.038 
 
 
 
 
 
0.000 
 
 
 
 
 
0.000 
 
 
250 (67.6%) 
78 (21.1%) 
26 (7.0%) 
16 (4.3%) 
 
 
273 (73.8%) 
66 (17.8%) 
15 (4.1%) 
16 (4.3%) 
 
 
281 (75.9%) 
65 (17.6%) 
8 (2.2%) 
16 (4.3%) 
 
231 (68.8%) 
73 (21.7%) 
20 (5.9%) 
12 (3.6%) 
 
 
252 (75%) 
59 (17.6%) 
13 (3.8%) 
12 (3.6%) 
 
 
262 (78.0%) 
57 (17.0%) 
5 (1.4%) 
12 (3.6%) 
 
19 (55.9%) 
5 (14.7%) 
6 (17.6%) 
4 (11.8%) 
 
 
21 (61.8%) 
7 (20.6%) 
2 (5.8%) 
4 (11.8%) 
 
 
19 (55.9%) 
8 (23.5%) 
3 (8.8%) 
4 (11.8%) 
 
0.020 
 
 
 
 
 
0.373
ð 
 
 
 
 
0.010
ð
 
 57 
 
BMI at 6 months in kg/m
2
  
Median (IQR) 
 
23 (21 – 27) 
 
23.2 (21 – 27) 
 
23 (20.7 – 26) 
 
0.0028
Þ 
 
24 (21 – 28.0) 
 
24 (21 – 29) 
 
23 (20.7 – 25)  
 
0.2020
 Þ
 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30  
Missing 
 
690 (4.8%) 
4755 (33.1%) 
2341 (16.3%) 
1174 (8.2%) 
5424 (37.6%) 
 
578 (4.4%) 
4093 (31.4%) 
2035 (15.6%) 
1032 (7.9%) 
5292 (40.7%) 
 
112 (8.3%) 
662 (48.9%) 
306 (22.6%) 
142 (10.5%) 
132 (9.7%) 
 
0.064 
 
21 (5.7%) 
102 (27.6%) 
54 (14.6%) 
42 (11.4%) 
151 (40.7%) 
 
19 (5.7%) 
85 (25.3%) 
48 (14.3%) 
40 (11.9%) 
144 (42.8%) 
 
2 (5.9%) 
17 (50%) 
6 (17.6%) 
2 (5.9%) 
7 (20.6%) 
 
0.267
ð 
Haemoglobin at 6 months in g/dl 
Median (IQR)  
 
13.2 (12 – 14.4) 
 
13.3 (12 – 14.5) 
 
13.1 (12 – 14.3) 
 
0.0539
Þ 
 
13.1 (12.1 – 14.6) 
 
12.9 (12 – 14.5) 
 
13.7 (12.5 – 14.7) 
 
0.4037
Þ 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
66 (0.5%) 
5694 (39.6%) 
8624 (59.9%) 
 
53 (0.4%) 
4802 (36.9%) 
8175 (62.7%) 
 
13 (1.0%) 
892 (65.9%) 
449 (33.2%) 
 
0.371 
 
1 (0.3%) 
135 (36.5%) 
234 (63.2%) 
 
0 (0%) 
118 (35.1%) 
218 (64.9%) 
 
1 (2.9%) 
17 (50%) 
16 (47.1%) 
 
0.132
ð
 
MCV at 6 months in fL 
Median (IQR) 
 
99.5 (92.9 – 106.5) 
 
100.5 (93.8 – 107.4) 
 
95.2 (90.4 – 101.2) 
 
0.0000
 Þ
 
 
107.7 (102.5 – 113.5) 
 
109.3 (103.4 – 114.2) 
 
100.2 (92.3 – 108.3) 
 
0.0004
 Þ
 
MCV at 6 months  
< 80fL: 
80 – 100fL: 
> 100fL: 
Missing: 
 
227 (1.6%) 
3030 (21.1%) 
3004 (20.9%) 
8123 (56.4%) 
 
186 (1.4%) 
2337 (17.9%) 
2710 (20.8%) 
7797 (59.9%) 
 
41 (3.0%)  
693 (51.2%) 
294 (21.7%) 
326 (24.1%) 
 
0.000 
 
2 (0.5%) 
24 (6.5%) 
131 (35.4%) 
213 (57.6%) 
 
1 (0.3%) 
13 (3.9%) 
119 (35.4%) 
203 (60.4%) 
 
1 (2.9%) 
11 (32.4%) 
12 (35.3%) 
10 (29.4%) 
 
0.000
ð 
Change in MCV at 6 months in 
fL 
Median (IQR)/ mean ± SD 
 
 
12.3 (5.7 – 18.4) 
 
 
13.5 (6.6 – 18.9) 
 
 
6.8 (2.6 – 11.8) 
 
 
0.0000
 Þ
 
 
 
13.5 ± 10.0 
 
 
14.3 ± 10.0 
 
 
8.0 ± 9.1 
 
 
0.0216
ƫ 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
Missing  
 
1952 (13.6%) 
2737 (19.0%) 
9695 (67.4%) 
 
1835 (14.1%) 
2184 (16.8%) 
9011 (69.1%) 
 
117 (8.6%) 
553 (40.8%) 
684 (50.6%) 
 
0.000
 
 
56 (15.1%) 
53 (14.3%) 
261 (70.6%) 
 
52 (15.5%) 
42 (12.5%) 
242 (72.0%) 
 
4 (11.8%) 
11 (32.4%) 
19 (55.8%) 
 
0.052
ð 
Change in CD4 count at 6 months 
in cells/mm
3
 
Median (IQR) 
 
 
128 (69 – 204) 
 
 
133 (75 – 207) 
 
 
97 (33 – 180) 
 
 
0.0000
Þ
 
 
 
95 (45 – 140)  
 
 
100.5 (54 – 145) 
 
 
52 (-9 – 61) 
 
 
0.0043
Þ 
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Change in CD4 count at 6 months 
in cells/mm
3
 
≥ expected  
< expected  
Missing 
 
 
4463 (31.0%) 
1191 (8.3%) 
8730 (60.7%) 
 
 
3853 (29.6%) 
891 (6.8%) 
8286 (63.6%) 
 
 
610 (45.1%) 
300 (22.2%) 
444 (32.7%) 
 
 
0.000 
 
 
86 (23.2%) 
37 (10%) 
247 (66.8%) 
 
 
80 (23.8%) 
26 (7.7%) 
230 (68.5%) 
 
 
6 (17.6%) 
11 (32.4%) 
17 (50%) 
 
 
0.001 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
-Missing: 
 
 
 
 
1428 (9.9%) 
 
1906 (13.3%) 
 
362 (2.5%) 
 
555 (3.9%) 
10133 (70.4%) 
 
 
 
 
1347 (10.3%) 
 
1596 (12.2%) 
 
341 (2.6%) 
 
367 (2.8%) 
9379 (72.1%) 
 
 
 
 
81 (6.0%) 
 
310 (22.9%) 
 
21 (1.6%) 
 
188 (13.9%) 
754 (55.6%) 
 
 
 
 
0.000 
 
 
 
 
37 (10%) 
 
29 (7.8%) 
 
11 (3.0%) 
 
20 (5.4%) 
273 (73.8%) 
 
 
 
 
35 (10.4%) 
 
26 (7.7%) 
 
9 (2.7%) 
 
13 (3.9%) 
253 (75.3%) 
 
 
 
 
2 (5.9%) 
 
3 (8.8%) 
 
2 (5.9%) 
 
7 (20.5%) 
20 (58.9%) 
 
 
 
 
0.022
ð
 
Regimen change 
No 
Yes 
 
13092 (91.0%) 
1292 (9.0%) 
 
11857 (91.0%) 
1173 (9.0%) 
 
1235 (91.2%) 
119 (8.8%) 
 
0.794 
 
358 (96.8%) 
12 (3.2%) 
 
327 (91.3%) 
9 (2.7%) 
 
31 (91.2%) 
3 (8.8%) 
 
0.088
ð
 
TB
α
: On TB treatment during first 
6 months on ART: 
Never 
At baseline 
During follow-up 
 
 
10743 (74.7%) 
3027 (21.0%) 
614 (4.3%) 
 
 
9733 (74.7%) 
2738 (21.0%) 
559 (4.3%) 
 
 
1010 (74.6%) 
289 (21.3%) 
55 (4.1%) 
 
 
0.898 
 
 
287 (77.6%) 
76 (20.5%) 
7 (1.9%) 
 
 
257 (76.5%) 
72 (21.4%) 
7 (2.1%) 
 
 
30 (88.2%) 
4 (11.8%) 
0 (0%) 
 
 
0.321
ð
 
Pregnancy
α
: Pregnancy during first 
6 months on ART: 
Never  
At baseline 
During follow-up 
Missing
γ
 
 
 
8664 (60.2%) 
163 (1.1%) 
224 (1.6%) 
5333 (37.1%) 
 
 
7904 (60.7%) 
148 (1.1%) 
192 (1.5%) 
4786 (36.7%) 
 
 
760 (56.1%) 
15 (1.1%) 
32 (2.4%) 
547 (40.4%) 
 
 
0.017 
 
 
195 (52.7%) 
3 (0.8%) 
6 (1.6%) 
166 (44.9%) 
 
 
183 (54.5%) 
3 (0.9%) 
3 (0.9%) 
147 (43.7%) 
 
 
12 (35.3%) 
0 (0%) 
3 (8.8%) 
19 (55.9%) 
 
 
0.011
ð
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 * 
On AZT-based regimens throughout the study period.  
Þ 
Wilcoxon rank sum test.
   ƫ 
t-test.
  ð Fisher’s exact test.  
δ 
The last self-reported adherence levels on, or after, the 3 month visit (70 days  
 post-initiation) and not more than 3 months (110 days) before the date of the viral load but at least 28 days before the viral load was done.  
α
 Variable has baseline and 6 month components.  
γ
 Male patients.  
 ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile range.  MCV: Mean cell volume.  SD: Standard deviation. TB: Tuberculosis.   
 
The clinical characteristics of patients at 6 months, shown in the table above, are the same as those in the table assuming that those with missing 
results had a viral load ≥ 400 copies/ml (Table 5c). They differ only in the distribution of patients in each variable by whether the viral load was 
< or ≥ 400 copies/ml. The table also shows p-values for the association between different variables and poor adherence at 6 months measured by 
viral load at 6 months. Except where otherwise stated, the chi-square test was used. 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse events or side effects 
No 
Yes 
 
13986 (97.2%) 
398 (2.8%) 
 
12649 (97.1%) 
381 (2.9%) 
 
1337 (98.7%) 
17 (1.3%) 
 
0.000 
 
368 (99.5%) 
2 (0.5%) 
 
334 (99.4%) 
2 (0.6%) 
 
34 (100%) 
0 (0%) 
 
1.000
ð 
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Table 6: Table showing the point at which the ART adherence was reported and the points at which the MCV, CD4 count and viral load 
at 6 months were done for the sensitivity analyses 
 
 
 
 
 
 
 
 
 
 
                            
* 
On AZT-based regimens throughout the study period. 
 
AZT: Zidovudine.  IQR: Interquartile range.  MCV: Mean cell volume.  
 
The table above shows that the MCV and CD4 count at 6 months for all patients and for patients on AZT were done at approximately the same 
time as in the main analysis (Table 2). The point at which the viral load was done was different from that for all eligible patients as the end-point 
was set at 183 days for all patients with a missing viral load. This is 20 days before the median end-point for eligible patients with a documented 
viral load result (Table 2). This may have compounded the problem of the sensitivity analyses having larger percentages of missing values for 
BMI, haemoglobin, MCV, change in MCV and CD4 count at 6 months than the main analysis. 
 
 
 
Variable All patients including those excluded due 
to missing viral load results  
All patients on AZT-based regimens 
including those excluded due to missing 
viral load results
*
  
Median (IQR) Median (IQR) 
Self-reported adherence 51 days (IQR: 42 – 75) before the viral load 
was done. 
44 days (IQR: 40 – 71) before the viral load 
was done. 
MCV at 6 months 198 days (IQR: 169 – 266) after ART 
initiation. 
203 days (IQR: 173 – 260) after ART 
initiation. 
CD4 count at 6 months 203 days (IQR: 170 – 270) after ART 
initiation. 
207.5 days (IQR: 175 – 264) after ART 
initiation. 
Viral load at 6 months 183 days (IQR: 183 – 203) after ART 
initiation. 
183 days (IQR: 183 – 203) after ART 
initiation. 
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3.4.2 Poisson regression with robust error variance for the sensitivity analysis 
In this section, univariate and multivariate Poisson regression models (with robust error variance) for all patients including those without a 
documented viral load result at 6 months are presented. 
 
Table 7a: Univariate and multivariate Poisson regression models with robust error variance assuming that those with missing viral load 
results had a viral load ≥ 400 copies/ml  
Variable All patients  All patients on AZT-based regimens
*
 
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P -
value 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P -
value 
Gender  
Females               
Males 
 
1 
1.03 (1.00 – 1.06) 
 
- 
0.027 
 
1 
1.10 (0.96 – 1.26) 
 
- 
0.170 
 
1 
1.06 (0.90 – 1.24) 
 
- 
0.497 
 
- 
- 
 
- 
- 
Age at initiation  
≤ 36.7 years 
> 36.7 years 
 
1 
0.99 (0.96 – 1.01) 
 
- 
0.297 
 
1 
0.92 (0.80 – 1.05) 
 
- 
0.212 
 
1 
0.85 (0.72 – 1.00) 
 
- 
0.044 
 
1 
1.40 (0.49 – 3.98) 
 
- 
0.528 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
1.00 (0.96 – 1.04) 
0.96 (0.88 – 1.05) 
 
- 
0.888 
0.356 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.11 (0.90 – 1.37) 
0.81 (0.46 – 1.45) 
 
- 
0.311 
0.485 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed 
 
1 
1.06 (1.03 – 1.09) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
1.02 (0.87 – 1.21) 
 
- 
0.784 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.93 (0.89 – 0.96) 
0.90 (0.86 – 0.95) 
0.90 (0.85 – 0.95) 
 
- 
0.000 
0.000 
0.000 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
0.97 (0.74 – 1.27) 
0.96 (0.69 – 1.36) 
0.90 (0.64 – 1.25) 
 
- 
0.834 
0.834 
0.519 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Baseline haemoglobin 
≤ 8 g/dl 
 
1 
 
- 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
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> 8g/dl  1.00 (0.94 – 1.06) 0.929 - - -‡ - - - 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.01 (0.97 – 1.06) 
0.95 (0.87 – 1.04) 
 
- 
0.661 
0.278 
 
1 
1.28 (1.02 – 1.62) 
0.89 (0.60 – 1.33) 
 
- 
0.037 
0.578 
 
1 
1.04 (0.77 – 1.40) 
0.61 (0.40 – 0.94) 
 
- 
0.789 
0.025 
 
- 
- 
- 
 
- 
- 
- 
Baseline CD4 count in cells/mm
3
 
> 200 
101 – 200 
51 – 100 
≤ 50  
 
1 
1.09 (1.04 – 1.14) 
1.09 (1.04 – 1.15) 
1.09 (1.04 – 1.15) 
 
- 
0.000 
0.001 
0.000 
 
1 
1.13 (0.91 – 1.40) 
1.29 (1.02 – 1.63) 
1.45 (1.17 – 1.79) 
 
- 
0.260 
0.035 
0.001 
 
1 
1.19 (0.92 – 1.54) 
1.19 (0.89 – 1.59) 
1.26 (0.96 – 1.65) 
 
- 
0.188 
0.248 
0.090 
 
1 
0.64 (0.07 – 5.88) 
2.44 (0.50 – 11.88) 
3.32 (0.44 – 24.77) 
 
- 
0.694 
0.270 
0.242 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.01 (0.97 – 1.05) 
1.02 (0.98 – 1.05) 
0.94 (0.89 – 0.99) 
 
- 
0.655 
0.336 
0.024 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
0.96 (0.64 – 1.42) 
1.35 (1.09 – 1.66) 
1.09 (0.77 – 1.55) 
 
- 
0.831 
0.006 
0.613 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.02 (0.97 – 1.08) 
1.06 (0.96 – 1.16) 
 
- 
0.343 
0.267 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.79 (0.48 – 1.28) 
1.12 (0.78 – 1.63) 
 
- 
0.336 
0.538 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
0.91 (0.88 – 0.94) 
0.79 (0.74 – 0.84) 
 
 
1 
0.88 (0.84 – 0.91) 
0.79 (0.72 – 0.87) 
 
 
1 
0.93 (0.89 – 0.96) 
0.87 (0.79 – 0.95) 
 
- 
0.000 
0.000 
 
 
- 
0.000 
0.000 
 
 
- 
0.000 
0.002 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.77 (0.61 – 0.98) 
0.95 (0.69 – 1.30) 
 
 
1 
0.86 (0.67 – 1.09) 
0.73 (0.42 – 1.27) 
 
 
1 
0.89 (0.70 – 1.13) 
1.20 (0.80 – 1.82) 
 
- 
0.034 
0.750 
 
 
- 
0.200 
0.266 
 
 
- 
0.331 
0.375 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30  
 
1 
0.89 (0.82 – 0.96) 
0.84 (0.77 – 0.92) 
0.83 (0.75 – 0.92)  
 
- 
0.004 
0.000 
0.000 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
0.88 (0.56 – 1.39) 
0.74 (0.44 – 1.26) 
1 (0.61 – 1.65) 
 
- 
0.585 
0.269 
1.000 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.56 (0.42 – 0.74) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
0.24 (0.17 – 0.32) 
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.24 (0.96 – 1.59) 
0.57 (0.44 – 0.75) 
 
- 
0.095 
0.000 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1 (0.24 – 4.25) 
0.27 (0.06 – 1.18) 
 
- 
1.000 
0.082 
 
- 
- 
- 
 
- 
- 
- 
Change in MCV at 6 months 
≥14.5fL 
<14.5fL 
 
1 
2.84 (2.42 – 3.33) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
1.81 (0.77 – 4.27) 
 
- 
0.174 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months in cells/mm
3
 
≥ expected  
< expected  
 
1 
1.73 (0.55 – 1.94) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
3.65 (1.53 – 8.71) 
 
- 
0.003 
 
1  
6.62 (1.35 – 32.35) 
 
- 
0.020 
Change in CD4 count at 6 months stratified by change in 
MCV at 6 months 
-Change in CD4 count ≥ expected and change in MCV ≥ 
14.5: 
-Change in CD4 count ≥ expected and change in MCV < 
14.5: 
-Change in CD4 count < expected and change in MCV ≥ 
14.5: 
-Change in CD4 count < expected and change in MCV < 
14.5: 
 
 
 
1 
 
2.73 (2.20 – 3.34) 
 
1.02 (0.67 – 1.55) 
 
5.46 (4.38 – 6.81) 
 
 
 
- 
 
0.000 
 
0.939 
 
0.000 
 
 
 
1 
 
2.81 (2.27 – 3.48) 
 
1.08 (0.70 – 1.65) 
 
5.92 (4.74 – 7.39) 
 
 
 
- 
 
0.000 
 
0.731 
 
0.000 
 
 
 
1 
 
1.91 (0.34 – 10.80) 
 
3.36 (0.53 – 21.40) 
 
6.48 (1.47 – 28.50) 
 
 
 
- 
 
0.462 
 
0.199 
 
0.013 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.89 (0.85 – 0.94) 
 
- 
0.000 
 
- 
0.79 (0.62 – 1.01) 
 
- 
0.058 
 
1 
1.23 (0.88 – 1.73) 
 
- 
0.226 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 6 months on ART: 
Never 
 
1 
 
- 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
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At baseline 
During follow-up 
1.01 (0.98 – 1.05) 
0.98 (0.91 – 1.05) 
0.505 
0.495 
- 
- 
- 
- 
1.27 (1.07 – 1.50) 
0.98 (0.51 – 1.88) 
0.005 
0.956 
- 
- 
- 
- 
Pregnancy: Pregnancy during first 6 months on ART: 
Never  
At baseline 
During follow-up 
 
1 
0.99 (0.87 – 1.13) 
0.82 (0.72 – 0.94) 
 
- 
0.936 
0.005 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.70 (1.51 – 1.91) 
1.13 (0.63 – 2.02) 
 
- 
0.000 
0.678 
 
- 
-
‡ 
7.36 (2.12 – 25.60) 
 
- 
- 
0.002 
Adverse events or side effects:  
No: 
Yes: 
 
1 
0.88 (0.81 – 0.97) 
 
- 
0.009 
 
- 
- 
 
- 
- 
 
1 
0.81 (0.20 – 3.27) 
 
- 
0.772 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period. 
 ‡ 
Cell has no observations.  ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  CI: Confidence 
interval.  IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis. WHO: World Health Organization. 
 
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens.  After adjusting for potential confounders, the variables independently associated with poor adherence for all 
patients were change in CD4 count stratified by change in MCV at 6 months, CD4 count at baseline and MCV at baseline. The IRR of poor 
adherence increased with decreasing CD4 count at baseline. The association between regimen change and poor adherence was marginally 
significant (p < 0.1). Model fit was good as evidenced by a p-value of 0.389 on the link test. Change in CD4 count at 6 months and pregnancy 
during the first 6 months on ART were the only independent predictors of poor adherence in the final multivariate model for patients on AZT-
based regimens. Model fit for this model was also good as evidenced by a p-value of 0.649 on the link test. 
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Table 7b: Univariate and multivariate regression models with robust error variance assuming that those with missing viral load results 
had a viral load < 400 copies/ml  
Variable All patients  All patients on AZT-based regimens
*
 
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P - 
value 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P - value 
Gender  
Females              
Males 
 
1 
1.15 (1.04 – 1.28) 
 
- 
0.008 
 
1 
1.09 (0.93 – 1.29) 
 
- 
0.283 
 
1 
1.56 (0.82 – 2.97) 
 
- 
0.179 
 
- 
- 
 
- 
- 
Age at initiation  
≤ 36.7 years 
> 36.7 years 
 
1 
0.95 (0.86 – 1.05) 
 
- 
0.296 
 
1 
0.95 (0.81 – 1.12) 
 
- 
0.567 
 
1 
0.57 (0.30 – 1.08) 
 
- 
0.082 
 
1 
1.17 (0.30 – 4.62) 
 
- 
0.823 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.88 (0.75 – 1.03) 
0.81 (0.59 – 1.12) 
 
- 
0.114 
0.202 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.15 (0.48 – 2.77) 
0.91 (0.13 – 6.29) 
 
- 
0.752 
0.926 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1  
1.03 (0.93 – 1.14) 
 
- 
0.615 
 
- 
- 
 
- 
- 
 
1  
0.82 (0.42 – 1.57) 
 
- 
0.541 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.96 (0.83 – 1.12) 
0.97 (0.80 – 1.16) 
0.93 (0.74 – 1.17) 
 
- 
0.603 
0.705 
0.526 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
2.97 (0.71 – 12.37) 
2.25 (0.43 – 11.67) 
0.43 (0.04 – 4.64) 
 
- 
0.136 
0.334 
0.489 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl  
 
1 
1.00 (0.78 – 1.27) 
 
- 
0.971 
 
- 
- 
 
- 
- 
 
1 
-
‡ 
 
- 
- 
 
- 
- 
 
- 
- 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.26 (1.02 – 1.55) 
1.55 (1.11 – 2.17) 
 
- 
0.031 
0.010 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.48 (0.17 – 1.36) 
0.59 (0.17 – 2.02) 
 
- 
0.169 
0.402 
 
- 
- 
- 
 
- 
- 
- 
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Baseline CD4 in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50   
 
1 
0.84 (0.71 – 1.00) 
0.99 (0.82 – 1.19) 
1.10 (0.92 – 1.30) 
 
- 
0.047 
0.877 
0.294 
 
1 
1.11 (0.84 – 1.46) 
1.14 (0.85 – 1.54) 
1.41 (1.07 – 1.85) 
 
- 
0.460 
0.386 
0.014 
 
1 
0.54 (0.21 – 1.37) 
0.57 (0.19 – 1.67) 
0.60 (0.22 – 1.63) 
 
- 
0.192 
0.305 
0.319 
 
1 
0.83 (0.07 – 9.43) 
3.15 (0.47 – 21.20) 
2.04 (0.11 – 38.88) 
 
- 
0.879 
0.237 
0.636 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.26 (1.07 – 1.48) 
1.26 (1.09 – 1.46) 
1.49 (1.24 – 1.80) 
 
- 
0.006 
0.002 
0.000 
 
1 
1.15 (0.90 – 1.48) 
1.28 (1.04 – 1.57) 
1.47 (1.15 – 1.89) 
 
- 
0.257 
0.018 
0.002 
 
1 
0.70 (0.17 – 2.93) 
0.81 (0.33 – 2.03) 
-
‡
 
 
- 
0.629 
0.660 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.05 (0.83 – 1.32) 
1.36 (0.92 – 2.03) 
 
- 
0.683 
0.125 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.75 (0.23 – 13.15) 
3.5 (0.51 – 24.25) 
 
- 
0.587 
0.205 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
1.07 (0.95 – 1.21) 
1.26 (1.05 – 1.52) 
 
 
1 
1.18 (1.04 – 1.34) 
1.71 (1.37 – 2.14) 
 
 
1 
1.17 (1.03 – 1.33) 
1.59 (1.25 – 2.01) 
 
- 
0.266 
0.013 
 
 
- 
0.009 
0.000 
 
 
- 
0.017 
0.000 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.84 (0.33 – 2.19) 
3.04 (1.33 – 6.93) 
 
 
1 
1.38 (0.61 – 3.11) 
1.73 (0.45 – 6.73) 
 
 
1 
1.82 (0.83 – 3.98) 
5.55 (2.05 – 15.01) 
 
- 
0.726 
0.008 
 
 
- 
0.439 
0.427 
 
 
- 
0.133 
0.001 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30  
 
1 
0.86 (0.71 – 1.03) 
0.81 (0.66 – 0.98)  
0.75 (0.59 – 0.94)  
 
- 
0.101 
0.033 
0.012 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.75 (0.44 – 7.03) 
1.17 (0.25 – 5.35) 
0.50 (0.07 – 3.32) 
 
- 
0.430 
0.843 
0.473 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
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Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.80 (0.49 – 1.30) 
 
- 
0.361 
 
- 
- 
 
- 
- 
 
1 
0.13 (0.08 – 0.20)  
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.27 (0.95 – 1.68) 
0.54 (0.40 – 0.73) 
 
- 
0.104 
0.000 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.92 (0.21 – 3.94) 
0.18 (0.04 – 0.81) 
 
- 
0.907 
0.026 
 
- 
- 
- 
 
- 
- 
- 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
 
1 
3.37 (2.79 – 4.08) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
2.91 (0.98 – 8.61) 
 
- 
0.054 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months in cells/mm
3
 
≥ expected  
< expected  
 
1 
1.84 (1.63 – 2.08) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
4.26 (1.70 – 10.70) 
 
- 
0.002 
 
1 
7.73 (0.96 – 62.40)  
 
- 
0.055 
Change in CD4 count at 6 months stratified by 
change in MCV at 6 months 
-Change in CD4count  ≥ expected and change in 
MCV ≥ 14.5: 
-Change in CD4 count ≥ expected and change in 
MCV < 14.5: 
-Change in CD4 count < expected and change in 
MCV ≥ 14.5: 
-Change in CD4 count < expected and change in 
MCV < 14.5:  
 
 
 
1 
 
2.87 (2.27 – 3.63) 
 
1.02 (0.64 – 1.63) 
 
5.97 (4.69 – 7.60) 
 
 
 
- 
 
0.000 
 
0.925 
 
0.000 
 
 
 
1 
 
3.04 (2.35 – 3.93) 
 
1.24 (0.77 – 2.01) 
 
6.73 (5.15 – 8.78) 
 
 
 
- 
 
0.000 
 
0.379 
 
0.000 
 
 
 
1 
 
1.91 (0.34 – 10.80) 
 
3.36 (0.53 – 21.40) 
 
6.48 (1.47 – 28.50) 
 
 
 
- 
 
0.462 
 
0.199 
 
0.013 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.98 (0.82 – 1.17) 
 
- 
0.794 
 
- 
- 
 
- 
- 
 
1 
2.89 (1.02 – 8.15) 
 
- 
0.045 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 6 months on 
ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.02 (0.90 – 1.15) 
0.95 (0.74 – 1.23) 
 
 
- 
0.804 
0.714 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.50 (0.18 – 1.39) 
-
‡
 
 
 
- 
0.184 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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Pregnancy: Pregnancy during first 6 months on 
ART: 
Never  
At baseline 
During follow-up 
 
 
1  
1.05 (0.64 – 1.71) 
1.63 (1.17 – 2.26) 
 
 
- 
0.847 
0.004 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
8.12 (3.07 – 21.48) 
 
 
- 
- 
0.000 
 
 
1 
-
‡
 
9.20 (2.16 – 39.18) 
 
 
- 
- 
0.003 
Adverse events or side effects 
No 
Yes 
 
1 
0.45 (0.28 – 0.71) 
 
- 
0.001 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
- 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period. 
 ‡
Cell has no observations.  ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  CI: Confidence 
interval.  IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis.  WHO: World Health Organization.  
 
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens. After adjusting for potential confounders, the variables independently associated with poor adherence for all 
patients were change in CD4 count stratified by change in MCV at 6 months, CD4 count at baseline and WHO stage at baseline. The IRR of 
poor adherence increased with decreasing CD4 count and increasing WHO stage at baseline. Model fit was good as evidenced by a p-value of 
0.778 on the link test. The change in CD4 count at 6 months and pregnancy during the first 6 months on ART were the only independent 
predictors of poor adherence in the final multivariate model for patients on AZT-based regimens. Model fit for this model was also good as 
evidenced by a p-value of 0.805 on the link test. 
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3.5 POISSON REGRESSION WITH ROBUST ERROR VARIANCE, USING A VIRAL LOAD DONE 90 – 270 DAYS AFTER ART 
INITIATION 
In this section, univariate and multivariate Poisson regression models (with robust error variance) for all patients with a documented viral load 
done 90 – 270 days after ART initiation are presented. 
 
Table 8a: Univariate and multivariate Poisson regression models with robust error variance for all eligible patients and eligible patients 
on AZT-based regimens with a documented viral load done 90 to 270 after ART initiation 
 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Crude IRR 
 (95% CI) 
P -
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Gender  
Females             
Males 
 
1 
1.17 (1.07 – 1.28) 
 
- 
0.000 
 
1 
1.07 (0.90 – 1.28) 
 
- 
0.434 
 
1  
1.78 (0.97 – 3.27) 
 
- 
0.064 
 
1 
1.80 (0.53 – 6.11) 
 
- 
0.343 
Age at initiation  
≤ 36.7 years 
> 36.7 years  
 
1 
0.93 (0.85 – 1.02) 
 
- 
0.117 
 
1 
0.86 (0.71 – 1.02) 
 
- 
0.088 
 
1  
0.99 (0.53 – 5.82) 
 
- 
0.962 
 
1 
1.10 (0.30 – 4.00) 
 
- 
0.890 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.98 (0.85 – 1.11) 
0.77 (0.57 – 1.04) 
 
- 
0.741 
0.088 
 
- 
- 
- 
 
- 
- 
- 
 
1  
1.62 (0.75 – 3.50) 
0.71 (0.12 – 5.43) 
 
- 
0.220 
0.812 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.08 (0.99 – 1.18) 
 
- 
0.092 
 
- 
- 
 
- 
- 
 
1 
1.07 (0.58 – 1.95) 
 
- 
0.839 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
 
1 
0.95 (0.84 – 1.08) 
0.85 (0.73 – 1.00) 
 
- 
0.449 
0.056 
 
- 
- 
- 
 
- 
- 
- 
 
1 
3.05 (0.73 – 12.50) 
1.17 (0.17 – 7.82) 
 
- 
0.121 
0.874 
 
- 
- 
- 
 
- 
- 
- 
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≥ 30 0.82 (0.67 – 1.01) 0.061 - - 0.46 (0.04 – 4.89) 0.520 - - 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
1 
1.01 (0.82 – 1.24) 
 
- 
0.958 
 
- 
- 
 
- 
- 
 
1 
-
‡ 
 
- 
- 
 
- 
- 
 
- 
- 
MCV at baseline
ɭ 
 
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.25 (1.05 – 1.49) 
1.46 (1.09 – 2.00) 
 
- 
0.013 
0.011 
 
1 
1.46 (1.07 – 1.99) 
1.03 (0.61 – 1.75) 
 
- 
0.016 
0.902 
 
1 
1.01 (0.43 – 2.39) 
0.87 (0.19 – 3.94) 
 
- 
0.977 
0.857 
 
- 
- 
- 
 
- 
- 
- 
Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
 
1  
1.02 (0.88 – 1.20) 
1.12 (0.95 – 1.33) 
1.14 (0.98 – 1.33) 
 
- 
0.757 
0.174 
0.098 
 
1  
1.12 (0.83 – 1.51) 
1.07 (0.77 – 1.49) 
1.28 (0.95 – 1.72) 
 
- 
0.442 
0.678 
0.107 
 
1  
0.91 (0.40 – 2.10) 
0.46 (0.14 – 1.59) 
0.69 (0.25 – 1.89) 
 
- 
0.823 
0.223 
0.473 
 
1 
1.07 (0.35 – 3.27) 
0.28 (0.04 – 1.79) 
0.40 (0.04 – 3.86) 
 
- 
0.904 
0.180 
0.431 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.18 (1.02 – 1.36) 
1.26 (1.12 – 1.43) 
1.30 (1.10 – 1.53) 
 
- 
0.023 
0.000 
0.002 
 
1 
1.18 (0.90 – 1.54) 
1.41 (1.13 – 1.76) 
1.44 (1.10 – 1.90) 
 
- 
0.232 
0.002 
0.009 
 
1 
1.11 (0.35 – 3.50) 
1.88 (0.38 – 2.04) 
-
‡
 
 
- 
0.858 
0.762 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60%  
 
1 
1.01 (0.83 – 1.23) 
1.51 (1.09 – 2.08) 
 
- 
0.899 
0.012 
 
- 
- 
- 
 
- 
- 
- 
 
1 
2.78 (0.72 – 10.63) 
4.44 (1.30 – 15.20) 
 
- 
0.136 
0.018 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
 
1 
1.02 (0.92 – 1.13) 
1.03 (0.87 – 1.22) 
 
 
1 
1.05 (0.94 – 1.18) 
1.21 (0.96 – 1.51) 
 
 
 
- 
0.693 
0.713 
 
 
- 
0.368 
0.100 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
 
1 
0.96 (0.42 – 2.17) 
2.53 (1.19 – 5.38) 
 
 
1 
1.68 (0.84 – 3.33) 
1.32 (0.34 – 5.06) 
 
 
 
- 
0.921 
0.016 
 
 
- 
0.140 
0.687 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
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0 
1 
≥ 2 
1 
1.12 (1.01 – 1.25) 
1.30 (1.05 – 1.62) 
- 
0.039 
0.018 
- 
- 
- 
- 
- 
- 
1 
1.96 (1.00 – 3.86) 
4.44 (1.71 – 11.51) 
- 
0.051 
0.002 
- 
- 
- 
- 
- 
- 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.84 (0.71 – 0.98) 
0.77 (0.64 – 0.92) 
0.74 (0.60 – 0.90) 
 
- 
0.031 
0.003 
0.003 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.74 (0.44 – 6.84) 
1.24 (0.28 – 5.42) 
0.53 (0.08 – 3.46) 
 
- 
0.429 
0.775 
0.508 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.79 (0.47 – 1.30) 
 
- 
0.349 
 
- 
- 
 
- 
- 
 
1 
0.12 (0.07 – 0.20) 
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months
ɭ
  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.35 (1.00 – 1.84) 
0.65 (0.48 – 0.90) 
 
- 
0.051 
0.009 
 
- 
- 
- 
 
- 
- 
- 
 
1 
3.58 (1.56 – 8.59) 
-
‡
 
 
- 
0.003 
- 
 
1 
5.54 (1.70 – 18.02) 
-
‡
 
 
- 
0.004 
- 
Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
2.82 (2.34 – 3.40) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
1.94 ( 0.60 – 6.24) 
 
- 
0.266 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months 
in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.72 (1.51 – 1.96) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
3.41 (1.16 – 10.01) 
 
 
- 
0.025 
 
 
- 
- 
 
 
- 
- 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected and 
change in MCV < 14.5fL: 
-Change in CD4 count < expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected and 
change in MCV < 14.5fL: 
 
 
 
 
1 
 
2.55 (2.01 – 3.23) 
 
0.96 (0.60 – 1.54) 
 
4.83 (3.77 – 6.20) 
 
 
 
 
- 
 
0.000 
 
0.856 
 
0.000 
 
 
 
 
1 
 
2.82 (2.16 – 3.67) 
 
1.20 (0.73 – 1.97) 
 
5.49 (4.13 – 7.30) 
 
 
 
 
- 
 
0.000 
 
0.471 
 
0.000 
 
 
 
 
1 
 
3.67 (0.40 – 33.70) 
 
6.60 (0.66 – 66.31) 
 
6.2 (0.69 – 55.61) 
 
 
 
 
- 
 
0.251 
 
0.109 
 
0.104 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
 72 
 
Regimen change 
No 
Yes 
 
1 
1.09 (0.94 – 1.26) 
 
- 
0.244 
 
- 
- 
 
- 
- 
 
1 
2.21 (0.66 – 7.42) 
 
- 
0.201 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.06 (0.95 – 1.18) 
0.98 (0.78 – 1.23) 
 
 
- 
0.298 
0.865 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.95 (0.46 – 1.96) 
-
‡
 
 
 
- 
0.887 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Pregnancy: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
 
 
1 
1.00 (0.65 – 1.55) 
1.10 (0.79 – 1.54) 
 
 
- 
0.990 
0.576 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
6.04 (2.29 – 15.93) 
 
 
- 
- 
0.000 
 
 
- 
- 
- 
 
 
- 
- 
- 
Adverse events or side effects  
No 
Yes 
 
1 
0.39 (0.25 – 0.60) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
- 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period.
 ɭ 
The reference group for patients on AZT-based regimens is > 100fL, the following group is 80 – 100 fL and the last group is 
< 80fL. This is because < 80fL had no observations for MCV at 6 months in patients on AZT-based regimens.
 ‡ Cell has no observations.  ART: Antiretroviral Therapy.  ARV: 
Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  CI: Confidence interval.   IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis. WHO: World Health 
Organization. 
 
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens. After adjusting for potential confounders, the variables independently associated with poor adherence for all eligible 
patients were change in CD4 count at 6 months stratified by change in MCV at 6 months, WHO stage at baseline and MCV at baseline. The IRR of 
poor adherence increased with increasing WHO stage at baseline. Model fit was good as evidenced by a p-value of 0.794 on the link test.  MCV at 6 
months was the only independent predictor of poor adherence in the final multivariate model for patients on AZT-based regimens. Model fit for this 
model was also good as evidenced by a p-value of 0.897 on the link test. 
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Table 8b: Univariate and multivariate Poisson regression models with robust error variance for all eligible patients and eligible patients 
on AZT-based regimens with a documented viral load (done 90 to 270 days after ART initiation) after multiple imputation 
 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Crude IRR 
 (95% CI) 
P -
value 
Adjusted IRR 
 (95% CI) 
P-
value 
Gender  
Females             
Males 
 
1 
1.17 (1.07 – 1.28) 
 
- 
0.000 
 
1 
1.09 (0.99 – 1.19) 
 
- 
0.067 
 
1  
1.78 (0.97 – 3.27) 
 
- 
0.064 
 
1 
1.72 (0.93 – 3.19) 
 
- 
0.086 
Age at initiation  
≤ 36.7 years 
> 36.7 years 
 
1 
0.93 (0.85 – 1.02) 
 
- 
0.117 
 
1 
0.95 (0.87 – 1.03) 
 
- 
0.210 
 
1  
0.99 (0.53 – 5.82) 
 
- 
0.962 
 
1 
1.04 (0.56 – 1.92) 
 
- 
0.901 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.97 (0.85 – 1.11) 
0.79 (0.59 – 1.06) 
 
- 
0.660 
0.114 
 
- 
- 
- 
 
- 
- 
- 
 
1  
1.40 (0.65 – 3.05) 
0.71 (0.10 – 4.86) 
 
- 
0.391 
0.725 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.08 (0.99 – 1.18) 
 
- 
0.096 
 
- 
- 
 
- 
- 
 
1 
1.07 (0.59 – 1.96) 
 
- 
0.814 
 
- 
- 
 
- 
- 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.96 (0.85 – 1.10) 
0.88 (0.75 – 1.03) 
0.82 (0.67 – 1.01) 
 
- 
0.573 
0.119 
0.061 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.83 (0.56 – 6.05) 
0.83 (0.16 – 4.37) 
0.52 (0.09 – 2.92) 
 
- 
0.318 
0.822 
0.460 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
1 
1.02 (0.83 – 1.25) 
 
- 
0.843 
 
- 
- 
 
- 
- 
 
1 
-
‡ 
 
- 
- 
 
- 
- 
 
- 
- 
MCV at baseline
ɭ 
 
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.20 (1.03 – 1.40) 
1.28 (0.97 – 1.71) 
 
- 
0.021 
0.079 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.06 (0.46 – 2.42) 
0.77 (0.17 – 3.43) 
 
- 
0.896 
0.734 
 
- 
- 
- 
 
- 
- 
- 
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Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
 
1  
1.02 (0.88 – 1.20) 
1.11 (0.95 – 1.31) 
1.14 (0.98 – 1.33) 
 
- 
0.733 
0.195 
0.090 
 
1  
1.12 (0.96 – 1.31) 
1.24 (1.05 – 1.46) 
1.26 (1.07 – 1.49) 
 
- 
0.136 
0.012 
0.005 
 
1  
0.93 (0.41 – 2.09) 
0.66 (0.22 – 1.99) 
0.95 (0.40 – 2.29) 
 
- 
0.859 
0.464 
0.911 
 
1 
0.83 (0.37 – 1.83) 
0.57 (0.19 – 1.73) 
0.72 (0.29 – 1.78) 
 
- 
0.640 
0.323 
0.473 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.15 (1.00 – 1.33) 
1.23 (1.09 – 1.38) 
1.24 (1.06 – 1.45) 
 
- 
0.044 
0.000 
0.006 
 
1 
1.11 (0.97 – 1.28) 
1.19 (1.06 – 1.34) 
1.19 (1.01 – 1.40) 
 
- 
0.131 
0.003 
0.033 
 
1 
1.03 (0.35 – 3.05) 
1.03 (0.48 – 2.23) 
-
‡
 
 
- 
0.955 
0.932 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.08 (0.85 – 1.19) 
1.53 (1.11 – 2.10) 
 
- 
0.925 
0.009 
 
1 
1.01 (0.86 – 1.18) 
1.55 (1.13 – 2.13) 
 
- 
0.941 
0.007 
 
1 
1.60 (0.50 – 5.12) 
3.26 (1.05 – 10.16) 
 
- 
0.428 
0.041 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
1.02 (0.92 – 1.13) 
1.03 (0.87 – 1.22) 
 
 
1 
1.05 (0.94 – 1.18) 
1.20 (0.96 – 1.51) 
 
 
1 
1.12 (1.01 – 1.25) 
1.30 (1.04 – 1.61) 
 
- 
0.693 
0.713 
 
 
- 
0.358 
0.104 
 
 
- 
0.039 
0.019 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
1.13 (1.01 – 1.26) 
1.19 (0.96 – 1.48) 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
0.024 
0.107 
 
1 
0.96 (0.42 – 2.17) 
2.53 (1.19 – 5.38) 
 
 
1 
1.66 (0.83 – 3.30) 
1.23 (0.32 – 4.70) 
 
 
1 
1.86 (0.97 – 3.59) 
4.00 (1.54 – 10.33) 
 
- 
0.921 
0.016 
 
 
- 
0.150 
0.762 
 
 
- 
0.063 
0.002 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
1.84 (0.94 – 3.61) 
3.71 (1.50 – 9.15) 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
0.077 
0.005 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
1 
0.81 (0.68 – 0.96) 
0.74 (0.62 – 0.88) 
0.70 (0.57 – 0.86) 
 
- 
0.016 
0.001 
0.001 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
1.44 (0.36 – 5.74) 
1.05 (0.25 – 4.47) 
0.39 (0.05 – 2.59) 
 
- 
0.608 
0.946 
0.331 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
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Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1 
0.68 (0.41 – 1.13) 
 
- 
0.136 
 
- 
- 
 
- 
- 
 
1 
0.13 (0.10 – 0.18) 
 
- 
0.000 
 
- 
- 
 
- 
- 
MCV at 6 months
ɭ
  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.24 (0.92 – 1.69) 
0.64 (0.47 – 0.87) 
 
- 
0.161 
0.005 
 
- 
- 
- 
 
- 
- 
- 
 
1 
2.09 (1.03 – 4.24) 
-
‡
 
 
- 
0.041 
- 
 
1 
2.00 ( 1.01 – 3.98) 
-
‡
 
 
- 
0.047 
- 
Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
2.23 (1.90 – 2.61) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
1.97 (0.84 – 4.61) 
 
- 
0.119 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 months 
in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.63 (1.45 – 1.83) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
2.24 ( 1.01 – 4.97) 
 
 
- 
0.048 
 
 
- 
- 
 
 
- 
- 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected and 
change in MCV < 14.5fL: 
-Change in CD4 count < expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected and 
change in MCV < 14.5fL: 
 
 
 
 
1 
 
2.14 (1.78 – 2.58) 
 
1.47 (1.13 – 1.92) 
 
3.57 (2.98 – 4.27) 
 
 
 
 
- 
 
0.000 
 
0.004 
 
0.000 
 
 
 
 
1 
 
2.18 (1.81 – 2.63) 
 
1.51 (1.16 – 1.96) 
 
3.69 (3.07 – 4.42) 
 
 
 
 
- 
 
0.000 
 
0.002 
 
0.000 
 
 
 
 
1 
 
2.39 (0.60 – 9.43) 
 
3.10 (0.62 – 15.46) 
 
4.36 (1.15 – 16.52) 
 
 
 
 
- 
 
0.211 
 
0.166 
 
0.031 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
1.09 (0.94 – 1.26) 
 
- 
0.244 
 
- 
- 
 
- 
- 
 
1 
2.21 (0.66 – 7.42) 
 
- 
0.201 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.06 (0.95 – 1.18) 
0.98 (0.78 – 1.23) 
 
 
- 
0.298 
0.865 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.95 (0.46 – 1.96) 
-
‡
 
 
 
- 
0.887 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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Pregnancy: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
 
 
1 
1.00 (0.65 – 1.55) 
1.10 (0.79 – 1.54) 
 
 
- 
0.990 
0.576 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
6.04 (2.29 – 15.93) 
 
 
- 
- 
0.000 
 
 
- 
- 
- 
 
 
- 
- 
- 
Adverse events or side effects  
No 
Yes 
 
1 
0.39 (0.25 – 0.60) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
- 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period.
 ɭ 
The reference group for patients on AZT-based regimens is > 100fL, the following group is 80 – 100 fL and the last group is 
< 80fL. This is because < 80fL had no observations for MCV at 6 months in patients on AZT-based regimens before multiple imputation.
 ‡ Cell has no observations.  ART: 
Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  CI: Confidence interval.   IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: 
Tuberculosis. WHO: World Health Organization. 
 
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens. After adjusting for potential confounders, the variables independently associated with poor adherence for all eligible 
patients were change in CD4 count at 6 months stratified by change in MCV at 6 months, CD4 count at baseline, WHO stage at baseline, self-reported 
adherence and number of missed medical visits. Model fit was good as evidenced by a p-value of < 0.05 on the FMI test.  MCV at 6 months and the 
number of missed medical visits were the only independent predictors of poor adherence in the final multivariate model for patients on AZT-based 
regimens. Model fit for this model was also good as evidenced by a p-value of < 0.05 on the FMI test. 
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CHAPTER FOUR 
 
DISCUSSION: 
In this chapter, the results are examined in detail. This includes an examination of the 
strengths, limitations and generalizability of the study. The aim of this study is to identify 
markers that can be used routinely to assess adherence to ART at Themba Lethu Clinic in 
Johannesburg, South Africa. The first viral load after initiation (viral load at end-point), 
which is usually done at 6 months, is used to define adherence 
(9, 10)
.  
  
The IRR is used to approximate the RR of poor adherence. Variables independently 
associated with poor adherence at 6 months were change in CD4 count stratified by change in 
MCV at 6 months, CD4 count at baseline, WHO stage at baseline and MCV at baseline.  For 
patients on AZT-based regimens the variables independently associated with poor adherence 
at 6 months were change in CD4 count at 6 months and pregnancy during the first 6 months 
on ART. 
 
The sensitivity analyses, subgroup analyses and analyses using a viral load done 90 to 270 
days after ART initiation yielded the same predictors of poor adherence. After multiple 
imputation, however, other variables like self-reported adherence, number of missed medical 
visits and regimen change were also found to be predictors of poor adherence in some of the 
models.  
 
The results are in keeping with the alternate hypothesis that adherence level (measured by 
viral load at 6 months) can be predicted from a combination of variables or markers and 
provides a basis to reject the null hypothesis.  
 
4.1 Markers of adherence: 
Previous studies have shown change in MCV to be a good marker of adherence 
(12, 17, 47-49)
. In 
this study, there was an interaction between change in MCV and change in CD4 count at 6 
months for all patients with a documented viral load result. In the presence of the interaction, 
change in MCV remained significantly associated with poor adherence (p < 0.001). Since 
most (62.9%) of the patients were on d4T or AZT-based regimens during the study period, it 
is not surprising that change in MCV at 6 months was a marker of adherence.  
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For patients on d4T or AZT-based regimens with a documented viral load result, the 
sensitivity, specificity, PPV and NPV of the change in MCV at 6 months were as follows: 
70.2%, 61.4%, 18.2% and 94.4% respectively (Table 4a). For patients on TDF-based 
regimens with a documented viral load result, the sensitivity, specificity, PPV and NPV of 
the change in MCV at 6 months were as follows: 97.4%, 3.1%, 24.4% and 78.4% 
respectively (Table 4a). This implies that a change in MCV at 6 months of ≥ 14.5fL rules out 
poor adherence. However, change in MCV is a marker specific to patients on d4T or AZT so 
a change in MCV at 6 months of < 14.5fL does not necessarily imply poor adherence in 
patients on TDF hence the very low specificity for these patients.  
 
To get a clearer picture of the interaction between change in MCV and change in CD4 count, 
change in CD4 count at 6 months was stratified by change in MCV at 6 months, showing 
how the two variables together can be used to predict poor adherence. The variable change in 
CD4 count stratified by change in MCV at 6 months was found to have a higher area under 
its ROC curve than change in CD4 count alone or change in MCV alone, indicating the 
strength of this stratified variable (Figure 2a, Figure 2b, Appendix 7A and Appendix 9A). 
The ROC curve for the stratified variable was also the closest to the ROC curve for the final 
multivariate model, indicating that it is the major contributor to the model (Figure 2a, Figure 
2b, Appendix 7A and Appendix 9A). Patients who had a change in CD4 count ≥ or < 
expected at 6 months and a change in MCV that is < 14.5fL were at a significantly higher risk 
of having a detectable viral load at 6 months than their counterparts. The aRR (adjusted 
relative risk) of poor adherence was highest for patients with a change in CD4 count that was 
< expected and a change in MCV < 14.5fL at 6 months. Table 4b thus shows that of the 3 
categories of the variable, this category had the lowest difference between sensitivity (69.9%) 
and specificity (79.2%). 
 
MCV is known to increase, particularly in adherent patients on AZT
(12, 16, 17, 47-49)
. For patients 
on AZT, however, despite a p < 0.2 on univariate analysis, neither MCV at 6 months nor 
change in MCV at 6 months were significantly associated with adherence in any of the final 
multivariate models before multiple imputation, except where the viral load was done 90 to 
270 days after ART initiation.  This could be attributed to the large proportions of missing 
values for MCV at 6 months and MCV at baseline. After multiple imputation, the variable 
MCV at 6 months was found to be a predictor of poor adherence in patients on AZT-based 
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regimens only where the viral load was done 90 to 270 days after ART initiation. Change in 
MCV at 6 months was, however, still not a predictor of poor adherence in patients on AZT 
after multiple imputation. The small proportions of patients on AZT-based regimens (< 3%) 
could have also been a contributing factor. There was also no interaction between change in 
MCV and change in CD4 count at 6 months for patients on an AZT-based regimen.  
 
For patients on AZT-based regimens, change in CD4 count at 6 months was one of the 
markers of adherence. The large aRR (7.66), marginal significance (p = 0.052) and wide CI 
(0.98 – 59.91) cast some doubt on the findings. This could be due to weak unmeasured 
confounders such as change in MCV at 6 months, which as mentioned above, had several 
missing values. The sensitivity and specificity of the change in CD4 count at 6 months for 
patients on AZT-based regimens in the main analysis were 64.7% and 75.2% respectively 
(Table 4a). The difference between the two was, however, not as high as that for all patients 
(33.0% and 81.4% respectively), which may explain why change in CD4 count at 6 months 
remained a significant predictor of poor adherence in patients on AZT-based regimens. 
Likewise, Figure 2c shows that change in CD4 count at 6 months also had a larger area under 
its ROC curve (0.7718) for patients on AZT-based regimens than it did for all patients as 
shown in Figure 2a (0.5784).  
 
Self-reported adherence is expected to be associated with viral load at 6 months, which is a 
surrogate marker for adherence. The variable was, however, notably absent from the final 
multivariate models before multiple imputation. This is contrary to a meta-analysis by 
Nieuwkerk and colleagues (2005), where self-reported adherence was found to distinguish 
between poor and good adherence, as evidenced by detectable and undetectable viral loads 
respectively 
(19)
. The absence of the self-reported adherence from the final multivariate 
models before multiple imputation may reflect the fact that the variable is not reliable as it is 
vulnerable to errors from patient recall and dishonesty
(11, 12)
. The results may also be 
testament to the fact that self-reported adherence is a measure of how ART is taken but does 
not encompass the full definition of adherence, which includes following other 
recommendations pertaining to food, etc
(13)
. Not following these other recommendations may 
lead to a detectable viral load at 6 months, despite taking the medication correctly. The 
absence of self-reported adherence from final multivariate models before multiple imputation 
may also be testament to the large proportion of patients (> 50%) without a self-reported 
adherence, making the results unreliable.  After multiple imputation, self-reported adherence 
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appeared in only one of the final multivariate models (Table 8b). These results must be 
interpreted with caution as self-reported adherence had an area under the ROC curve of only 
0.5247 (Appendix 7A). 
 
Pregnancy during the first 6 months on ART was also found to increase the risk of having a 
detectable viral load at 6 months in patients on AZT-based regimens. Though this variable 
had a high specificity of 97.6% (Table 4a) in patients on AZT-based regimens, the sensitivity 
was very low (20%). This means that a pregnancy during follow up could mean poor 
adherence but no conclusions can be drawn if a patient is not pregnant. This implies that the 
variable is not a very reliable marker of adherence. The aRRs for this variable were also 
unusually high with very wide CIs. This may be due to weak unmeasured confounders, 
particularly as very few patients (< 3%) were on AZT-based regimens during the study 
period. Consequently a lot of the variables, such as change in MCV discussed earlier, either 
had large proportions of missing values or no observations for some categories in patients on 
AZT-based regimens. The variable pregnancy during the first 6 months on ART had no 
observations for the category pregnant at baseline. For all the above reasons, the appearance 
of the variable pregnancy during the first 6 months on ART as a marker of poor adherence 
should be interpreted with caution. However, when combined with an inadequate increase in 
CD4 count at 6 months, pregnancy during the first 6 months on ART may be a strong 
predictor of poor adherence. This is demonstrated by an area of 0.8938 under the ROC curve 
for the final multivariate model for patients on AZT-based regimens (Figure 2c). The strength 
of the variable, however, remains in question as the area under the ROC curve for this 
variable was only 0.5012 in the subgroup analysis (Appendix 9B). In addition, the variable 
was not found to be a predictor of poor adherence for patients with a viral load done 90 to 
270 days after ART initiation or in any of the multiple imputation models. 
 
Except for pregnancy during the first 6 months on ART (PPV 60% and NPV 87.0%), all 
other markers of adherence identified had low PPVs (< 40%) and high NPVs (> 75%). 
Conclusions are difficult to draw from these figures before multiple imputation as the 
prevalence of a detectable viral load at 6 months varies for the different variables and differs 
from the overall prevalence due to varying proportions of missing values. The figures do not 
change much after multiple imputation implying that the variables are better predictors of 
good adherence than poor adherence. 
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Lower CD4 count at baseline and higher WHO stage at baseline were also significantly 
associated with a detectable viral load at 6 months and hence poor adherence. These results 
are contrary to the findings of Maqutu and colleagues in South Africa (2010), where first 
month poor adherence (< 95%) measured by pill count was found to be associated with 
higher CD4 count at baseline
(30)
. The results are also contrary to a study by Heckman and 
colleagues in the USA (2004), which found good adherence by self-report to be associated 
with progression to AIDS
(65)
. The DART trial carried out by Muyingo and colleagues in 
Uganda and Zimbabwe (2008), however, had similar findings to this study. This was that 
complete (100%) adherence, measured by pill count, was associated with a higher baseline 
CD4 count
(41)
.  
 
4.2 Other variables: 
In patients on AZT-based regimens after multiple imputation in the main analysis, those    
> 36.7 years at initiation had half (aRR 0.54, 95% CI 0.35 – 0.58; p = 0.041) the risk of 
virological failure that their counterparts aged 18 to 36.7 years had (Table 3b). Age was, 
however, not significantly associated with poor adherence in any of the other multivariate 
analyses. This is contrary to some previous studies that have associated younger age with 
poor adherence
(33, 45, 58)
. Gender was also not significantly associated with poor adherence in 
any of the final multivariate models. Godin and colleagues in a longitudinal study in the USA 
(2005), found male gender to be a predictor of good adherence
(61)
. In a retrospective review 
of patient records in South Africa (2011), Maqutu and colleagues, however, found that males 
have better adherence than females but discovered that after the age of 50, females have 
better adherence levels than males
(32)
. A prior baseline survey done by Maqutu and 
colleagues (2010) found first month good adherence to be associated with higher age in 
patients who owned cell phones or were a source of household income in the urban setting
(30)
. 
It would thus appear that there is interplay of several other factors with gender and age 
resulting in poor adherence and, hence, detectable viral load at 6 months.  
 
Education level and professional status at ART initiation were also not significantly 
associated with poor adherence in any of the final multivariate models. A cohort study by El-
Khatib and colleagues in South Africa (2011), had similar findings
(21)
. Average poor 
adherence measured by pill count, during the 6 month study period, was associated with less 
education and lack of support from a partner at initiation. Education level and lack of support 
from a partner at initiation were, however, not associated with viral load at 6 months. In the 
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same study, socioeconomic status at initiation was neither associated with average poor 
adherence measured by pill count nor viral load at 6 months. These findings imply that with 
education about treatment given as part of ART provision, adult patients on ART should be 
able to achieve a viral load < 400 copies/ml at 6 months despite their education level or 
professional status at ART initiation. 
 
The numbers of missed ARV visits and missed medical visits were also not significantly 
associated with poor adherence in the final multivariate models before multiple imputation. 
Over 70% of the patients had no missed ARV or medical visits and about 20% of patients had 
1 missed ARV or medical visit during the study period. The variables may be absent from the 
final multivariate model because on-time drug pick up does not guarantee adherence
(46)
. 
Furthermore, an adherent patient who misses an appointment due to having enough 
medication left over cannot be classified as non-adherent. For this reason, even though the 
number of missed medical visits was a marker of poor adherence after multiple imputation 
(Table 8b and Appendix 8B), the area under the ROC curve remained only around 0.5 for this 
variable (Appendices 7A & 7B: 0.5167 and Appendix 9B: 0.5059). 
 
A quarter of the patients were on TB treatment during the study period. This is because TB 
co-infection is common among HIV positive patients
(70)
. This variable was expected to 
influence the outcome but it has no association with the viral load at 6 months in the final 
multivariate models for all patients. This is because TB, which may impair the ability to 
adhere due to severe ill health affecting memory or strength to take medication, is curable and 
thus transient. Likewise, TB medication increases the pill burden, with the possibility of 
reducing adherence only temporarily. Furthermore, treating active TB should put the 
virological response on a par with that of patients without TB. Note that the variable 
measures being on TB treatment as a proxy for having TB. It is also possible that some 
patients with TB and a detectable viral load at 6 months died or were lost to follow-up or 
transferred to other facilities before the end-point and were thus excluded from the study. 
This could be responsible for leaving the impression that the relative risk of having a 
detectable viral load at 6 months for patients on TB treatment is the same as that for patients 
not on TB treatment during the study period. 
 
Haemoglobin level was also not significantly associated with poor adherence in any of the 
final multivariate models. This may be because only a small proportion of patients had a 
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haemoglobin ≤ 8g/dl (4.7% at baseline and 0.7 % at 6 months in the main analysis). It may 
also be due to the fact that there are measures that can be taken to improve haemoglobin 
levels hence the levels improved during the course of treatment. Russell and colleagues in 
South Africa (2010) found low haemoglobin levels to be a predictor of early mortality in 
adults starting ART
(71)
. This implies that patients with low haemoglobin levels in this study 
may have died before 6 months on ART, resulting in the variable not being a predictor of 
poor adherence. In keeping with the findings of Tedaldi and colleagues in the USA (2006), 
BMI was also not significantly associated with poor adherence
(72)
.  
 
Adverse events or side effects represent another variable that is not significantly associated 
with poor adherence in the final multivariate model despite being significantly associated 
with poor adherence on univariate analysis. This is contrary to the findings of Protopopescu 
and colleagues in a prospective cohort study done in France (2009), showing that side effects 
were significantly associated with poor adherence
(58)
. In that study, however, the follow up 
period was 1 to 10 years and adherence was measured by self-report. Adverse events or side 
effects are not in the final model in this study probably as they occur rarely (2.9% 
experienced side effects during the study period in the main analysis). The variable may also 
be inaccurate as 2 – 3% of patients in the different models had a documented side effect 
during the study period but 9 – 10% of patients had a change of regimen yet most 
substitutions during this time are due to side effects (68). 
 
A subgroup analysis (Appendix 8A) of 6793 patients with a documented viral load result 
(excluding 95 patients with a history of documented prior ART use such as NVP prophylaxis 
and 272 patients changed to a non-standard or second-line ART regimen before 6 months on 
treatment) was done. This subgroup had 18.7% of patients exhibiting a detectable viral load 
at 6 months. The subgroup analysis yielded the same predictors of poor adherence as those in 
the main analysis (Table 3a). The only extra variable was regimen change (Appendix 8A). 
Adding this variable improved the model despite the marginal significance. It thus seems 
possible that drug substitutions within a 1
st
 line regimen may lower the risk of having a 
detectable viral load at 6 months in this subgroup (No change in regimen; aRR 1 and change 
in regimen; aRR 0.68 95% CI 0.45 – 1.03, p = 0.066, ROC area: 0.5121). The variable was 
also in the final multivariate model for the subgroup analysis after multiple imputation 
(Appendix 8B: aRR 0.76 95% CI 0.59 – 0.97, p = 0.028, ROC area: 0.5114) and in the 
sensitivity analysis assuming that all patients with a missing viral load had a viral load ≥ 400 
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copies/ml (Table 7a: aRR 0.79 95% CI 0.62 – 1.01, p = 0.058). Most patients have 
substitutions within a 1
st
 line regimen due to side effects
(68)
. Since drug substitution provides 
relief from these toxicities, adherence is expected to improve after a substitution. The ROC 
areas of about 0.5, however, cast doubt on the validity of regimen change as a predictor of 
poor adherence.   
 
4.3 Strengths and limitations: 
 The study uses all available data in TherapyEdge-HIV
TM
 and not a sample. This improves 
the power of the study. The study design also permits the ascertainment of the temporal 
relationship between the exposures and the outcome variable.  
 
In addition, the results of the sensitivity analysis are almost exactly the same as those of the 
main analysis implying that the patients with a documented viral load at 6 months were 
representative of the entire study population. Furthermore, multiple imputation was done to 
cater for missing values. 
 
Missing data for both exposure and outcome variables is a common limitation of the 
retrospective design. The proportion of missing data ranged from 1.5% for professional status 
among eligible patients to 70.0% for self-reported adherence in patients on AZT-based 
regimens with a documented viral load result in the main analysis. Half of the eligible 
patients did not have a viral load at 6 months. Other variables with large proportions of 
missing data included, MCV at 6 months, change in MCV at 6 months and change in CD4 
count at 6 months. The missing data was thought to have contributed to all markers of 
adherence having ROC areas of < 0.8 so that no variable or marker could be considered a 
particularly accurate predictor of poor adherence. After multiple imputation, however, the 
baseline characteristics remained similar to those before multiple imputation. In addition, 
areas under the ROC curves remained < 0.8. 
 
Furthermore, professional status and education level are recorded only at initiation so it is not 
possible to adjust for any changes in the two variables during the study period. In addition, 
viral load testing is not routinely done at baseline so it was not practical to adjust for this 
variable in the multivariate model. 
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Loss to follow up is another disadvantage of the retrospective design. Patients that were 
excluded due to loss to follow up during the study period may bias the results of the study if 
they are systematically different from the other patients (selection bias). Patients that died or 
were transferred out during the study period may also introduce selection bias into the results 
of the study if they are systematically different from those that did not die or get transferred 
out. This is because patients that were lost to follow up or died during the first 6 months on 
ART are likely to have had poor adherence. This early poor adherence may be a strong 
predictor of loss to follow up and ultimately progression to AIDS and mortality (73, 74).  
 
Results may also be biased by the fact that the 6 months was defined as a wide range of days 
after ART initiation not a fixed point in time. Tables 2 and 6 show that the variation between 
the points at which MCV, CD4 count and viral load at 6 months were taken was minimal. 
The validity and reliability of the sensitivity analyses is, however, hampered by the 
dissimilarity between the proportions of patients with an MCV at 6 months, change in MCV 
at 6 months and change in CD4 count at 6 months in the main analysis and the sensitivity 
analysis. This dissimilarity also reduces the comparability value of the sensitivity analysis. In 
addition, self-reported adherence, defined as the last self-reported adherence value on, or 
after, 3 months (70 days) on ART and not more than 110 days before the viral load was done, 
but at least 28 days before the end-point, was taken at different points in time for the 
sensitivity analysis and the main analysis, limiting comparability (Tables 2 and 6).  
 
An additional limitation is that the outcome variable viral load at end-point is itself a 
surrogate marker of adherence as poor adherence is the most common cause of a virological 
failure. Other factors, that are not routinely captured in TherapyEdge-HIV
TM
, such as 
malabsorption, drug interactions, diabetes mellitus and the acquisition of a drug-resistant HIV 
strain may, however, contribute to a detectable viral load at 6 months, despite good 
adherence.  
  
There were also a few statistical limitations. The first was that log-binomial regression using 
RRs had to be replaced with Poisson regression with robust error variance, where IRRs were 
used to approximate the RRs, due to the frequent occurrence of failure to converge. Another 
was that RRs could not be ascertained where cells had no observations, for patients on AZT-
based regimens. 
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It is worth noting that there is no known surrogate clinical marker for the detection of 
adherence levels for TDF, 3TC, FTC, NVP and EFV. Change in MCV at 6 months is a 
marker only for patients on AZT-based regimens as well as the patients on d4T-based 
regimens, who are the majority (62.9%). 
  
4.4 Generalizability 
The results of the study are generalizable to adult patients on first-line ART at Themba Lethu 
Clinic, who were ART-naïve at the time of initiation, for their first 6 months on ART or up to 
the point of their first viral load. They should also, by extension, be generalizable to similar 
patients on first-line ART in other public urban CCMT sites in South Africa.  
 
4.5 Conclusion and recommendations: 
In conclusion, the marker of adherence to ART among HIV positive adults at Themba Lethu 
Clinic is change in CD4 count at 6 months stratified by change in MCV at 6 months. MCV, 
CD4 count and WHO stage at baseline are also predictors of viral load at 6 months and hence 
predictors of poor adherence. For adult patients on AZT-based regimens, the markers of 
adherence to ART are change in CD4 count at 6 months and pregnancy during the first 6 
months on ART.  
 
The fact that the aRR of a detectable viral load at 6 months increases with lower CD4 count 
and higher WHO stage at baseline emphasises the need for people to know their HIV status 
and start ART on time if HIV positive. The fact that almost one third of the patients were 
initiated in WHO stage I suggests that this message is getting to people. HIV testing and pre-
ART service delivery need to be strengthened to increase this percentage as well as the 
baseline CD4 count at ART initiation as patients who start earlier are less likely to have a 
detectable viral load at 6 months. 
 
In addition, attention should be paid to the above-mentioned markers of adherence. These 
markers could help health workers identify poor adherence in the absence of viral load testing 
and target patients for adherence interventions to prevent virological failure. Interventions 
such as intensified counselling, coupled with unannounced pill count or micro-electronic 
monitoring (MEM) could be used to improve the adherence of patients found to have poor 
adherence. These findings also suggest that provision of family planning services must be 
strengthened for all women of child-bearing age on ART. The latest (2013) National ART 
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Guidelines stipulate that an FBC, from which MCV is obtained be done only at baseline, 3 
and 6 months for patients on AZT-based regimens to detect AZT toxicity
(15)
. However, the 
findings of this study make the case for MCV monitoring for patients on d4T as well, to 
gauge adherence. Beyond 6 months on ART, MCV monitoring may still be necessary for 
patients on AZT and d4T-based regimens to assess adherence. The interaction between 
change in MCV and change in CD4 count at 6 months also implies that CD4 count may need 
to be tested at 6 months and beyond the currently stipulated baseline and 1 year points on 
ART
(15)
. Further studies are, however, needed to verify whether the markers of adherence 
remain the same over longer periods on ART. It is worth noting that with TDF-based 
regimens currently being the first-line of treatment, the markers of adherence may change. In 
other words the association of variables such as MCV (markers of adherence for AZT and 
d4T) with viral load at 6 months may become less significant. 
 
In future work, the above markers could be used in a composite score system to identify 
patients with poor adherence, using sensitivity, specificity, PPV and NPV of the composite 
score to determine how predictive it would be. 
 
Further studies are also needed to assess, verify and explain the influence of self-reported 
adherence, number of missed medical visits and regimen change. This is because these 
variables appeared in one of the sensitivity analyses as well as in some of the final 
multivariate models after multiple imputation.  
 
Another recommendation is that self-reported adherence be assessed and documented 
consistently at each visit as multivariate regression after multiple imputation suggests that it 
may also be a marker of poor adherence. Furthermore, additional emphasis needs to be placed 
on ensuring that all blood tests are done on schedule according to the National Guidelines for 
the benefit of the patient and for ease and accuracy of data analysis in case of future studies. 
More attention also needs to be paid to data accuracy on entry and data cleaning to rectify 
inaccuracies before they accumulate.  
 
4.6 Dissemination: 
Results will be published in relevant journals and presented orally or in poster format at 
scientific meetings.  
 
 88 
 
REFERENCES: 
1. Hovarth T, Azman H, Kennedy GE and Rutherford GW. Mobile phone text   
            messaging for promoting adherence to antiretroviral therapy in patients with HIV  
            infection. Cochrane Database of Syst Rev. 2012 Mar 14; 3(CD009756): 1-38. 
2. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA et al.  
            Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS.  
           2011 Nov 13; 25(17): 2177-81.  
3.        Reynolds C, de Koning CB, Pelly SC, van Otterlo WAL and Bode ML. In search of a  
           treatment for HIV - current therapies and the role of non-nucleoside reverse  
           transcriptase inhibitors (NNRTIs). Chem Soc Rev. 2012 Jul 7; 41(13): 4657-70. 
4.        UNAIDS. UNAIDS Global report on global AIDS epidemic 2010 [Internet]. 2010  
           [updated 2010; cited 8 Dec 2012]. Available from:  
           http://www.unaids.org/globalreport/global_report.htm. 
5.        Larson E, O'Bra H, Brown J, Mbengashe T and Klausner J. Supporting the massive  
           scale-up of antiretroviral therapy: the evolution of PEPFAR-supported treatment  
           facilities in South Africa, 2005-2009. BMC Public Health. 2012 Mar 9; 12(1): 173. 
6.        World Health Organization. MDG 6: HIV/AIDS, malaria and other diseases,  
           antiretroviral therapy coverage among people with advanced HIV [Internet]. 2011  
           [updated 2011; cited 8 Dec 2012]. Available from:  
            http://apps.who.int/ghodata/?vid=360. 
7.        Fox MP, Maskew M, MacPhail AP, Long L, Brennan AT, Westreich D et al. Cohort  
           Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J  
           Epidemiol. 2013 Apr; 42(2): 430-9. 
8.        Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C and Sanne I. Pregnancy  
            and virologic response to antiretroviral therapy in South Africa. PLoS One. 2011 Aug  
            2; 6(8): 1-8.  
9. Allen D, Conradie F, Coovadia A, Cotton M, Duma MW, Fomundam H et al.  
            National Antiretroviral Treatment Guidelines [Internet]. 2004 [updated 2004; cited 8  
            Dec 2012]. Available from:  
            http://www.doh.gov.za/list.php?type=HIV%20and%20AIDS&year=2004. 
10. Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents.  
            2nd ed. [Internet]. 2010 [updated 2010; cited 8 Dec 2012]. Available  
            from:http://www.sahivsoc.org/practise-guidelines/national-dept-of-health-guidelines.  
11. Berg KM and Arnsten JH. Practical and conceptual challenges in measuring  
 89 
 
            antiretroviral adherence. JAIDS. 2006 Dec 1; 43: S79-S87.  
12. Segeral O, Madec Y, Ban B, Ouk V, Hak CR, Le Tiec C et al. Simplified assessment  
            of antiretroviral adherence and prediction of virological efficacy in HIV-infected  
            patients in Cambodia. AIDS Res Treat. 2010 Jan 1; 2010: 1-6.  
13. Tiyou A, Belachew T, Alemseged F and Biadgilign S. Predictors of adherence to  
            antiretroviral therapy among people living with HIV/AIDS in resource-limited setting  
            of southwest Ethiopia. AIDS Res Ther. 2010 Oct 30; 7(1): 1-10. 
14. Brennan AT, Maskew M, Sanne I and Fox MP. The importance of clinic attendance  
             in the first six months on antiretroviral treatment: a retrospective analysis at a large  
             public sector HIV clinic in South Africa. J Int AIDS Soc. 2010 Dec 7; 13(1): 1-10. 
15. The South African Antiretroviral Treatment Guidelines 2013. South Africa2013  
            [Internet]. 2013 [updated 2013; cited 27 Aug 2013]. Available from:       
http//www.sahivsoc.org/upload/documents/2013%20ART%20Treatment%20Guideli
nes%20Final%2025%20March%202013%20corrected.pdf. 
16. Bartlett JG, Gallant JE and Pham PA. 2009-2010 Medical Management of HIV  
            infection. 15
th
 ed. Durham, North Carolina: Knowledge Source Solutions LLC; 2009. 
17. Rivas P, Gorgolas M and Fernandez-Guerrero ML. Zidovudine and red-cell  
            distribution width. NEJM. 2005 May 19; 352(20): 2141-2.  
18. Mugisha JO, Donegan K, Fidler S, Ramjee G, Hodson A, Dunn DT et al. Mean     
            corpuscular volume as a marker for adherence to zidovudine-containing therapy in   
            HIV-infected adults. Open AIDS J. 2012; 6: 45-52. 
19. Nieuwkerk PT and Oort FJ. Self-reported adherence to antiretroviral therapy for HIV- 
            1 infection and virologic treatment response: a meta-analysis. JAIDS. 2005 Apr 1;  
            38(4): 445-8. 
20. Tuboi SH, Harrison LH, Sprinz E, Albernaz RKM and Schechter M. Predictors of  
            virologic failure in HIV-1-infected patients starting highly active antiretroviral  
            therapy in Porto Alegre, Brazil. JAIDS . 2005 Nov 1; 40(3): 324-8. 
21. El-Khatib Z, Ekstrom A, Coovadia A, Abrams E, Petzold M, Katzenstein D et al.  
             Adherence and virologic suppression during the first 24 weeks on antiretroviral  
            therapy among women in Johannesburg, South Africa - a prospective cohort study.  
            BMC Public Health. 2011 Feb 8; 11(1): 1-13. 
22. Huynh TK, Luttichau HR, Roge BT and Gerstoft J. Natural history of  
            hyperlactataemia in human immunodeficiency virus-1-infected patients during highly  
            active antiretroviral therapy. Scand J Infect Dis. 2003 Apr 11; 35(1): 62-6. 
 90 
 
23. Levy A, McCandless L, Harrigan PR, Hogg R, Bondy G, Iloeje U et al. Changes in  
            lipids over twelve months after initiating protease inhibitor therapy among persons  
            treated for HIV/AIDS. Lipids Health Dis. 2005 Feb 10; 4(1): 1-7.  
24. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H et al. Atazanavir  
            concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.  
            Clin Infect Dis. 2011 May 15; 52(10): 1267-75. 
25. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E et al. Low  
            lopinavir plasma or hair concentrations explain second-line protease inhibitor failures  
            in a resource-limited setting. JAIDS. 2011 Apr 1; 56(4): 333-9. 
26. Podsadecki T, Vrijens B, Tousset E, Rode R and Hanna G. “White coat compliance”  
            limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV  
            Clin Trials. 2008 Aug 26; 9(4): 238-46. 
27. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP et al.  
            Randomized control trial of peer-delivered, modified directly observed therapy for  
            HAART in Mozambique. JAIDS. 2007 Oct 1; 46(2): 238-44.  
28. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S et al. Short- and long- 
            term efficacy of modified directly observed antiretroviral treatment in Mombasa,  
            Kenya: a randomized trial. JAIDS. 2008 Aug 15; 48(5): 611-9. 
29. Hill S and Kavookjian J. Motivational interviewing as a behavioral intervention to  
            increase HAART adherence in patients who are HIV-positive: a systematic review of  
            the literature. AIDS Care. 2012 May 1; 24(5): 583-92. 
30. Maqutu D, Zewotir T, North D, Naidoo K and Grobler A. Factors affecting first- 
            month adherence to antiretroviral therapy among HIV-positive adults in South Africa.  
            Afr J AIDS Res. 2010 Sep 22; 9(2): 117-24. 
31. Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Marion SD et al.  
            Age-associated predictors of medication adherence in HIV-positive adults: health  
            beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007 Jan 11; 26(1):  
            40-9. 
32. Maqutu D, Zewotir T, North D, Naidoo K and Grobler A. Determinants of optimal  
            adherence over time to antiretroviral therapy amongst HIV-positive adults in South  
            Africa: a longitudinal study. AIDS Behav. 2011 Oct; 15(7): 1465-74. 
33. Hinkin CH HD, Mason KI, Castellon SA, Durvasula RS, Lam MN and Stefaniak M.  
            Medication adherence in HIV-infected adults: effect of patient age, cognitive status,  
            and substance abuse. AIDS. 2004 Jan 1; 18(1): S19-S25.   
 91 
 
34. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence  
            to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern  
            Med. 2000 Jul 4; 133(1): 21-30. 
35. Hofer CB, Schechter M and Harrison LH. Effectiveness of antiretroviral therapy  
            among patients who attend public HIV Clinics in Rio de Janeiro, Brazil. JAIDS. 2004  
            Aug 1; 36(4): 967-71.  
36. Bangsberg DR. Less than 95% adherence to non-nucleoside reverse transcriptase  
            inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006 Oct 1; 43(7):  
            939-41.   
37. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L et al. Adherence  
            to highly active antiretroviral therapy assessed by pharmacy claims predicts survival  
            in HIV-infected South African adults. JAIDS. 2006 Sep; 43(1): 78-84. 
38. Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S et al. HIV  
            treatment adherence, patient health literacy, and health care provider-patient  
            communication: results from the 2010 AIDS Treatment for Life International Survey.  
            JIAPAC. 2012 Mar 30; 11(2): 128-33.  
39. Levine AJ, Hinkin CH, Castellon SA, Mason KI, Lam MN, Perkins A et al.  
            Variations in patterns of highly active antiretroviral therapy (HAART) adherence.  
            AIDS Behav. 2005 Sep 1; 9(3): 355-62.  
40. Johnson MO, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH et al.  
            Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage. 2005  
            Feb; 29(2): 193-205. 
41. Muyingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F et al. Patterns of  
            individual and population-level adherence to antiretroviral therapy and risk factors for  
            poor adherence in the first year of the DART trial in Uganda and Zimbabwe. JAIDS.  
            2008 Aug 1; 48(4): 468-75. 
42. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL et al.  
            Predictors of incomplete adherence, virologic failure, and antiviral drug resistance  
            among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect  
            Dis. 2007 Dec 1; 45(11): 1492-8. 
43. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S et al. Adherence to  
            antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.  
            JAMA. 2006 Aug 9; 296(6): 679-90. 
44. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W et al. Adherence to  
 92 
 
            antiretroviral therapy in a home-based AIDS care programme in rural Uganda.  
            Lancet. 2006 Nov 4; 368(9547): 1587-94.  
45. Kunutsor S, Evans M, Thoulass J, Walley J, Katabira E, Newell JN et al. Ascertaining  
            baseline levels of antiretroviral therapy adherence in Uganda: a multimethod    
            approach. JAIDS. 2010 Oct 1; 55(2): 221-4.  
46. Harrigan PR, Hogg RS, Dong WWY, Yip B, Wynhoven B, Woodward J et al.  
            Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort  
            initiating triple antiretroviral therapy. J Infect Dis. 2005 Feb 1; 191(3): 339-47. 
47. Steele RH, Keogh GL, Quin J, Fernando SL and Stojkova V. Mean cell volume  
            (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase  
            inhibitors (NRTIs): a surrogate marker for adherence. Int J STD AIDS. 2002 Nov 1;  
            13(11): 748-54.  
48. Romanelli F, Empey K and Pomeroy C. Macrocytosis as an indicator of medication  
            (zidovudine) adherence in patients with HIV infection. AIDS Patient Care STDs.  
            2002 Sep; 16(9): 405-11. 
49. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F,  
            Mwebaze-Songa P et al. Predictors of long-term viral failure among Ugandan children  
            and adults treated with antiretroviral therapy. JAIDS. 2007 Oct 1; 46(2): 187-93. 
50. Kantor R, Diero L, DeLong A, Kamle L, Muyonga S, Mambo F et al.  
            Misclassification of first-line antiretroviral treatment failure based on immunological  
            monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009 Aug 1;  
            49(3): 454-62. 
51. van Oosterhout JJG, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N et  
            al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical  
            and immunological WHO criteria. Trop Med Int Health. 2009 Aug; 14(8): 856-61. 
52. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I et al. Failure  
            of immunologic criteria to appropriately identify antiretroviral treatment failure in  
            Uganda. AIDS. 2009 Mar 27; 23(6): 697-700. 
53. Mee P, Fielding KL, Charalambous S, Churchyard GJ and Grant AD. Evaluation of  
            the WHO criteria for antiretroviral treatment failure among adults in South Africa.  
            AIDS. 2008 Oct 1; 22(15): 1971-7. 
54. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P et  
            al. Multiple validated measures of adherence indicate high levels of adherence to  
            generic HIV antiretroviral therapy in a resource-limited setting. JAIDS. 2004 Aug 15;  
 93 
 
            36(5): 1100-2. 
55. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N et al.  
            Normalisation of CD4 counts in patients with HIV-1 infection and maximum  
            virological suppression who are taking combination antiretroviral therapy: an  
            observational cohort study. Lancet. 2007 Aug 4; 370(9585): 407-13.  
56. Moore RD and Keruly JC. CD4+ cell count 6 years after commencement of highly  
            active antiretroviral therapy in persons with sustained virologic suppression. Clin  
            Infect Dis. 2007 Feb 1; 44(3): 441-6. 
57. García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M et al. Long-term  
            CD4+ T-cell response to highly active antiretroviral therapy according to baseline  
            CD4+ T-cell count. JAIDS. 2004 Jun 1; 36(2): 702-13. 
58. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B et al. Factors  
            associated with non-adherence to long-term highly active antiretroviral therapy: a 10    
            year follow-up analysis with correction for the bias induced by missing data. J  
            Antimicrob Chemother. 2009 Sep 1; 64(3): 599-606. 
59. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L et al.  
            Antiretroviral therapy adherence, virologic and immunologic outcomes in  
            adolescents compared with adults in Southern Africa. JAIDS. 2009 May 1; 51(1): 65- 
            71. 
60. Sherr L, Harding R, Lampe F, Johnson M, Anderson J, Zetler S et al. Clinical and  
            behavioural aspects of aging with HIV infection. Psychol Health Med. 2009 May 1;  
            14(3): 273-9.  
61. Godin G, Côté J, Naccache H, Lambert LD and Trottier S. Prediction of adherence to  
            antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005 May 1; 17(4):  
            493-504. 
62. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE et  
            al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South  
            Africa. AIDS Res Hum Retroviruses. 2004 Oct; 20(10): 1053-6. 
63. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P et al. Adherence to  
            HAART: A systematic review of developed and developing nation patient-reported   
            barriers and facilitators. PLoS Med. 2006 Nov 21; 3(11): 2039-2063. 
64. Buscher A, Hartman C, Kallen MA and Giordano TP. Impact of antiretroviral dosing  
            frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve  
            HIV patients. Int J STD AIDS. 2012 May 1; 23(5): 351-5. 
 94 
 
65. Heckman BD, Catz SL, Heckman TG, Miller JG and Kalichman SC. Adherence to  
            antiretroviral therapy in rural persons living with HIV disease in the United States.  
            AIDS Care. 2004 Feb 1; 16(2): 219-30. 
66. Schneider J, Kaplan S, Greenfield S, Li W and Wilson I. Better physician-patient  
            relationships are associated with higher reported adherence to antiretroviral therapy in  
            patients with HIV infection. J Gen Intern Med. 2004 Nov; 19(11): 1096-1103.   
67. Rosen S, Fox MP and Gill CJ. Patient retention in antiretroviral therapy programs in      
            Sub-Saharan Africa: a systematic review. PLoS Med. 2007 Oct 16; 4(10): 1691-1700. 
68. Sanne I, Westreich D, Macphail A, Rubel D, Majuba P and Van Rie A. Long term  
            outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South  
            Africa: a prospective cohort study. J Int AIDS Soc. 2009 Dec 17; 12(1): 1-11. 
69. Geis S, Maboko L, Saathoff E, Hoffmann O, Geldmacher C, Mmbando D et al. Risk  
            factors for HIV-1 infection in a longitudinal, prospective cohort of adults from the  
            Mbeya region, Tanzania. JAIDS. 2011 Apr 15; 56(5): 453-9.  
70. Naidoo S,Taylor M and Jinabhai CC. Critical risk factors driving the tuberculosis  
            epidemic in Kwazulu-Natal South Africa. SAJEI. 2007; 22(2,3): 45-9.  
71. Russell EC, Charalambous S, Pemba L, Churchyard GJ, Grant AD and Fielding K.  
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy 
in an HIV care programme in South Africa: a cohort study. BMC Public Health. 2010 
Jul 23; 10(1): 1-8  
72. Tedaldi EM, Brooks JT, Weidle PJ, Richardson JT, Baker RK, Buchacz K et al.    
            Increased Body Mass Index does not alter response to initial Highly Active  
            Antiretroviral Therapy in HIV-1 – infected patients. J Acquir Immune Defic Syndr.  
            2006 Sep; 43(1): 35-41. 
73. Hambisa MT, Ali A and Dessie Y. Determinants of mortality among HIV-positives  
           after initiating antiretroviral therapy in Western Ethiopia: A hospital-based  
           retrospective cohort Study. ISRN AIDS. 2013; 2013(2013): 1-7. 
74.       Tran DA, Ngo AD, Shakeshaft A, Wilson DP, Doran C and Zhang L. Trends in and  
            determinants of loss to follow up and early mortality in a rapid expansion of the  
            antiretroviral treatment program in Vietnam: Findings from 13 outpatient clinics.  
            PLoS One. 2013; 8(9): 1-8. 
 95 
 
APPENDIX 1: Summary of different types of adherence measurement methods 
 
Method  Surrogate or 
non-surrogate 
Description Advantages Disadvantages 
Appointment 
keeping  
Surrogate Adherence measured 
by whether a patient 
attends a visit on 
schedule or not. 
1. Cheap and easy method of 
assessing adherence. 
1. On-time drug pick up does not 
guarantee adherence
(46)
.  
2. An adherent patient who misses 
an appointment due to having 
enough medication left over cannot 
be classified as non-adherent. 
CD4 count Surrogate A measure of cluster 
of differentiation 
number 4 helper T 
lymphocytes/mm
3
 of 
blood. 
1. Comparison with a previous 
value tells us if the patient is 
responding well to treatment 
(immunologically) or not. 
2. Cheaper than a viral load test. 
1. Detects long-term adherence but 
is poor at detecting recent 
adherence levels. 
2. There is no consensus on the 
expected rate of CD4 count rise for 
patients on ART
(16, 55 – 57)
. 
3. Poor predictor of virological 
treatment failure
(50 – 53)
.
 
4. Other factors such as 
malabsorption, drug interactions, 
diabetes mellitus and the 
acquisition of a drug-resistant HIV 
strain may contribute to a 
persistently low CD4 despite good 
adherence.  
5. Invasive. 
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Directly 
observed 
therapy 
Non-surrogate A second person 
observes the patient 
taking medication. 
1. Direct / non-surrogate measure 
of adherence. 
1. May not be practical as it 
requires the guaranteed presence of 
a constant treatment supporter who 
is willing and able to directly 
observe medication being taken 
correctly. 
Drug levels 
in hair 
Non-surrogate A small thatch of 
hair is cut as close as 
possible to the scalp 
from the occiput
(24)
. 
The hair sample is 
then tested for drug 
levels. 
1. Direct / non-surrogate measure 
of adherence.  
2. May allow for detection or 
prevention of drug toxicity, which 
can lead to poor adherence
(11)
.  
1. Expensive. 
2. Detect long-term adherence but 
are poor at detecting recent 
adherence levels. 
3. Levels may be low for reasons 
other than poor adherence e.g diet, 
drug interactions
(11)
. 
Mean cell 
volume 
(MCV) 
Surrogate Mean volume of red 
blood cells, a 
parameter obtained 
from a full blood 
count (FBC). 
1. Cheaper than a viral load test. 1. Useful only for patients on d4T 
or AZT-based regimens. 
2. Detects long-term adherence but 
is poor at detecting recent 
adherence levels.  
3. Other factors such as vitamin 
B12 and/or folic acid deficiency, 
hepatic disease and alcoholism may 
also cause an elevated MCV. 
4. Invasive. 
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Micro-
electronic 
monitoring 
(MEM) 
Surrogate Adherence 
calculated by 
electronic caps 
attached to the 
medication bottle to 
digitally record 
adherence based on 
how often and at 
what times of the 
day, the medication 
bottle was opened. 
1. Adherence measures correlate 
closely with the viral load
(11)
. 
1. Expensive. 
2. Vulnerable to technological 
malfunction
(11)
. 
3. Tells you the time the pill bottle 
was opened but not whether 
medication was actually taken or 
whether food restrictions were 
adhered to. 
4. May underestimate adherence 
rates among patients who remove 
an additional dose from their pill 
bottle with the intention of taking it 
later, making the use of pill boxes 
problematic
(11, 33)
. 
Pill count Surrogate Adherence 
calculated as the 
percentage of pills 
expected to be taken 
that were actually 
taken. 
1. Cheap method of assessing 
adherence. 
2. Quantifiable measure of 
adherence. 
1. Time-consuming. 
2. Prone to error as the patient may 
remove medication and throw it 
away so this measure may be more 
accurate if it is unannounced
(36, 44)
.
 
3. Does not tell you whether the 
medication was taken at the correct 
time with the appropriate dietary 
requirements. 
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Self-reported 
adherence 
Surrogate Patient’s assessment 
of pills taken over a 
certain period e.g in 
the last week 
computed to a 
percentage. 
1. Cheap and easy method of 
assessing adherence. 
2. Computation of patient’s 
assessment to a percentage 
adherence does not take as long as 
pill count followed by calculation 
of the adherence percentage.  
 
1. Subject to errors from patient 
recall (recall bias) and 
dishonesty
(11, 12)
. 
2. Does not encompass the full 
definition of adherence, which 
includes following other 
recommendations pertaining to 
food, etc. 
3. No standardized questions
(11)
.  
Serum drug 
levels 
Non-surrogate Serum drug levels 
measured from a 
sample of the 
patient’s blood. 
1. Direct / non-surrogate measure 
of adherence. 
2. Plasma concentration directly 
determines virologic response
(11)
. 
3. May allow for detection or 
prevention of drug toxicity, which 
can lead to poor adherence
(11).
 
1. Expensive. 
2. Detect only recent adherence 
levels hence vulnerable to white 
coat adherence
(11, 24, 26)
. 
3. Cannot routinely measure 
nucleoside reverse transcriptase 
inhibitor (NRTI) levels because 
active moieties are intracellular
(11, 
16)
. 
4. There is substantial intra-patient 
variation in drug concentrations
(11, 
16)
.  
5. Levels may be low for reasons 
other than poor adherence e.g diet, 
drug interactions
(11)
. 
6. Invasive
(11)
. 
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Serum lactate 
levels 
Surrogate Measurement of 
lactic acid levels 
from a sample of the  
patient’s blood 
(plasma). 
1. Assists in the prevention and 
detection of drug toxicity. 
1. Useful only for patients on d4T 
or ddI. 
2. Serum lactate elevation does not 
occur in all patients. 
3. Detect long-term adherence but 
are poor at detecting recent 
adherence levels. 
4. Stringent lab requirements 
needed for accurate results i.e the 
patient must be well hydrated and 
must not have exercised within the 
past 24 hours and blood must be 
collected without a tourniquet or 
clenched feast into a pre-chilled 
fluoride-oxalate tube and 
transported on ice for processing 
within 4 hours
(16)
. 
5. Other factors such as 
uncontrolled diabetes mellitus, 
renal and hepatic disease may 
contribute to elevated lactate levels. 
6. Invasive. 
Serum lipid 
levels  
Surrogate Measurement of 
cholesterol and 
triglyceride levels 
from a sample of the 
patient’s blood 
(plasma). Lipid 
1. Assists in the prevention and 
detection of drug toxicity.  
1. Useful only for PIs other than 
unboosted ATV
(16, 23)
.  
2. Detect long-term adherence but 
are poor at detecting recent 
adherence levels.  
3. Other factors such as metabolic 
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levels rise over time 
in patients on PIs
(16, 
23)
. 
syndrome may contribute to 
elevated lipid levels. 
4. Invasive. 
Viral load Surrogate A measure of HIV 
viral ribonucleic acid 
copies/ml of blood 
(plasma). 
1. Most reliable surrogate marker 
of adherence
(14, 20, 21, 54)
.
 
2. Tells us if the patient is 
responding well to treatment 
(virologically) or not. 
3. Benchmark against which the 
efficacy of other routinely 
collected and more affordable 
markers can be assessed as 
measures of adherence. 
1. Expensive. 
2. Other factors such as 
malabsorption, drug interactions, 
diabetes mellitus and the 
acquisition of a drug-resistant HIV 
strain may contribute to a 
persistently detectable viral load 
despite good adherence.  
3. Invasive. 
 
Visual 
analogue 
scale (VAS) 
Surrogate Patients estimate 
their adherence by 
placing a mark on 
the scale.  
1. Cheap and easy method of 
assessing adherence.  
2. Adherence assessment does not 
take as long as pill count followed 
by calculation of the adherence 
percentage.  
 
1. Subject to errors from patient 
recall (recall bias) and dishonesty. 
2. Does not encompass the full 
definition of adherence, which 
includes following other 
recommendations pertaining to 
food etc.  
             
            The table above shows the different types of adherence measurement methods, their advantages and disadvantages. All reference numbers  
         (superscripts) in the table above correspond to references in the reference list above the table. 
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APPENDIX 2:  Adherence by self report at Themba Lethu Clinic 
 
Adherence Category 
Response to “How many of your pills have you taken in 
the past week?” 
> 90% 
> 60-90% 
> 30-60%                                   
10-30% 
< 10% 
  
All  
Most  
About half  
A few  
None 
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APPENDIX 3A 
Tables showing formulae for calculating sensitivity, specificity, PPV and NPV of change 
in MCV at 6 months and change in CD4 count at 6 months  
 
Sensitivity = d/(b+d) 
Specificity = a/(a+c) 
PPV = d/(c+d) 
NPV = a/(a+b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in MCV at 6 months Viral load < 400 copies/ml Viral load ≥ 400 copies/ml 
≥ 14.5fL a b 
< 14.5fL c d 
Change in CD4 count at 6 
months 
Viral load < 400 copies/ml Viral load ≥ 400 copies/ml 
≥ expected a b 
< expected c d 
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APPENDIX 3B 
Table showing formulae for calculating sensitivity, specificity, PPV and NPV of each 
category of change in CD4 count stratified by change in MCV at 6 months for all 
patients with a documented viral load result 
 
-Sensitivity for change in CD4 count ≥ expected and change in MCV < 14.5fL: d/(b+d) 
-Sensitivity for change in CD4 count < expected and change in MCV ≥ 14.5fL: f/(b+f) 
-Sensitivity for change in CD4 count < expected and change in MCV < 14.5fL: h/(b+h) 
 
-Specificity for change in CD4 count ≥ expected and change in MCV < 14.5fL: a/(a+c) 
-Specificity for change in CD4 count < expected and change in MCV ≥ 14.5fL: a(a+e) 
-Specificity for change in CD4 count < expected and change in MCV < 14.5fL: a/(a+g) 
 
-PPV for change in CD4 count ≥ expected and change in MCV < 14.5fL: d/(c+d) 
-PPV for change in CD4 count < expected and change in MCV ≥ 14.5fL: f/(e+f) 
-PPV for change in CD4 count < expected and change in MCV < 14.5fL: h/(g+h) 
 
-NPV for change in CD4 stratified by change in MCV: a/(a+b) 
  
 
 
 
 
 
 
 Viral load < 400 copies/ml Viral load ≥ 400 copies/ml 
Change in CD4 count ≥ 
expected and change in 
MCV ≥ 14.5fL 
a b 
Change in CD4 count ≥ 
expected and change in 
MCV< 14.5fL 
c d 
Change in CD4 count < 
expected and change in 
MCV ≥ 14.5fL 
e f 
Change in CD4 count < 
expected and change in 
MCV< 14.5fL 
g h 
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APPENDIX 3C 
Table showing formulae for calculating overall sensitivity, specificity, PPV and NPV of 
change in CD4 count stratified by change in MCV at 6 months for all patients with a 
documented viral load result 
 
Sensitivity: d/(b+d) 
Specificity: a/(a+c) 
PPV: d/(c+d) 
NPV: a/(a+b) 
  
 
 
 
 Viral load < 400 copies/ml Viral load ≥ 400 copies/ml 
Change in CD4 count ≥ 
expected and change in 
MCV ≥ 14.5fL 
a b 
Change in CD4 count ≥ 
expected and change in 
MCV< 14.5fL  
or 
Change in CD4 count < 
expected and change in 
MCV ≥ 14.5fL 
or 
Change in CD4 count < 
expected and change in 
MCV< 14.5fL 
c d 
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APPENDIX 3D 
Table showing formulae for calculating sensitivity, specificity, PPV and NPV for 
pregnancy during the first 6 months on ART for patients on AZT with a documented 
viral load result  
 
Pregnant during the first 6 
months on ART 
Viral load < 400 copies/ml Viral load ≥ 400 copies/ml 
Never a b 
At baseline No observations No observations 
During follow-up c d 
 
Sensitivity: d/(b+d) 
Specificity: a/(a+c) 
PPV: d/(c+d) 
NPV: a/(a+b) 
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APPENDIX 4A 
Baseline demographic characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens 
with a documented viral load result  
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 143200 
Viral load 
< 400 copies/ml 
N = 116120 
Viral load 
≥ 400 copies/ml 
N = 27080 
Total 
N = 3540 
Viral load 
< 400 copies/ml 
N = 2860 
Viral load 
≥ 400 copies/ml 
N = 680 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Gender  
Females               
Males 
 
90460 (63.2%) 
52740 (36.8%) 
 
74320 (64%) 
41800 (36%) 
 
16140 (59.6%) 
10940 (40.4%) 
 
1940 (54.8%) 
1600 (45.2%) 
 
1640 (57.3%) 
1220 (42.7%) 
 
300 (44.1%) 
380 (55.9%) 
Age at initiation in years 
≤ 36.7 
> 36.7 
 
72060 (50.3%) 
71140 (49.7%) 
 
58020 (50.0%) 
58100 (50.0%) 
 
14040 (51.8%) 
13040 (48.2%) 
 
1200 (33.9%) 
2340 (66.1%) 
  
860 (30.1%) 
2000 (69.9%) 
 
340 (50%) 
340 (50%) 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
113849 (79.5%) 
24480 (17.1%) 
4871 (3.4%) 
 
91769 (79.0%) 
20259 (17.5%) 
4092 (3.5%) 
 
22080 (81.5%) 
4221 (15.6%) 
779 (2.9%) 
 
2656 (75.0%) 
723 (20.4%) 
161 (4.6%) 
 
2149 (75.1%) 
571 (20.0%) 
140 (4.9%) 
 
507 (74.6%) 
152 (22.3%) 
21 (3.1%) 
Professional status    
Employed 
Unemployed 
 
 
74835 (52.3%) 
68365 (47.7%) 
 
 
61283 (52.8%) 
54837 (47.2%) 
 
 
13552 (50.0%) 
13528 (50.0%) 
 
 
1810 (51.1%) 
1730 (48.9%) 
 
 
1440 (50.3%) 
1420 (49.7%) 
 
 
370 (54.4%) 
310 (45.6%) 
 
             * 
On AZT-based regimens throughout the study period.  AZT: Zidovudine.   
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APPENDIX 4B 
Baseline clinical characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens with a 
documented viral load result  
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 143200 
Viral load 
< 400 copies/ml 
N = 116120 
Viral load 
≥ 400 copies/ml 
N = 27080 
Total 
N = 3540 
Viral load 
< 400 copies/ml 
N = 2860 
Viral load 
≥ 400 copies/ml 
N = 680 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
23714 (16.6%) 
78567 (54.9%) 
27884 (19.5%) 
13035 (9.0%) 
 
18691 (16.1%) 
63783 (54.9%) 
22799 (19.6%) 
10847 (9.4%) 
 
5023 (18.5%) 
14784 (54.6%) 
5085 (18.9%) 
2188 (8.0%) 
 
509 (14.4%) 
1880 (53.1%) 
588 (16.6%) 
563 (15.9%) 
 
433 (15.1%) 
1433 (50.1%) 
470 (16.4%) 
524 (18.4%) 
 
76 (11.2%) 
447 (65.7%) 
118 (17.4%) 
39 (5.7%) 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
7122 (5.0%) 
136078 (95.0%) 
 
5781 (5.0%) 
110339 (95.0%) 
 
1341 (5.0%) 
25739 (95.0%) 
 
35 (1.0%) 
3505 (99.0%) 
 
29 (1.0%) 
2831 (99.0%) 
 
6 (0.9%) 
674 (99.1%) 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
 
17741 (12.4%) 
119706 (83.6%) 
5753 (4.0%) 
 
14881 (12.8%) 
96636 (83.2%) 
4603 (4.0%) 
 
2860 (10.6%) 
23070 (85.2%) 
1150 (4.2%) 
 
341 (9.6%) 
2413 (68.2%) 
786 (22.2%) 
 
238 (8.3%) 
1943 (67.9%) 
679 (23.7%) 
 
103 (15.2%) 
470 (69.1%) 
107 (15.7%) 
Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
 
23157 (16.2%) 
48899 (34.1%) 
27984 (19.6%) 
43160 (30.1%) 
 
19064 (16.4%) 
40550 (34.9%) 
22545 (19.4%) 
33961 (29.3%) 
 
4093 (15.1%) 
8349 (30.8%) 
5439 (20.1%) 
9199 (34.0%) 
 
1178 (33.3%) 
986 (27.8%) 
618 (17.5 %) 
758 (21.4%) 
 
922 (32.2%) 
826 (28.9%) 
508 (17.8%) 
604 (21.1%) 
 
256 (37.6%) 
160 (23.5%) 
110 (16.2%) 
154 (22.7%) 
WHO stage at baseline 
 I 
II 
III 
IV 
 
54522 (38.1%) 
28769 (20.1%) 
42657 (29.8%) 
17252 (12.0%) 
 
45530 (39.2%) 
23047 (19.9%) 
33940 (29.2%) 
13603 (11.7%) 
 
8992 (33.2%) 
5722 (21.1%) 
8717 (32.2%) 
3649 (13.5%) 
 
1943 (54.9%) 
513 (14.5%) 
760 (21.5%) 
324 (9.1%) 
 
1557 (54.4%) 
424 (14.8%) 
583 (20.4%) 
296 (10.4%) 
 
386 (56.8%) 
89 (13.1%) 
177 (26.0%) 
28 (4.1%) 
                       * 
On AZT-based regimens throughout the study period.  AZT: Zidovudine.  BMI: Body Mass Index.  MCV: Mean cell volume.  WHO: World Health Organization.   
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APPENDIX 4C 
6 month clinical characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens with a 
documented viral load result  
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 143200 
Viral load 
< 400 copies/ml 
N = 116120 
Viral load 
≥ 400 copies/ml 
N = 27080 
Total 
N = 3540 
Viral load 
< 400 copies/ml 
N = 2860 
Viral load 
≥ 400 copies/ml 
N = 680 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Self-reported adherence
δ
 
> 90% 
> 60 – 90% 
≤ 60% 
 
127078 (88.7%) 
14670 (10.2%) 
1452 (1.1%) 
 
103344 (89%) 
11769 (10.1%) 
1007 (0.9%) 
 
23734 (87.6%) 
2901 (10.7%) 
445 (1.7%) 
 
3126 (88.3%) 
374 (10.5%) 
40 (1.2%) 
 
2533 (88.6%) 
307 (10.7%) 
20 (0.7%) 
 
593 (87.2%) 
67 (9.9%) 
20 (2.9%) 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0: 
1: 
≥ 2: 
 
92340 (64.5%) 
36080 (25.2%) 
12460 (8.7%) 
2320 (1.6%) 
 
 
106534 (74.4%) 
30576 (21.4%) 
6090 (4.2%) 
 
 
108874 (76.0%) 
28828 (20.1%) 
5498 (3.9%) 
 
74620 (64.3%) 
29500 (25.4%) 
10180 (8.8%) 
1820 (1.5%) 
 
 
86538 (74.5%) 
24888 (21.4%) 
4694 (4.1%) 
 
 
88623 (76.3%) 
23264 (20.0%) 
4233 (3.7%) 
 
17720 (65.4%) 
6580 (24.3%) 
2280 (8.5%) 
500 (1.8%) 
 
 
19996 (73.8%) 
5688 (21%) 
1396 (5.2%) 
 
 
20251 (74.8%) 
5564 (20.5%) 
1265 (4.7%) 
 
2140 (60.5%) 
880 (24.9%) 
320 (9.0%) 
200 (5.6%) 
 
 
2543 (71.8%) 
790 (22.3%) 
207 (5.9%) 
 
 
2640 (74.6%) 
796 (22.5%) 
104 (2.9%) 
 
1760 (61.5%) 
780 (27.3%) 
200 (7.0%) 
120 (4.2%) 
 
 
2067 (72.3%) 
631 (22.1%) 
162 (5.6%) 
 
 
2202 (77.0%) 
615 (21.5%) 
43 (1.5%) 
 
380 (55.9%) 
100 (14.7%) 
120 (17.7%) 
80 (11.7%) 
 
 
476 (70%) 
159 (23.4%) 
45 (6.6%) 
 
 
438 (64.4%) 
181 (26.6%) 
61 (9.0%) 
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BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
10261 (7.2%) 
75959 (53.0%) 
38405 (26.8%) 
18575 (13.0%) 
 
7831 (6.7%) 
61253 (52.8%) 
31516 (27.1%) 
15520 (13.4%) 
 
2430 (9.0%) 
14706 (54.3%) 
6889 (25.4%) 
3055 (11.9%) 
 
275 (7.8%) 
1769 (50.0%) 
958 (27.1%) 
538 (15.1%) 
 
229 (8.0%) 
1351 (47.2%) 
791 (27.7%) 
489 (17.2%) 
 
46 (6.8%) 
418 (61.5%) 
167 (24.6%) 
49 (7.1%) 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1002 (0.7%) 
142198 (99.3%) 
 
741 (0.6%) 
115379 (99.4%) 
 
261 (1.0%) 
26819 (99.0%) 
 
20 (0.6%) 
3520 (99.4%) 
 
0 (0%) 
2860 (100%)  
 
20 (2.9%) 
660 (97.1%) 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
4640 (3.2%) 
69146 (48.3%) 
69414 (48.5%) 
 
3725 (3.2%) 
51182 (44.1%) 
61213 (52.7%) 
 
915 (3.4%)  
17964 (66.3%) 
8201 (30.3%) 
 
42 (1.2%) 
718 (20.3%) 
2780 (78.5%) 
 
20 (0.7%) 
377 (13.2%) 
2463 (86.1%) 
 
22 (3.2%) 
341 (50.2%) 
317 (46.6%) 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
 
57281 (40%) 
85919 (60%) 
 
51753 (44.6%) 
64637 (55.4%) 
 
5528 (20.4%) 
21552 (79.6%) 
 
1765 (49.9%) 
1775 (50.1%) 
 
1562 (54.6%) 
1298 (45.4%) 
 
203 (29.9%) 
477 (70.1%) 
Change in CD4 count at 6 months in 
cells/mm
3
 
≥ expected  
< expected  
 
 
111903 (78.1%) 
31297 (21.9%) 
 
 
93757 (80.7%) 
22363 (19.3%) 
 
 
18146 (67.0%) 
8934 (33.0%) 
 
 
2489 (70.3%) 
1051 (29.7%) 
 
 
2158 (75.5%) 
702 (24.5%) 
 
 
331 (48.7%) 
349 (51.3%) 
Change in CD4 count at 6 months 
stratified by change in MCV at 6 
months 
-Change in CD4 count ≥ expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected and 
change in MCV < 14.5fL: 
-Change in CD4 count < expected and 
change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected and 
change in MCV < 14.5fL: 
 
 
 
 
45323 (31.7%) 
 
66580 (46.5%) 
 
11958 (8.4%) 
 
19339 (13.4) 
 
 
 
 
41384 (35.6%) 
 
52373 (45.1%) 
 
10369 (8.9%) 
  
11994 (10.4%) 
 
 
 
 
3939 (14.6%) 
 
14207 (52.5%) 
 
1589 (5.9%) 
 
7345 (27.0%) 
 
 
 
 
1346 (38.0%) 
 
1143 (32.3%) 
 
419 (11.8%) 
 
632 (17.9%) 
 
 
 
 
1229 (43.0%) 
 
929 (32.5%) 
 
333 (11.6%) 
 
369 (12.9%) 
 
 
 
 
117 (17.2%) 
 
214 (31.5%) 
 
86 (12.7%) 
 
263 (38.6%) 
Regimen change 
No 
Yes 
 
128900 (90.0%) 
14300 (10.0%) 
 
104200 (89.7%) 
11920 (10.3%) 
 
24700 (91.2%) 
2380 (8.8%) 
 
3420 (96.6%) 
120 (3.4%) 
 
2800 (97.9%) 
60 (2.1%)  
 
620 (91.2%) 
60 (8.8%) 
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TB
α
: On TB treatment during first 6 
months on ART: 
Never 
At baseline 
During follow-up 
 
 
107100 (74.8%) 
29860 (20.9%) 
6240 (4.3%) 
 
 
86900 (74.8%) 
24080 (20.7%) 
5140 (4.5%) 
 
 
20200 (74.6%) 
5780 (21.3%) 
1100 (4.1%) 
 
 
3000 (84.7%) 
480 (13.6%) 
60 (1.7%) 
 
 
2400 (83.9%) 
400 (14.0%) 
60 (2.1%) 
 
 
600 (88.2%) 
80 (11.8%) 
0 (0%) 
Pregnancy
α
: Pregnancy during first 6 
months on ART: 
Never  
At baseline 
During follow-up 
Missing
γ
 
 
 
85880 (60.0%) 
1640 (1.1%) 
2940 (2.1%) 
52740 (36.8%) 
 
 
70680 (60.9%) 
1340 (1.2%) 
2300 (1.9%) 
41800 (36.0%) 
 
 
15200 (56.1%) 
300 (1.1%) 
640 (2.4%) 
10940 (40.4%) 
 
 
1840 (52.0%) 
0 (0%) 
100 (2.8%) 
1600 (45.2%) 
 
 
1600 (55.9%) 
0 (0%) 
40 (1.4%) 
1220 (42.7%) 
 
 
240 (35.3%) 
0 (0%) 
60 (8.8%) 
380 (55.9%) 
Adverse events or side effects 
No 
Yes 
 
139100 (97.1%) 
4100 (2.9%) 
 
112360 (96.8%) 
3760 (3.2%) 
 
26740 (98.7%) 
340 (1.3%) 
 
3520 (99.4%) 
20 (0.6%) 
 
2840 (99.3%) 
20 (0.7%) 
 
680 (100%) 
0 (0%) 
* 
On AZT-based regimens throughout the study period.  
δ 
The last self-reported adherence levels on, or after, the 3 month visit (70 days post-initiation) and not more than 3 months 
(110 days) before the date of the viral load but at least 28 days before the viral load was done.  
α 
Variable has baseline and 6 month components.  
γ 
Male patients.  ART: Antiretroviral 
Therapy.  ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  MCV: Mean cell volume.  TB: Tuberculosis.     
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APPENDIX 5A 
Baseline demographic characteristics and their associations with poor adherence for all eligible patients and eligible patients on AZT-
based regimens with a documented viral load done 90 – 270 days after ART initiation 
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 11724 
Viral load 
< 400 copies/ml 
N = 10011 
Viral load 
≥ 400 copies/ml 
N = 1713 
P-value Total 
N = 285 
Viral load 
< 400 copies/ml 
N = 247 
Viral load 
≥ 400 copies/ml 
N = 38 
P-value 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Gender  
Females               
Males 
 
7409 (63.2%) 
4315 (36.8%) 
 
6391 (63.8%) 
3620 (36.2%) 
 
1018 (59.4%) 
695 (40.6%) 
 
0.000 
 
153 (53.7%) 
132 (46.3%) 
 
138 (55.9%) 
109 (44.1%) 
 
15 (39.5%) 
23 (60.5%) 
 
0.059 
Age at initiation in years 
Median (IQR)  
 
36.7 (31.5 – 43.3) 
 
36.8 (31.5 – 43.3) 
 
36.3 (31.1 – 43) 
 
0.0644
Þ
 
 
39.3 (33.6 – 45.7) 
 
39.3 (33.8 – 45.8) 
 
39.9 (31.1 – 45.6)      
 
0.5245
Þ
 
Age at initiation in years 
≤ median (36.7)
α
 
> median (36.7) 
 
5893 (50.3%) 
5831 (49.7%) 
 
5002 (50.0%) 
5009 (50.0%) 
 
891 (52.0%) 
822 (48.0%) 
 
0.117 
 
104 (36.5%) 
181 (63.5%) 
  
90 (36.4%) 
157 (63.6%) 
 
14 (36.8%) 
24 (63.2%) 
 
0.962 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
Missing 
 
7062 (60.2%) 
1484 (12.7%) 
343 (2.9%) 
2835 (24.2%) 
 
5996 (59.9%) 
1265 (12.6%) 
303 (3.0%) 
2447 (24.5%) 
 
1066 (62.2%) 
219 (12.8%) 
40 (2.3%) 
388 (22.7%) 
 
0.215 
 
148 (51.9%) 
43 (15.1%) 
11 (3.9%) 
83 (29.1%) 
 
131 (53.0%) 
35 (14.2%) 
10 (4.1%) 
71 (28.7%) 
 
17 (44.7%) 
8 (21.1%) 
1 (2.6%) 
12 (31.6%) 
 
0.441
ð 
Professional status    
Employed 
Unemployed 
Missing 
 
5913 (50.4%) 
5639 (48.1%) 
172 (1.5%) 
 
5086 (50.8%) 
4788 (47.8%) 
137 (1.4%) 
 
827 (48.3%) 
851 (49.7%) 
35 (2.0%) 
 
0.092 
 
133 (46.7%) 
147 (51.6%) 
5 (1.7%) 
 
116 (47.0%) 
127 (51.4%) 
4 (1.6%) 
 
17 (44.7%) 
20 (52.6%) 
1 (2.7%) 
 
0.839
 
* 
On AZT-based regimens throughout the study period. 
 α 
The median age at ART initiation for all eligible patients with a documented viral load result.  
Þ 
Wilcoxon rank sum 
test.
  ð Fisher’s exact test.  AZT: Zidovudine.  IQR: Interquartile range.   
Note: Except where otherwise stated, the chi-square test was used. 
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APPENDIX 5B 
Baseline clinical characteristics and their associations with poor adherence for all eligible patients and eligible patients on AZT-based 
regimens with a documented viral load done 90 – 270 days after ART initiation  
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 11724 
Viral load 
< 400 copies/ml 
N = 10011 
Viral load 
≥ 400 copies/ml 
N = 1713 
P-value Total 
N = 285 
Viral load 
< 400 copies/ml 
N = 247 
Viral load 
≥ 400 copies/ml 
N = 38 
P-value 
n (%)  n (%) n(%) n (%)  n (%) n (%) 
BMI at initiation in kg/m
2
 
Median (IQR) 
 
22 (19 – 25) 
 
22 (19 – 25) 
 
21.4  (19 – 25) 
 
0.0041
Þ
 
 
22.0  (19.5 – 26.3) 
 
22.0  (19.5 – 28) 
 
21.5  (19.8 – 24) 
 
0.4221
 Þ
 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
Missing 
 
1736 (14.8%) 
5549 (47.3%) 
1923 (16.4%) 
900 (7.7%) 
1616 (13.8%) 
 
1473 (14.7%) 
4749 (47.4%) 
1674 (16.7%) 
788 (7.9%) 
1327 (13.3%) 
 
263 (15.4%) 
800 (46.7%) 
249 (14.5%) 
112 (6.5%) 
289 (16.9%) 
 
0.103 
 
35 (12.3%) 
109 (38.2%) 
30 (10.5%) 
38 (13.3%) 
73 (25.7%) 
 
33 (13.4%) 
90 (36.4%) 
28 (11.3%) 
37 (15.0%) 
59 (23.9%) 
 
2 (5.3%) 
19 (50%) 
2 (5.3%) 
1 (2.6%) 
14 (36.8%) 
 
0.042
ð
 
Baseline haemoglobin in g/dl 
Median (IQR) 
 
11.7 (10.1 – 13.1) 
 
11.7 (10.2 – 13.1) 
 
11.6 (10.1 – 13) 
 
0.2566
Þ
 
 
12.6 (11.6 – 14) 
 
12.6 (11.2 – 14) 
 
12.9 (12 – 14.2) 
 
0.3854
Þ
 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
579 (4.9%) 
10108 (86.2%) 
1037 (8.9%) 
 
498 (5.0%) 
8686 (86.8%) 
827 (8.2%) 
 
81 (4.7%) 
1422 (83.0%) 
210 (12.3%) 
 
0.958 
 
1 (0.4%) 
227 (79.6%) 
57 (20%) 
 
1 (0.4%) 
198 (80.2%) 
48 (19.4%) 
 
0 (0%) 
29 (76.3%) 
9 (23.7%) 
 
1.000
ð
 
MCV at baseline in fL  
Median (IQR)  
 
88.2 (83.6 – 92.2) 
 
88.4 (83.9 – 92.3) 
 
88.1  (83.5 – 92.1) 
 
0.0001
Þ 
 
90.9 (86.6 – 99.0) 
 
90.5 (86.6 – 99) 
 
92.5 (86.9 – 97.5) 
 
0.5783
Þ
 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
1196 (10.2%) 
8012 (68.3%) 
376 (3.2%) 
2140 (18.3%) 
 
1072 (10.7%) 
6974 (69.7%) 
319 (3.2%) 
1646 (16.4%) 
 
124 (7.2%) 
1038 (60.6%) 
57 (3.3%) 
494 (28.9%) 
 
0.015 
 
18 (6.3%) 
147 (51.6%) 
47 (16.5%) 
73 (25.6%) 
 
16 (6.5%) 
128 (51.8%) 
41 (16.6%) 
62 (25.1%) 
 
2 (5.3%) 
19 (50%) 
6 (15.8%) 
11 (28.9%) 
 
1.000
ð
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Baseline CD4 count in 
cells/mm
3 
Median (IQR)  
 
99 (39 – 171) 
 
100 (39 – 172) 
 
94 (36 – 168) 
 
0.0376
Þ 
 
124 (55 – 209) 
 
120  (55 – 207) 
 
168 (61 – 244) 
 
0.2628
Þ
 
Baseline CD4 count in 
cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50  
Missing 
 
1473 (12.6%) 
3638 (31.0%) 
2069 (17.6%) 
3154 (26.9%) 
1390 (11.9%) 
 
1281 (12.8%) 
3152 (31.5%) 
1766 (17.6%) 
2685 (26.8%) 
1127 (11.3%) 
 
192 (11.2%) 
486 (28.4%) 
303 (17.7%) 
469 (27.4%) 
263 (15.3%) 
 
0.167 
 
65 (22.8%) 
64 (22.5%) 
42 (14.7 %) 
47 (16.5%) 
67 (23.5%) 
 
55 (22.3%) 
55 (22.3%) 
39 (15.8%) 
42 (17%) 
56 (22.6%) 
 
10 (26.3%) 
9 (23.7%) 
3 (7.9%) 
5 (13.2%) 
11 (28.9%) 
 
0.619 
WHO stage at baseline 
 I 
II 
III 
IV 
Missing 
 
3850 (32.8%) 
1926 (16.4%) 
3066 (26.2%) 
1084 (9.2%) 
1798 (15.4%) 
 
3397 (33.9%) 
1659 (16.6%) 
2610 (26.1%) 
918 (9.2%) 
1427 (14.2%) 
 
453 (26.4%) 
267 (15.6%) 
456 (26.6%) 
166 (9.7%) 
371 (21.7%) 
 
0.000 
 
111 (38.9%) 
20 (7.0%) 
59 (20.7%) 
20 (7.0%) 
75 (26.4%) 
 
96 (38.9%) 
17 (6.9%) 
52 (21.1%) 
20 (8.1%) 
62 (25.1%) 
 
15 (39.5%) 
3 (7.9%) 
7 (18.4%) 
0 (0%) 
13 (34.2%) 
 
0.366
ð
 
* 
On AZT-based regimens throughout the study period. 
 Þ 
Wilcoxon rank sum test.
   ð Fisher’s exact test.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile range.  MCV: Mean cell 
volume.  WHO: World Health Organization. 
Note: Except where otherwise stated, the chi-square test was used.  
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APPENDIX 5C  
6 month clinical characteristics and their associations with poor adherence for all eligible patients and eligible patients on AZT-based 
regimens with a documented viral load done 90 – 270 days after ART initiation   
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 11724 
Viral load 
< 400 copies/ml 
N = 10011 
Viral load 
≥ 400 copies/ml 
N = 1713 
P- 
value 
Total 
N = 285 
Viral load 
< 400 copies/ml 
N = 247 
Viral load 
≥ 400 copies/ml 
N = 38 
P- value 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
Missing 
 
5381 (45.9%) 
644 (5.5%) 
135 (1.1%) 
5564 (47.5%) 
 
4589 (45.8%) 
548 (5.5%) 
105 (1.0%) 
4769 (47.7%) 
 
792 (46.2%) 
96 (5.6%) 
30 (1.8%) 
795 (46.4%) 
 
0.054 
 
111 (38.9%) 
8 (2.8%) 
5 (1.9%) 
161 (56.4%) 
 
101 (40.9%) 
6 (2.4%) 
3 (1.2%) 
137 (55.5%) 
 
10 (26.3%) 
2 (5.3%) 
2 (5.3%) 
24 (63.1%) 
 
0.045
ð
 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
Missing 
 
Number of missed medical 
visits 
0: 
1: 
≥ 2: 
Missing: 
 
7944 (67.8%) 
2790 (23.8%) 
846 (7.2%) 
144 (1.2%) 
 
 
9042 (77.1%) 
2145 (18.3%) 
382 (3.3%) 
155 (1.3%) 
 
 
 
9016 (76.9%) 
2171 (18.5%) 
382 (3.3%) 
155 (1.3%) 
 
6798 (67.9%) 
2379 (23.8%) 
720 (7.2%) 
114 (1.1%) 
 
 
7749 (77.4%) 
1822 (18.2%) 
316 (3.2%) 
124 (1.2%) 
 
 
 
7747 (77.4%) 
1828 (18.3%) 
312 (3.1%) 
124 (1.2%) 
 
1146 (66.9%) 
411 (24.0%) 
126 (7.4%) 
30 (1.7%) 
 
 
1293 (75.5%) 
323 (18.9%) 
66 (3.8%) 
31 (1.8%) 
 
 
 
1269 (74.1%) 
343 (20.0%) 
70 (4.1%) 
31 (1.8%) 
 
0.882 
 
 
 
 
 
0.203 
 
 
 
 
 
 
0.013 
 
181 (63.5%) 
66 (23.2%) 
25 (8.8%) 
13 (4.5%) 
 
 
203 (71.2%) 
55 (19.3%) 
14 (5.0%) 
13 (4.5%) 
 
 
 
207 (72.6%) 
58 (20.4%) 
7 (2.5%) 
13 (4.5%) 
 
161 (65.2%) 
59 (23.9%) 
18 (7.3%) 
9 (3.6%) 
 
 
181 (73.3%) 
45 (18.2%) 
12 (4.9%) 
9 (3.6%) 
 
 
 
187 (75.7%) 
47 (19.0%) 
4 (1.7%) 
9 (3.6%) 
 
20 (52.6%) 
7 (18.4%) 
7 (18.4%) 
4 (10.6%) 
 
 
22 (57.9%) 
10 (26.3%) 
2 (5.2%) 
4 (10.6%) 
 
 
 
20 (52.6%) 
11 (28.9%) 
3 (7.9%) 
4 (10.6%) 
 
0.048 
 
 
 
 
 
0.277
ð 
 
 
 
 
 
0.013
ð 
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BMI at 6 months in kg/m
2
 
Median (IQR) 
 
23.0 (21 – 27) 
 
23.4 (21 – 27) 
 
23 (20.9 – 26) 
 
0.0002
Þ 
 
24 (21.2 – 28)  
 
24 (21.3 – 28.4) 
 
23 (21 – 25)  
 
0.2831
Þ 
BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
Missing 
 
606 (5.2%) 
4277 (36.5%) 
2102 (17.9%) 
1050 (9.0%) 
3689 (31.4%) 
 
471 (4.7%) 
3479 (34.8%) 
1742 (17.4%) 
878 (8.8%) 
3441 (34.3%) 
 
135 (7.9%) 
798 (46.6%) 
360 (21.0%) 
172 (10.0%) 
248 (14.5%) 
 
0.010 
 
17 (6.0%) 
88 (30.9%) 
48 (16.8%) 
32 (11.2%) 
100 (35.1%) 
 
15 (6.1%) 
70 (28.3%) 
41 (16.6%) 
30 (12.1%) 
91 (36.9%) 
 
2 (5.3%) 
18 (47.4%) 
7 (18.4%) 
2 (5.3%) 
9 (23.6%) 
 
0.292
ð 
Haemoglobin at 6 months in 
g/dl 
Median (IQR) 
 
 
13.2 (12 – 14.4) 
 
 
13.3 (12.1 – 14.5) 
 
 
13.1 (12 – 14.3) 
 
 
0.0000
Þ 
 
 
13.1 (12.0 – 14.6) 
 
 
13.1 (12 – 14.6) 
 
 
13.4 (11 – 14.6) 
 
 
0.7142
Þ 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
Missing 
 
56 (0.5%) 
4990 (42.6%) 
6678 (56.9%) 
 
44 (0.4%) 
4150 (41.5%) 
5817 (58.1%) 
 
12 (0.7%) 
840 (49.0%) 
861 (50.3%) 
 
0.361
 
 
1 (0.4%) 
115 (40.4%) 
169 (59.2%) 
 
0 (0%) 
101 (40.9%) 
146 (59.1%) 
 
1 (2.6%) 
14 (36.8%) 
23 (60.6%) 
 
0.129
ð
 
MCV at 6 months in fL 
Median (IQR) 
 
99.4 (92.9 – 106.4) 
 
100.3 (93.7 – 107.2) 
 
95.5 (90.5 – 102.1)
 
 
0.0000
 Þ
 
 
107.5  (102.4 – 113.5) 
 
108.6 (103.2 – 113.7) 
 
102 (96.4 – 112.5)  
 
0.0158
Þ
 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
Missing 
 
213 (1.8%) 
2786 (23.8%) 
2721 (23.2%) 
6004 (51.2%) 
 
177 (1.8%) 
2148 (21.5%) 
2420 (24.2%) 
5266 (52.5%) 
 
36 (2.1%)  
638 (37.2%) 
301 (17.6%) 
738 (43.1%) 
 
0.000 
 
2 (0.7%) 
21 (7.4%) 
118 (41.4%) 
144 (50.5%) 
 
2 (0.8%) 
14 (5.7%) 
107 (43.3%) 
124 (50.2%) 
 
0 (0%) 
7 (18.4%) 
11 (28.9%) 
20 (52.7%) 
 
0.026
ð
 
Change in MCV at 6 months in 
fL 
Median (IQR) 
 
 
12.2 (5.7 – 18.3) 
 
 
13.2 (6.4 – 18.8) 
 
 
7.1 (2.7 – 12.6) 
 
 
0.0000
Þ 
 
 
15.7 (4.6 – 20.3) 
 
 
16.1  (4.2 – 21.6) 
 
 
8.9 (6.2 – 17.6) 
 
 
0.2722
Þ 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
Missing 
 
1756 (15.0%) 
2512 (21.4%) 
7456 (63.6%) 
 
1633 (16.3%) 
2016 (20.1%) 
6362 (63.6%) 
 
123 (8.6%) 
496 (40.8%) 
1094 (50.6%) 
 
0.000 
 
51 (17.9%) 
46 (16.1%) 
188 (66.0%) 
 
47 (19.0%) 
39 (15.8%) 
161 (65.2%) 
 
4 (10.5%) 
7 (18.4%) 
27 (71.1%) 
 
0.205
ð 
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Change in CD4 count at 6 
months in cells/mm
3
 
Median (IQR) 
 
 
128 (69 – 204) 
 
 
133 (74 – 207) 
 
 
99 (34 – 188) 
 
 
0.0000
 Þ
 
 
 
96 (48 – 142) 
 
 
103 (49 – 146) 
 
 
52.5 ( 5.5 – 84.5) 
 
 
0.0333
Þ 
Change in CD4 count at 6 
months in cells/mm
3
 
≥ expected  
< expected  
Missing 
 
 
4108 (35.0%) 
1079 (9.2%) 
6537 (55.8%) 
 
 
3522 (35.2%) 
814 (8.1%) 
5675 (56.7%) 
 
 
586 (34.2%) 
265 (15.5%) 
862 (50.3%) 
 
 
0.000 
 
 
78 (27.4%) 
32 (11.2%) 
175 (61.4%) 
 
 
73 (29.6%) 
25 (10.1%) 
149 (60.3%) 
 
 
5 (13.2%) 
7 (18.4%) 
26 (68.4%) 
 
 
0.018 
Change in CD4 count at 6 
months stratified by change in 
MCV at 6 months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
Missing: 
 
 
 
 
1283 (10.9%) 
 
1776 (15.1%) 
 
331 (2.8%) 
 
495 (4.2%) 
7839 (67.0%) 
 
 
 
 
1202 (12.0%) 
 
1490 (14.9%) 
 
311 (3.1%) 
  
344 (3.4%) 
6664 (66.6%) 
 
 
 
 
81 (4.7%) 
 
286 (16.7%) 
 
20 (1.2%) 
 
151 (8.8%) 
1175 (68.6%) 
 
 
 
 
0.000 
 
 
 
 
33 (11.6%) 
 
27 (9.5%) 
 
10 (3.5%) 
 
16 (5.6%) 
199 (69.8%) 
 
 
 
 
32 (13.0%) 
 
24 (9.7%) 
 
8 (3.2%) 
 
13 (5.3%) 
170 (68.8%) 
 
 
 
 
1 (2.6%) 
 
3 (7.9%) 
 
2 (5.3%) 
 
3 (7.9%) 
29 (76.3%) 
 
 
 
 
0.146
ð
 
Regimen change 
No 
Yes 
 
10648 (90.8%) 
1076 (9.2%) 
 
9105 (90.9%) 
906 (9.1%) 
 
1543 (90.1%) 
170 (9.9%) 
 
0.247 
 
278 (97.5%) 
7 (2.5%) 
 
242 (98.0%) 
5 (2.0%)  
 
36 (94.7%) 
2 (5.3%) 
 
0.236
ð 
TB
α
: On TB treatment during 
first 6 months on ART: 
Never 
At baseline 
During follow-up 
 
 
8777 (74.9%) 
2460 (21.0%) 
487 (4.1%) 
 
 
7509 (75.0%) 
2084 (20.8%) 
418 (4.2%) 
 
 
1268 (74.0%) 
376 (21.9%) 
69 (4.1%) 
 
 
0.560 
 
 
217 (76.1%) 
61 (21.4%) 
7 (2.5%) 
 
 
187 (75.7%) 
53 (21.5%) 
7 (2.8%) 
 
 
30 (78.9%) 
8 (21.1%) 
0 (0%) 
 
 
0.808
ð 
Pregnancy
α
: Pregnancy during 
first 6 months on ART: 
Never  
At baseline 
 
 
7079 (60.4%) 
131 (1.1%) 
 
 
6109 (61.0%) 
113 (1.1%) 
 
 
970 (56.6%) 
18 (1.1%) 
 
 
0.857 
 
 
 
145 (50.9%) 
2 (0.7%) 
 
 
133 (53.8%) 
2 (0.8%) 
 
 
12 (31.6%) 
0 (0%) 
 
 
0.022
ð 
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During follow-up 
Missing
γ
 
199 (1.7%) 
4315 (36.8%) 
169 (1.7%) 
3620 (36.2%) 
30 (1.7%) 
695 (40.6%) 
6 (2.1%) 
132 (46.3%) 
3 (1.2%) 
109 (44.2%) 
3 (7.9%) 
23 (60.5%) 
Adverse events or side effects 
No 
Yes 
 
11379 (97.1%) 
345 (2.9%) 
 
9686 (96.8%) 
325 (3.2%) 
 
1693 (98.8%) 
20 (1.2%) 
 
0.000 
 
284 (99.6%) 
1 (0.4%) 
 
246 (99.6%) 
1 (0.4%) 
 
38 (100%) 
0 (0%) 
 
1.000
ð 
* 
On AZT-based regimens throughout the study period.  
Þ 
Wilcoxon rank sum test.
  ð Fisher’s exact test.  
 α 
Variable has baseline and 6 month components.  
γ 
Male patients.  ART: Antiretroviral Therapy.  
ARV: Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  IQR: Interquartile range.  MCV: Mean cell volume.  TB: Tuberculosis. 
Note: Except where otherwise stated, the chi-square test was used.  
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APPENDIX 6A 
Baseline demographic characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens 
with a documented viral load done 90 – 270 days after ART initiation 
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 234480 
Viral load 
< 400 copies/ml 
N = 200220 
Viral load 
≥ 400 copies/ml 
N = 34260 
Total 
N = 5700 
Viral load 
< 400 copies/ml 
N = 4940 
Viral load 
≥ 400 copies/ml 
N = 760 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Gender  
Females               
Males 
 
148180 (63.2%) 
86300 (36.8%) 
 
127820 (63.8%) 
72400 (36.2%) 
 
20360 (59.4%) 
13900 (40.6%) 
 
3060 (53.7%) 
2640 (46.3%) 
 
2760 (55.9%) 
2180 (44.1%) 
 
300 (39.5%) 
460 (60.5%) 
Age at initiation in years 
≤ 36.7  
> 36.7 
 
117860 (50.3%) 
116620 (49.7%) 
 
100040 (50.0%) 
100180 (50.0%) 
 
17820 (52.0%) 
16440 (48.0%) 
 
2080 (36.5%) 
3620 (63.5%) 
  
1800 (36.4%) 
3140 (63.6%) 
 
280 (36.8%) 
480 (63.2%) 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
185465 (79.1%) 
41301 (17.6%) 
7714 (3.3%) 
 
158037 (78.9%) 
35372 (17.7%) 
6811 (3.4%) 
 
27428 (80.1%) 
5929 (17.3%) 
903 (2.6%) 
 
4236 (74.3%) 
1209 (21.2%) 
255 (4.5%) 
 
3711 (75.1%) 
997 (20.2%) 
232 (4.7%) 
 
525 (69.1%) 
212 (27.9%) 
23 (3.0%) 
Professional status    
Employed 
Unemployed 
 
120011 (51.2%) 
114469 (48.8%) 
 
103122 (51.5%) 
97098 (48.5%) 
 
16889 (49.3%) 
17371 (50.7%) 
 
2720 (47.7%) 
2980 (52.3%) 
 
2371 (48%) 
2569 (52%) 
 
349 (45.9%) 
411 (54.1%) 
* 
On AZT-based regimens throughout the study period. 
 
AZT: Zidovudine.     
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APPENDIX 6B 
Baseline clinical characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens with a 
documented viral load done 90 – 270 days after ART initiation  
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 234480 
Viral load 
< 400 copies/ml 
N = 200220 
Viral load 
≥ 400 copies/ml 
N = 34260 
Total 
N = 5700 
Viral load 
< 400 copies/ml 
N = 4940 
Viral load 
≥ 400 copies/ml 
N = 760 
n (%)  n (%) n(%) n (%)  n (%) n (%) 
BMI at initiation in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
40809 (17.4%) 
128489 (54.8%) 
44724 (19.1%) 
20458 (8.7%) 
 
34475 (17.2%) 
109275 (54.6%) 
38623 (19.3%) 
17847 (8.9%) 
 
6334 (18.5%) 
19214 (56.1%) 
6101 (17.8%) 
2611 (7.6%) 
 
951 (16.7%) 
2985 (52.4%) 
863 (15.1%) 
901 (15.8%) 
 
853 (17.3%) 
2445 (49.5%) 
790 (16.0%) 
852 (17.2%) 
 
98 (12.9%) 
540 (71.1%) 
73 (9.6%) 
49 (6.4%) 
Baseline haemoglobin 
≤ 8 g/dl 
> 8g/dl 
 
12121 (5.2%) 
222359 (94.8%) 
 
10384 (5.2%) 
189836 (94.8%) 
 
1737 (5.1%) 
32523 (94.9%) 
 
41 (0.7%) 
5659 (99.3%) 
 
33(0.7%) 
4907 (99.3%) 
 
8 (1.1%) 
752(98.9%) 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fL 
 
29925 (12.8%) 
196384 (83.8%) 
8171 (3.4%) 
 
26216 (13.1%) 
167140 (83.5%) 
6864 (3.4%) 
 
3709 (10.8%) 
29244 (85.4%) 
1307 (3.8%) 
 
521 (9.1%) 
4206 (73.8%) 
973 (17.1%) 
 
467(9.5%) 
3627 (73.4%) 
846 (17.1%) 
 
54 (7.1%) 
579 (76.2%) 
127 (16.7%) 
Baseline CD4 count in cells/mm
3
 
 > 200 
101 – 200 
51 – 100 
≤ 50 
 
33157 (14.1%) 
82533 (35.2%) 
46999 (20.0%) 
71791 (30.7%) 
 
28654 (14.3%) 
71025 (35.5%) 
39888 (19.9%) 
60653 (30.3%) 
 
4503 (13.1%) 
11508 (33.6%) 
7111 (20.8%) 
11138 (32.5%) 
 
1474 (25.9%) 
1747 (30.6%) 
1139 (20.0 %) 
1340 (23.5%) 
 
1257 (25.4%) 
1507 (30.5%) 
1025 (20.7%) 
1151 (23.4%) 
 
217 (28.6%) 
240 (31.6%) 
114 (15%) 
189 (24.8%) 
WHO stage at baseline 
 I 
II 
III 
IV 
 
91921 (39.2%) 
46000 (19.6%) 
71844 (30.6%) 
24715 (10.6%) 
 
79986 (40.0%) 
39106 (19.5%) 
60402 (30.2%) 
20726 (10.3%) 
 
11935 (34.8%) 
6894 (20.1%) 
11442 (33.4%) 
3989 (11.7%) 
 
2874 (50.4%) 
681 (12.0%) 
1620 (28.4%) 
525 (9.2%) 
 
2474 (50.1%) 
581 (11.8%) 
1386 (28.1%) 
499 (10.0%) 
 
400 (52.6%) 
100 (13.2%) 
234 (30.8%) 
26 (3.4%) 
* 
On AZT-based regimens throughout the study period. 
 
AZT: Zidovudine.  BMI: Body Mass Index.  MCV: Mean cell volume.  WHO: World Health Organization. 
 120 
 
APPENDIX 6C  
6 month clinical characteristics after multiple imputation for all eligible patients and eligible patients on AZT-based regimens with a 
documented viral load done 90 – 270 days after ART initiation   
Characteristics All eligible patients All eligible patients on AZT-based regimens
*
 
Total 
N = 234480 
Viral load 
< 400 copies/ml 
N = 200220 
Viral load 
≥ 400 copies/ml 
N = 34260 
Total 
N = 5700 
Viral load 
< 400 copies/ml 
N = 4940 
Viral load 
≥ 400 copies/ml 
N = 760 
n (%)  n (%) n (%) n (%)  n (%) n (%) 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
206040 (87.9%) 
25727 (11.0%) 
2713 (1.1%) 
 
176147 (88.0%) 
21961 (11.0%) 
2112 (1.0%) 
 
29893 (87.3%) 
3766 (11.0%) 
601 (1.7%) 
 
5108 (89.6%) 
491 (8.6%) 
101 (1.8%) 
 
4487 (90.8%) 
392 (7.9%) 
61 (1.2%) 
 
621 (81.7%) 
99 (13.0%) 
40 (5.3%) 
Number of missed visits 
0 
1 
≥ 2 
Missing 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical 
visits 
0: 
1: 
≥ 2: 
 
158880 (67.8%) 
55800 (23.8%) 
16920 (7.2%) 
2880 (1.2%) 
 
 
183237 (78.1%) 
43573 (18.6%) 
7670 (3.3%) 
 
 
 
182705 (77.9%) 
44110 (18.8%) 
7665 (3.3%) 
 
135960 (67.9%) 
47580 (23.8%) 
14400 (7.2%) 
2280 (1.1%) 
 
 
156907 (78.4%) 
36971 (18.5%) 
6342 (3.1%) 
 
 
 
156856 (78.3%) 
37107 (18.5%) 
6257 (3.2%) 
 
22920 (66.9%) 
8220 (24.0%) 
2520 (7.4%) 
600 (1.7%) 
 
 
26330 (76.9%) 
6602 (19.3%) 
1328 (3.8%) 
 
 
 
25849 (75.5%) 
7003 (20.4%) 
1408 (4.1%) 
 
3620 (63.5%) 
1320 (23.2%) 
500 (8.8%) 
260 (4.5%) 
 
 
4257 (74.7%) 
1163 (20.4%) 
280 (4.9%) 
 
 
 
4331 (76.0%) 
1227 (21.5%) 
142 (2.5%) 
 
3220 (65.2%) 
1180 (23.9%) 
360 (7.3%) 
180 (3.6%) 
 
 
3762 (76.2%) 
938 (19.0%) 
240 (4.8%) 
 
 
 
3873 (78.4%) 
985 (19.9%) 
82 (1.7%) 
 
400 (52.6%) 
140 (18.4%) 
140 (18.4%) 
80 (10.6%) 
 
 
495 (65.1%) 
225 (29.6%) 
40 (5.3%) 
 
 
 
458 (60.3%) 
242 (28.9%) 
60 (7.9%) 
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BMI at 6 months in kg/m
2
 
< 18.5
 
18.5 – < 25  
25 – < 30  
≥ 30 
 
16502 (7.0%) 
125949 (53.7%) 
62609 (26.7%) 
29420 (12.6%) 
 
13449 (6.7%) 
107068 (53.5%) 
54077 (27.0%) 
25626 (12.8%) 
 
3053 (8.9%) 
18881 (55.1%) 
8532 (24.9%) 
3794 (11.1%) 
 
448 (7.9%) 
2804 (49.2%) 
1480 (26.0%) 
968 (16.9%) 
 
393 (8.0%) 
2329 (47.1%) 
1296 (26.2%) 
922 (18.7%) 
 
55 (7.2%) 
475 (62.5%) 
184 (24.2%) 
46 (6.1%) 
Haemoglobin at 6 months 
≤ 8 g/dl 
> 8g/dl 
 
1122 (0.5%) 
233358 (99.5%) 
 
882 (0.4%) 
199338 (99.6%) 
 
240 (0.7%) 
34020 (99.3%) 
 
20 (0.4%) 
5680 (99.6%) 
 
0 (0%) 
4940 (100%) 
 
20 (2.6%) 
740 (97.4%) 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
5816 (2.5%) 
113518 (48.4%) 
115146 (49.1%) 
 
4946 (2.5%) 
91526 (45.7%) 
103748 (51.8%) 
 
870 (2.5%)  
21992 (64.2%) 
11398 (33.3%) 
 
65 (1.1%) 
1726 (30.3%) 
3909 (68.6%) 
 
64 (1.3%) 
1366 (27.7%) 
3510 (71.0%) 
 
1 (0.1%) 
360 (47.4%) 
399 (52.5%) 
Change in MCV at 6 months 
≥ 14.5fL 
< 14.5fL 
 
96253 (41.0%) 
138227 (59.0%) 
 
88088 (44%) 
112132 (56%) 
 
8165 (23.8%) 
26095 (76.2%) 
 
2669 (46.8%) 
3031 (53.2%) 
 
2432 (49.2%) 
2508 (50.8%) 
 
237 (31.2%) 
523 (68.8%) 
Change in CD4 count at 6 
months in cells/mm
3
 
≥ expected  
< expected  
 
 
182951 (78.0%) 
51529 (22.0%) 
 
 
159463 (79.6%) 
40757 (20.4%) 
 
 
23488 (68.6%) 
10772 (31.4%) 
 
 
4206 (73.8%) 
1494 (26.2%) 
 
 
3783 (76.6%) 
1157 (23.4%) 
 
 
423 (55.7%) 
337 (44.3%) 
Change in CD4 count at 6 
months stratified by change in 
MCV at 6 months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
 
 
 
 
75412 (32.2%) 
 
107539 (45.9%) 
 
20841 (8.9%) 
 
30688 (13.0%) 
 
 
 
 
69613 (34.8%) 
 
89850 (44.9%) 
 
18475 (9.2%) 
  
22282 (11.1%) 
 
 
 
 
5799 (16.9%) 
 
17689 (51.6%) 
 
2366 (6.9%) 
 
8406 (24.6%) 
 
 
 
 
2068 (36.3%) 
 
2138 (37.5%) 
 
601 (10.5%) 
 
893 (15.7%) 
 
 
 
 
1942 (39.3%) 
 
1841 (37.3%) 
 
490 (9.9%) 
 
667 (13.5%) 
 
 
 
 
126 (16.6%) 
 
297 (39.1%) 
 
111 (14.6%) 
 
226 (29.7%) 
Regimen change 
No 
Yes 
 
212960 (90.8%) 
21520 (9.2%) 
 
182100 (90.9%) 
18120 (9.1%) 
 
30860 (90.1%) 
3400 (9.9%) 
 
5560 (97.5%) 
140 (2.5%) 
 
4840 (98.0%) 
100 (2.0%)  
 
720 (94.7%) 
40 (5.3%) 
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TB
α
: On TB treatment during 
first 6 months on ART: 
Never 
At baseline 
During follow-up 
 
 
175540 (74.9%) 
49200 (21.0%) 
9740 (4.1%) 
 
 
150180 (75.0%) 
41680 (20.8%) 
8360 (4.2%) 
 
 
25360 (74.0%) 
7520 (21.9%) 
1380 (4.1%) 
 
 
4340 (76.1%) 
1220 (21.4%) 
140 (2.5%) 
 
 
3740 (75.7%) 
1060 (21.5%) 
140 (2.8%) 
 
 
600 (78.9%) 
160 (21.1%) 
0 (0%) 
Pregnancy
α
: Pregnancy during 
first 6 months on ART: 
Never  
At baseline 
During follow-up 
Missing
γ
 
 
 
141580 (60.4%) 
2620 (1.1%) 
3980 (1.7%) 
86300 (36.8%) 
 
 
122180 (61.0%) 
2260 (1.1%) 
3380 (1.7%) 
72400 (36.2%) 
 
 
19400 (56.6%) 
360 (1.1%) 
600 (1.7%) 
13900 (40.6%) 
 
 
2900 (50.9%) 
40 (0.7%) 
120 (2.1%) 
2640 (46.3%) 
 
 
2660 (53.8%) 
40 (0.8%) 
60 (1.2%) 
2180 (44.2%) 
 
 
240 (31.6%) 
0 (0%) 
60 (7.9%) 
460 (60.5%) 
Adverse events or side effects 
No 
Yes 
 
227580 (97.1%) 
6900 (2.9%) 
 
193720 (96.8%) 
6500 (3.2%) 
 
33860 (98.8%) 
400 (1.2%) 
 
5680 (99.6%) 
20 (0.4%) 
 
4920 (99.6%) 
20 (0.4%) 
 
760 (100%) 
0 (0%) 
* 
On AZT-based regimens throughout the study period.  
α 
Variable has baseline and 6 month components.  
γ 
Male patients.  ART: Antiretroviral Therapy.  ARV: 
Antiretroviral.  AZT: Zidovudine.  BMI: Body Mass Index.  MCV: Mean cell volume.  TB: Tuberculosis. 
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APPENDIX 7A: ROC curves for different  markers of adherence for all  eligible patients with a documented viral load, done 90 to 270 days after ART initiation  
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APPENDIX 7B: ROC curves for different markers of adherence for eligible patients on AZT-based regimens with a documented viral load (done 90 
to 270 days after ART initiation)  
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APPENDIX 8A 
Univariate and multivariate Poisson regression models with robust error variance for all eligible patients and eligible patients on AZT-
based regimens, with a documented viral load result, excluding patients with a history of prior ART use such as NVP prophylaxis and 
excluding patients switched to second-line or a non-standard ART regimen before 6 months on treatment 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis  
Crude IRR  
(95% CI) 
P - 
value 
Adjusted IRR  
(95% CI) 
P - 
value 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P - 
value 
Gender  
Females             
Males 
 
1 
1.17 (1.05 – 1.29) 
 
- 
0.003 
 
1 
1.09 (0.92 – 1.30) 
 
- 
0.293 
 
1 
1.44 (0.75 – 2.76) 
 
- 
0.271 
 
- 
- 
 
- 
- 
Age at initiation 
≤ 36.7 years 
> 36.7 years 
 
1 
0.93 (0.84 – 1.03) 
 
- 
0.157 
 
1 
0.91 (0.77 – 1.07) 
 
- 
0.260 
 
1 
0.53 (0.28 – 1.00) 
 
- 
0.051 
 
1 
2.72 (0.78 – 9.40) 
 
- 
0.115 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.92 (0.79 – 1.07) 
0.81 (0.59 – 1.11) 
 
- 
0.297 
0.197 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.41 (0.61 – 3.26) 
0.81 (0.12 – 5.30) 
 
- 
0.414 
0.826 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.09 (0.99 – 1.21) 
 
- 
0.079 
 
- 
- 
 
- 
- 
 
1 
0.93 (0.48 – 1.81) 
 
- 
0.838 
 
- 
- 
 
- 
- 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fl 
 
1 
1.29 (1.04 – 1.60) 
1.50 (1.07 – 2.08) 
 
- 
0.020 
0.017 
 
1 
1.40 (1.04 – 1.87) 
1.07 (0.66 – 1.74) 
 
- 
0.024 
0.775 
 
1 
0.69 (0.23 – 2.08) 
0.46 (0.12 – 1.77) 
 
- 
0.506 
0.256 
 
- 
- 
- 
 
- 
- 
- 
Baseline CD4 count in cells/mm
3 
> 200 
 
1 
 
- 
 
1 
 
- 
 
1 
 
- 
 
1 
 
- 
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101 – 200  
51 – 100 
 ≤ 50   
0.97 (0.82 – 1.15) 
1.10 (0.91 – 1.32) 
1.22 (1.03 – 1.45) 
0.724 
0.317 
0.019 
1.08 (0.81 – 1.44) 
1.07 (0.78 – 1.47) 
1.35 (1.01 – 1.79) 
0.585 
0.687 
0.042 
1 (0.38 – 2.64) 
1.04 (0.35 – 3.12) 
1.43 (0.53 – 3.87)  
1.000 
0.939 
0.483 
1.03 (0.07 – 14.84) 
3.97 (0.48 – 32.89) 
6.93 (0.52 – 92.81) 
0.982 
0.202 
0.143 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.23 (1.05 – 1.45) 
1.25 (1.08 – 1.44) 
1.34 (1.18 – 1.61) 
 
- 
0.010 
0.002 
0.002 
 
1 
1.20 (0.93 – 1.54) 
1.26 (1.02 – 1.56) 
1.53 (1.19 – 1.98) 
 
- 
0.164 
0.031 
0.001 
 
1 
0.74 (0.18 – 3.00) 
1.34 (0.56 – 3.20) 
-
‡
 
 
- 
0.678 
0.509 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.11 (0.89 – 1.37) 
1.29 (0.88 – 1.90) 
 
- 
0.351 
0.192 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.4 (0.20 – 9.58) 
3.5 (0.72 – 17.12)  
 
- 
0.732 
0.122 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
0.93 (0.83 – 1.05) 
0.92 (0.77 – 1.11) 
 
 
1 
0.97 (0.86 – 1.10) 
1.22 (0.98 – 1.53) 
 
 
1 
1.00 (0.88 – 1.13) 
1.24 (0.99 – 1.56) 
 
- 
0.239 
0.404 
 
 
- 
0.646 
0.075 
 
 
- 
0.970 
0.067 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.80 (0.31 – 2.04) 
2.45 (1.08 – 5.59) 
 
 
1 
1.20 (0.52 – 2.77) 
1.60 (0.45 – 5.73) 
 
 
1 
1.49 (0.67 – 3.34) 
4.35 (1.86 – 10.19) 
 
- 
0.635 
0.033 
 
 
- 
0.673 
0.472 
 
 
- 
0.329 
0.001 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.35 (1.00 – 1.82) 
0.56 (0.41 – 0.77) 
 
- 
0.050 
0.000 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.78 (0.17 – 3.51) 
0.20 (0.04 – 0.88) 
 
- 
0.744 
0.034 
 
- 
- 
- 
 
- 
- 
- 
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Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
3.48 (2.86 – 4.24) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
1.97 (0.61 – 6.36) 
 
- 
0.255 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 
months in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.85 (1.63 – 2.10) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
3.31 (1.24 – 8.85) 
 
 
- 
0.017 
 
 
1 
6.09 (1.10 – 33.75) 
 
 
- 
0.039 
Change in CD4 count at 6 
months stratified by change in 
MCV at 6 months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
 
 
 
 
1 
 
3.06 (2.39 – 3.90) 
 
1.10 (0.69 – 1.76) 
 
6.26 (4.86 – 8.06) 
 
 
 
 
- 
 
0.000 
 
0.684 
 
0.000 
 
 
 
 
1 
 
3.16 (2.42 – 4.13) 
 
1.31 (0.81 – 2.14) 
 
6.90 (5.23 – 9.10) 
 
 
 
 
- 
 
0.000 
 
0.271 
 
0.000 
 
 
 
 
1 
 
1.98 (0.35 – 11.18) 
 
3.36 (0.53 – 21.41) 
 
4.35 (0.87 – 21.69) 
 
 
 
 
- 
 
0.438 
 
0.199 
 
0.073 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.70 (0.55 – 0.89) 
 
- 
0.004 
 
1 
0.68 (0.45 – 1.03) 
 
- 
0.066 
 
1 
-
‡‡
 
 
- 
- 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 
6 months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.00 (0.89 – 1.13) 
0.89 (0.68 – 1.16) 
 
 
- 
0.972 
0.371 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.89 (0.34 – 2.33) 
-
‡
 
 
 
- 
0.814 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
Pregnancy: Pregnancy during 
first 6 months on ART: 
Never  
At baseline 
 
 
1 
1.10 (0.68 – 1.76) 
 
 
- 
0.705 
 
 
- 
- 
 
 
- 
- 
 
 
1 
-
‡ 
 
 
- 
- 
 
 
1 
-
‡
 
 
 
- 
- 
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During follow-up 1.19 (0.81 – 1.75) 0.381 - - 7.5 (4.42 – 12.74) 0.000 35.66 (4.49 – 283.24) 0.001 
Adverse events or side effects 
No 
Yes 
 
1 
0.34 (0.19 – 0.58) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period.  
‡ 
Cell has no observations.  
‡‡ 
Cells have no observations.
  
ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: 
Zidovudine.  CI: Confidence interval.  IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis.  WHO: World Health Organization.  
     
For the table above, multivariate Poisson regression analysis with robust error variance was done first for all eligible patients then for all eligible 
patients on AZT-based regimens. After adjusting for potential confounders, the variables independently associated with poor adherence for all 
patients were change in CD4 count at 6 months stratified by change in MCV at 6 months, CD4 count at baseline, WHO stage at baseline and 
MCV at baseline. The association between regimen change and poor adherence was marginally significant (p < 0.1). Change in CD4 count at 6 
months and pregnancy during the first 6 months on ART were the only independent predictors of poor adherence in the final multivariate model 
for patients on AZT-based regimens. Model fit for the multivariate models was good as evidenced by a p-value of 0.827 on the link test for the 
model for all patients and 0.622 on the link test for the model for patients on AZT-based regimens.  
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APPENDIX 8B 
 
Univariate and multivariate Poisson regression models with robust error variance after multiple imputation, for all eligible patients and 
eligible patients on AZT-based regimens, with a documented viral load result, excluding patients with a history of prior ART use such as 
NVP prophylaxis and excluding patients switched to second-line or a non-standard ART regimen before 6 months on treatment 
 
Variable All eligible patients All eligible patients on AZT-based regimens
*
  
Univariate Analyses Multivariate Analysis Univariate Analyses Multivariate Analysis  
Crude IRR  
(95% CI) 
P - 
value 
Adjusted IRR  
(95% CI) 
P - 
value 
Crude IRR 
 (95% CI) 
P - 
value 
Adjusted IRR 
 (95% CI) 
P - 
value 
Gender  
Females             
Males 
 
1 
1.17 (1.05 – 1.29) 
 
- 
0.003 
 
1 
1.07 (0.97 – 1.18) 
 
- 
0.195 
 
1 
1.44 (0.75 – 2.76) 
 
- 
0.271 
 
1 
1.36 (0.70 – 2.64) 
 
- 
0.360 
Age at initiation 
≤ 36.7 years 
> 36.7 years 
 
1 
0.93 (0.84 – 1.03) 
 
- 
0.157 
 
1 
0.96 (0.87 – 1.05) 
 
- 
0.359 
 
1 
0.53 (0.28 – 1.00) 
 
- 
0.051 
 
1 
0.56 (0.29 – 1.07) 
 
- 
0.078 
Education level 
≥ Secondary school 
Primary school 
< Primary school 
 
1 
0.92 (0.79 – 1.08) 
0.84 (0.61 – 1.15) 
 
- 
0.315 
0.282 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.19 (0.51 – 2.73) 
0.87 (0.13 – 5.71) 
 
- 
0.688 
0.888 
 
- 
- 
- 
 
- 
- 
- 
Professional status    
Employed 
Unemployed  
 
1 
1.09 (0.99 – 1.21) 
 
- 
0.072 
 
- 
- 
 
- 
- 
 
1 
0.93 (0.48 – 1.79) 
 
- 
0.821 
 
- 
- 
 
- 
- 
MCV at baseline  
< 80fL 
80 – 100fL 
> 100fl 
 
1 
1.26 (1.02 – 1.55) 
1.35 (0.99 – 1.85) 
 
- 
0.031 
0.057 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.78 (0.28 – 2.22) 
0.50 (0.14 – 1.87) 
 
- 
0.649 
0.306 
 
- 
- 
- 
 
- 
- 
- 
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Baseline CD4 count in cells/mm
3 
> 200 
101 – 200  
51 – 100 
 ≤ 50   
 
1 
0.98 (0.83 – 1.16) 
1.09 (0.90 – 1.32) 
1.22 (1.03 – 1.45) 
 
- 
0.802 
0.359 
0.020 
 
1 
1.12 (0.95 – 1.32) 
1.30 (1.08 – 1.57) 
1.52 (1.28 – 1.80) 
 
- 
0.181 
0.006 
0.000 
 
1 
1.04 (0.42 – 2.63) 
1.11 (0.38 – 3.23) 
1.46 (0.51 – 4.13)  
 
- 
0.920 
0.841 
0.479 
 
1 
1.03 (0.42 – 2.50) 
1.11 (0.36 – 3.42) 
1.31 (0.47 – 3.71) 
 
- 
0.945 
0.857 
0.603 
WHO stage at baseline 
 I 
II 
III 
IV 
 
1 
1.21 (1.04 – 1.42) 
1.24 (1.07 – 1.43) 
1.29 (1.08 – 1.54) 
 
- 
0.016 
0.004 
0.005 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
1 
0.83 (0.24 – 2.90) 
1.22 (0.55 – 2.69) 
-
‡
 
 
- 
0.768 
0.624 
- 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
Self-reported adherence 
> 90% 
> 60 – 90% 
≤ 60% 
 
1 
1.09 (0.87 – 1.37) 
1.56 (1.06 – 2.29) 
 
- 
0.459 
0.024 
 
- 
- 
- 
 
- 
- 
- 
 
1 
1.21 (0.33 – 4.50) 
2.90 (0.69 – 12.21) 
 
- 
0.769 
0.147 
 
- 
- 
- 
 
- 
- 
- 
Number of missed visits 
0 
1 
≥ 2 
 
Number of missed ARV visits 
0 
1 
≥ 2 
 
Number of missed medical visits 
0 
1 
≥ 2 
 
1 
0.93 (0.83 – 1.05) 
0.92 (0.77 – 1.11) 
 
 
1 
0.97 (0.86 – 1.10) 
1.22 (0.98 – 1.53) 
 
 
1 
1.00 (0.88 – 1.13) 
1.24 (0.98 – 1.56) 
 
- 
0.239 
0.404 
 
 
- 
0.635 
0.076 
 
 
- 
0.973 
0.070 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
1 
0.80 (0.31 – 2.04) 
2.45 (1.08 – 5.59) 
 
 
1 
1.20 (0.53 – 2.70) 
1.53 (0.43 – 5.49) 
 
 
1 
1.43 (0.65 – 3.14) 
3.76 (1.58 – 8.94) 
 
- 
0.635 
0.033 
 
 
- 
0.662 
0.510 
 
 
- 
0.376 
0.003 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
1.34 (0.61 – 2.97) 
2.85 (1.35 -  6.02) 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
0.467 
0.006 
 131 
 
MCV at 6 months  
< 80fL 
80 – 100fL 
> 100fL 
 
1 
1.42 (1.05 – 1.92) 
0.64 (0.47 – 0.87) 
 
- 
0.024 
0.005 
 
- 
- 
- 
 
- 
- 
- 
 
1 
0.89 (0.19 – 4.10) 
0.26 (0.05 – 1.23) 
 
- 
0.880 
0.089 
 
- 
- 
- 
 
- 
- 
- 
Change in MCV at 6 months 
≥ 14.5 fL 
< 14.5 fL 
 
1 
2.62 (2.18 – 3.15) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
2.09 (0.84 – 5.18) 
 
- 
0.111 
 
- 
- 
 
- 
- 
Change in CD4 count at 6 
months in cells/mm
3
  
≥ expected  
< expected  
 
 
1 
1.76 (1.56 – 1.98) 
 
 
- 
0.000 
 
 
- 
- 
 
 
- 
- 
 
 
1 
2.03 (0.96 – 4.32) 
 
 
- 
0.065 
 
 
- 
- 
 
 
- 
- 
Change in CD4 count at 6 
months stratified by change in 
MCV at 6 months 
-Change in CD4 count ≥ expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count ≥ expected 
and change in MCV < 14.5fL: 
-Change in CD4 count < expected 
and change in MCV ≥ 14.5fL: 
-Change in CD4 count < expected 
and change in MCV < 14.5fL: 
 
 
 
 
1 
 
2.46 (1.96 – 3.08) 
 
1.50 (1.07 – 2.09) 
 
4.39 (3.53 – 5.47) 
 
 
 
 
- 
 
0.000 
 
0.019 
 
0.000 
 
 
 
 
1 
 
2.51 (2.00 – 3.15) 
 
1.58 (1.12 – 2.22) 
 
4.64 (3.70 – 5.81) 
 
 
 
 
- 
 
0.000 
 
0.009 
 
0.000 
 
 
 
 
1 
 
2.10 (0.62 – 7.16) 
 
2.11 (0.47 – 9.39) 
 
3.72 (1.18 – 11.77) 
 
 
 
 
- 
 
0.232 
 
0.326 
 
0.026 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
- 
 
- 
 
- 
 
- 
Regimen change 
No 
Yes 
 
1 
0.70 (0.55 – 0.89) 
 
- 
0.004 
 
1 
0.76 (0.59 – 0.97) 
 
- 
0.028 
 
1 
-
‡‡
 
 
- 
- 
 
- 
- 
 
- 
- 
TB: On TB treatment during first 
6 months on ART: 
Never 
At baseline 
During follow-up 
 
 
1 
1.00 (0.89 – 1.13) 
0.89 (0.68 – 1.16) 
 
 
- 
0.972 
0.371 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
0.89 (0.34 – 2.33) 
-
‡
 
 
 
- 
0.814 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
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Pregnancy: Pregnancy during 
first 6 months on ART: 
Never  
At baseline 
During follow-up 
 
 
1 
1.10 (0.68 – 1.76) 
1.19 (0.81 – 1.75) 
 
 
- 
0.705 
0.381 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
1 
-
‡ 
7.5 (4.42 – 12.74) 
 
 
- 
- 
0.000 
 
 
- 
- 
- 
 
 
- 
- 
- 
Adverse events or side effects 
No 
Yes 
 
1 
0.34 (0.19 – 0.58) 
 
- 
0.000 
 
- 
- 
 
- 
- 
 
1 
-
‡
 
 
- 
 
 
- 
- 
 
- 
- 
* 
On AZT-based regimens throughout the study period.  
‡ 
Cell has no observations.  
‡‡ 
Cells have no observations.
  
ART: Antiretroviral Therapy.  ARV: Antiretroviral.  AZT: 
Zidovudine.  CI: Confidence interval.  IRR: Incidence rate ratio.  MCV: Mean cell volume.  TB: Tuberculosis.  WHO: World Health Organization. 
 
For the table above, multiple imputation (20 imputations) was done for all patients with a documented viral load result using multivariate normal 
regression. The imputation was done for explanatory variables in the final multivariate models with missing values. Multiple imputation was 
followed by multivariate Poisson regression analysis with robust error variance. After adjusting for potential confounders, the variables 
independently associated with poor adherence for all eligible patients were change in CD4 count at 6 months stratified by change in MCV at 6 
months, regimen change and CD4 count at baseline. Model fit was good as evidenced by a p-value of < 0.05 on the FMI test.  Number of missed 
medical visits was the only independent predictor of poor adherence in the final multivariate model for patients on AZT-based regimens. Model 
fit for this model was also good as evidenced by a p-value of < 0.05 on the FMI test. 
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APPENDIX 9A: ROC curves for different markers of adherence for eligible patients with a documented viral load, excluding patients 
with a history of prior ART use such as NVP prophylaxis and excluding patients switched to second-line or a non-standard ART 
regimen before 6 months on treatment 
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APPENDIX 9B: ROC curves for different markers of adherence for eligible patients  on AZT-based regimens with a documented viral 
load, excluding patients with a history of prior ART use such as NVP prophylaxis and excluding patients switched to second-line or a 
non-standard ART regimen before 6 months on treatment 
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APPENDIX 10:   Permission letter to use TherapyEdge-HIV
TM 
 
 
                      
 
 
 
 
Date:  30th July, 2012 
 
 
This is to certify that Maria Nnambalirwa has been granted permission to use data from the Themba 
Lethu Clinic cohort stored on TherapyEdgeTM for a research project titled “Markers of Adherence 
among HIV-positive Adults on Antiretroviral Therapy at Themba Lethu Clinic”. 
The standard operating procedures for the Clinical HIV Unit have been complied with. 
 
 
…………………………………………… 
Professor AP MacPhail. 
 
 
University  
of the Witwatersrand, 
Johannesburg 
 
  SECRETARIAT: Suite 176, Private Bag x2600, Houghton 2041, South Africa • Tel: +27-11-276-8800 • Fax: +27-11-482-2130  
Clinical HIV Research Unit 
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APPENDIX 11: Ethics clearance certificate 
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APPENDIX 12 
 
Confidentiality Agreement 
 
Patient’s health records and personal information are confidential. I understand that I may become 
aware of patient information in the course of my association with any of the Right to Care Clinics and 
I am prohibited from divulging or communicating this information both during and after such 
association. I agree to respect the patient’s right to confidentiality and privacy. I agree to access 
patient’s personal health information only as permitted in the performance of my duties/course of 
my research or as otherwise directed. I agree to preserve the confidentiality of all clinical or patient 
information and not to divulge this in any form. Any breach of this agreement during or after my 
association with the Clinic will be taken seriously. Any violation can or may result in legal or 
disciplinary action. 
 
I……………………………………………………….., acknowledge that I have read this confidentiality agreement 
and understand my responsibilities as they pertain to confidentiality of personal information and 
agree to the principles as stated above. 
 
…………………………………………….                                                     ………………………… 
Signature of Employee/Investigator                                                         Date                       
